

**IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF ILLINOIS
EASTERN DIVISION**

IN RE: TESTOSTERONE REPLACEMENT THERAPY PRODUCTS LIABILITY LITIGATION	MDL No. 2545 Master Docket Case No. 1:14-cv-01748 Honorable Matthew F. Kennelly
This document relates to: <i>Konrad v. AbbVie Inc.</i> , No. 1:15-cv-00966	

FINAL PRE-TRIAL ORDER

In accordance with the Court’s instructions for *Preparation of Final Pretrial Order for Civil Cases Before Judge Kennelly* (Revised 3/2015) (the “Court’s Instructions”), and this matter having been set for a Final Pretrial Conference on May 25, 2017 pursuant to Rule 16 of the Federal Rules of Civil Procedure, and counsel for the parties having conferred, the parties hereby certify that each of the categories identified by the Court’s Instructions is included in the enclosed proposed Final Pretrial Order. This Order will control the course of the trial and may not be amended except by consent of the parties, or by order of the Court to prevent manifest injustice.

Date: May 11, 2017

Respectfully submitted,

/s/Christopher A. Seeger
Christopher A. Seeger
David R. Buchanan
SEEGER WEISS LLP
77 Water Street
New York, NY 10005
Phone: (212) 584-0700
Fax: (212) 584-0799
Email: cseeger@seegerweiss.com
dbuchanan@seegerweiss.com

/s/Michelle Hart Yeary
Michelle Hart Yeary
DECHERT LLP
902 Carnegie Center, Suite 500
Princeton, NJ 08540-6531
Tel: (609) 955-3200
Fax: (609) 955-3259
Email: michelle.yeary@dechert.com

Matthew P. Teague

Hope S. Freiwald
Friedrich-Wilhelm W. Sachse
DECHERT LLP

BEASLEY, ALLEN, CROW, METHVIN,
PORTIS & MILES, P.C.
P.O. Box 4160
Montgomery, AL 36103-4160
Tel: (334) 269-2343
Fax: (334) 954-7555
Email: matt.teague@beasleyallen.com

*Counsel for Plaintiffs Jeffrey Konrad and
Jana Konrad*

2929 Arch St., Cira Centre
Philadelphia, PA 19104-2808
Tel: (215) 994-4000
Fax: (215) 665-4000
Email: hope.freiwald@dechert.com
will.sachse@dechert.com

Nathan Hoffman
DECHERT LLP
35 W. Wacker Dr., Suite 3400
Chicago, IL 60601-1608
Tel: (312) 646-5800
Fax: (312) 646-5858
Email: nathan.hoffman@dechert.com

*Counsel for Defendants AbbVie Inc. and
Abbott Laboratories*

David M. Bernick
PAUL, WEISS, RIFKIND, WHARTON &
GARRISON LLP
1285 Avenue of the Americas
New York, NY 10019-6064
Tel: (212) 373-3000
Fax: (212) 757-3990
Email: dbernick@paulweiss.com

Counsel for Defendant AbbVie Inc.

**IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF ILLINOIS
EASTERN DIVISION**

IN RE: TESTOSTERONE REPLACEMENT
THERAPY PRODUCTS LIABILITY
LITIGATION

MDL No. 2545

Master Docket Case No. 1:14-cv-01748

Honorable Matthew F. Kennelly

This document relates to:

Konrad v. AbbVie Inc., No. 1:15-cv-00966

FINAL PRE-TRIAL ORDER

This matter having come before the Court at a pretrial conference held pursuant to Rule 16 of the Federal Rules of Civil Procedure, and counsel for the parties having appeared, the following actions were taken:

1. Subject Matter Jurisdiction. The Court has subject matter jurisdiction over this action pursuant to 28 U.S.C. § 1332(a). The parties are citizens of different states and the amount in controversy exceeds \$75,000.00, exclusive of interest and costs. Jurisdiction is not disputed.

2. Summary of Claims and Defenses.

a. Plaintiff's Statement of the Case: Jeffrey Konrad and his wife, Jana Konrad, have brought this lawsuit against Defendants AbbVie Inc. and Abbott Laboratories (together referred to as, "AbbVie") for personal injuries caused by AbbVie's prescription testosterone drug, called "AndroGel." In May 2010, Mr. Konrad was prescribed AndroGel by his family physician. Approximately two months later, while taking AndroGel, Mr. Konrad suffered a heart attack. Mr. and Mrs. Konrad allege that AndroGel was unreasonably dangerous, and that AbbVie misrepresented that AndroGel was a safe and effective treatment for the symptoms for which Mr.

Konrad sought treatment. Plaintiffs further allege that AbbVie failed to warn of the dangers of AndroGel that it knew or should have known about. Plaintiffs allege that Defendants' conduct, and their drug AndroGel, were a cause of Mr. Konrad's heart attack. Mr. and Mrs. Konrad seek compensatory damages for their injuries and losses, and punitive damages arising out of the Defendants' wrongful conduct.

b. AbbVie's Statement of the Case¹: In April 2010, Mr. Konrad was diagnosed by the Konrads' family physician with hypogonadism based upon blood tests showing low production of testosterone and his telling his physician that he was suffering from fatigue and decreased endurance and stamina. AndroGel was prescribed to increase his testosterone levels and he used it for about 65 days. In July 2010, Mr. Konrad suffered a heart attack. At the hospital, he was first diagnosed with coronary artery disease, which he had been at risk of developing for some time. Mr. Konrad's heart attack was relatively mild, and within months he had resumed his hobby of running long distance races.

AbbVie contends that Mr. Konrad's heart attack was caused by risk factors unrelated to AndroGel, such as hyperlipidemia, obesity, and high blood pressure. AndroGel was first approved by the FDA as safe and effective in 2000 and testosterone replacement therapies have been approved for many years before that. AndroGel was simply a gel form of testosterone. AbbVie contends that it made no misrepresentations about the safety or effectiveness of AndroGel to Mr. Konrad or his doctor. AndroGel had labeled warnings and disclosures that were approved by the FDA, and AbbVie further contends that AndroGel was not unreasonably dangerous.

¹ It is AbbVie's understanding that the Court will not be putting the preemption issue to the jury and that all affirmative defenses previously pleaded are preserved.

There are no counterclaims or cross claims.

3. Relief sought. Plaintiffs seek compensatory and punitive damages, including past medical expenses in the amount of \$55,082.84 and an amount to compensate them for physical pain and mental suffering, permanent injury, loss of enjoyment of life and Jana Konrad's loss of consortium.

4. Witnesses. Except for rebuttal witnesses not presently identifiable, attached as Schedule A and Schedule B hereto are lists of names and addresses of Plaintiffs' and AbbVie's respective witnesses: (a) who will be called; (b) who may be called; and (c) whose deposition may be used. As previously guided by the Court, deposition designations and objections to those designations will be submitted to the Court for a ruling after the Final Pretrial Conference. Schedule A and Schedule B include a statement of any objections to the calling of any witness, including expert witnesses, except that objections to any particular deposition designation will be provided separately as noted above and are not waived if omitted from Schedule A or Schedule B.

5. Exhibits. Attached as Schedule C and Schedule D hereto are list of exhibits that Plaintiffs or AbbVie, respectively, may presently introduce at trial, identified by trial exhibit number, with a brief description of each exhibit. The parties have agreed to reasonable supplementation of exhibits prior to and during the course of trial. Schedule C and Schedule D include a statement of any objections to each exhibit. The parties have conferred concerning the exchange of demonstrative exhibits and recognize the necessity of deferring the exchange of demonstratives to a later date.

6. Type and length of trial. The Court has scheduled a jury trial to commence on June 5, 2017, and the parties expect the length of trial to be three weeks subject to the provisions of Case Management Order No. 44.

7. Proposed voir dire questions. Attached as Schedule E hereto is a list of proposed voir dire questions, to be formatted as a written questionnaire consistent with the sample jury questionnaire for civil personal injury cases available on the Court's website. Schedule E lists (i) questions from the Court's sample questionnaire; (ii) questions proposed jointly by Plaintiffs and AbbVie; (iii) questions proposed only by Plaintiffs (together with AbbVie's objections, if any); and (iv) questions proposed by AbbVie (together with Plaintiffs' objections, if any).

Additionally, Schedule E includes questions proposed by the parties to be asked by the Court during voir dire. The Parties jointly request that any questions they submitted in the proposed written questionnaire, which are not included in the final questionnaire, be asked during oral voir dire, along with any additional oral questions the parties seek the Court to ask during voir dire. Additionally, consistent with the Court's individual practices regarding jury selection procedures, the parties have conferred concerning a request for limited attorney-conducted voir dire as a supplement to the Court's jury selection procedure. In that regard, the parties jointly request the opportunity for the counsel to conduct limited voir dire of the panel.

8. Proposed jury instructions. Pursuant to the Court's prior guidance, the parties will submit preliminary requests to charge on or before May 18, 2017, listing the agreed proposed jury instructions and the disputed proposed jury instructions, identifying the proponent and noting the proponent's supporting authority and the objecting party's supporting authority.

Matthew F. Kennelly, U.S.D.J.

Date: _____

/s/Christopher A. Seeger

Christopher A. Seeger
David R. Buchanan
SEEGER WEISS LLP
77 Water Street
New York, NY 10005
Phone: (212) 584-0700
Fax: (212) 584-0799
Email: cseeger@seegerweiss.com
dbuchanan@seegerweiss.com

Matthew P. Teague
BEASLEY, ALLEN, CROW, METHVIN,
PORTIS & MILES, P.C.
P.O. Box 4160
Montgomery, AL 36103-4160
Tel: (334) 269-2343
Fax: (334) 954-7555
Email: matt.teague@beasleyallen.com

Counsel for Plaintiffs Jeffrey Konrad and Jana Konrad

David M. Bernick
PAUL, WEISS, RIFKIND, WHARTON &
GARRISON LLP
1285 Avenue of the Americas
New York, NY 10019-6064
Tel: (212) 373-3000
Fax: (212) 757-3990
Email: dbernick@paulweiss.com

Counsel for Defendant AbbVie Inc.

Hope S. Freiwald
Friedrich-Wilhelm W. Sachse
DECHERT LLP
2929 Arch St., Cira Centre
Philadelphia, PA 19104-2808
Tel: (215) 994-4000
Fax: (215) 665-4000
Email: hope.freiwald@dechert.com
will.sachse@dechert.com

Nathan Hoffman
DECHERT LLP
35 W. Wacker Dr., Suite 3400
Chicago, IL 60601-1608
Tel: (312) 646-5800
Fax: (312) 646-5858
Email: nathan.hoffman@dechert.com

Michelle Hart Yeary
DECHERT LLP
902 Carnegie Center, Suite 500
Princeton, NJ 08540-6531
Tel: (609) 955-3200
Fax: (609) 955-3259
Email: michelle.yeary@dechert.com

Counsel for Defendants AbbVie Inc. and Abbott Laboratories

CERTIFICATE OF SERVICE

I hereby certify that on May 11, 2017, I electronically transmitted the foregoing document to the Clerk of the United States District Court using the CM/ECF system for filing and service to all parties/counsel registered to received copies in this case.

/s/ Brendan A. Smith

Brendan A. Smith

SIMMONS HANLY CONROY

One Court Street

Alton, IL 62002

Phone: (618) 259-2222

Fax: (618) 259-2252

Email: bsmith@simmonsfirm.com

Schedule A

SCHEDULE A TO FINAL PRETRIAL ORDER
PLAINTIFFS' WITNESSES IN KONRAD

General Objection: Further, to the extent the parties have moved in limine to exclude certain categories of evidence, those objections apply equally to any testimony proffered by any witness on such topics. The parties have noted below, specific additional objections to certain witnesses.

Plaintiffs' Witness	Objection
I. Case-Specific Witnesses	
1. Jeffrey Konrad (will call – live) 10566 Tenby Cove Collierville, TN 38017	
2. Jana Konrad (may call – live) 10566 Tenby Cove Collierville, TN 38017	
3. Paul Konrad (may call – live) 139 Riverwalk Place Memphis, TN 38103	AbbVie objects to this witness's testimony to the extent it is cumulative of that to be proffered by Jana Konrad and Kelly Konrad. AbbVie further objects to this proffer to the extent it suggests that this witness has a claim in this case or that Plaintiff has a claim by virtue of his relationship to this witness.
4. Kelly Konrad (may call – live) 10566 Tenby Cove Collierville, TN 38017	AbbVie objects to this witness's testimony to the extent it is cumulative of that to be proffered by Jana Konrad and Paul Konrad. AbbVie further objects to this proffer to the extent it suggests that this witness has a claim in this case or that Plaintiff has a claim by virtue of his relationship to this witness.
5. Jennifer Morrow, MD (will call – via deposition) 8060 Wolf River Blvd Germantown, TN 38138	
6. Steven Overby, MD (will call – via deposition) 8040 Wolf River Blvd Germantown, TN 38138	

Plaintiffs' Witness	Objection
7. Jennie Worthen Fields (may call – via deposition) 1865 Jackson Ave Memphis TN 38107-4604	AbbVie objects to this witness's testimony to the extent it is cumulative of that to be proffered by Jason Thornton and Chris Buren.
8. Jason Overby Thornton (may call – via deposition) 1754 Fernhall Cv Collierville TN 38017-3344	AbbVie objects to this witness's testimony to the extent it is cumulative of that to be proffered by Jennie Fields and Chris Buren.
9. Christopher Buren (may call – via deposition) 7617 Beech Spring Ct Louisville, KY 40241-6410	AbbVie objects to this witness's testimony to the extent it is cumulative of that to be proffered by Jennie Fields and Jason Thornton.
II. Expert Witnesses	

Plaintiffs' Witness	Objection
<p>1. Hossein Ardehali, MD, PhD, FACC, FAHA (will call – live) Northwestern University Medical Center Tarry 14-733 303 E. Chicago Ave. Chicago, IL 60611</p>	<p>AbbVie objects to this witness's testimony on the grounds set forth in AbbVie's motion <i>in limine</i> II.B. (Plaintiffs' Experts Should Be Barred from Providing Opinions at Trial That Were Not Timely Disclosed). AbbVie further objects to the testimony of this witness to the extent it is duplicative and cumulative of other expert witnesses being proffered by Plaintiff.</p>
<p>2. Phillip Cuculich, MD (will call – live) Washington University School of Medicine 660 South Euclid Avenue Campus Box 8086 Saint Louis, MO 63110</p>	<p>AbbVie objects to this witness's testimony on the grounds set forth in AbbVie's motion <i>in limine</i> II.B. (Plaintiffs' Experts Should Be Barred from Providing Opinions at Trial That Were Not Timely Disclosed). AbbVie further objects to the testimony of this witness to the extent it is duplicative and cumulative of other expert witnesses being proffered by Plaintiff.</p>

Plaintiffs' Witness	Objection
<p>3. David A. Kessler, JD, MD (will call – live) 2715 Steiner Street San Francisco, CA 94123</p>	<p>AbbVie objects to this witness's testimony on the grounds set forth in AbbVie's motions <i>in limine</i> I.H. (Evidence Regarding General Criticisms of the FDA That Are Not Tied to the Facts at Issue Should Be Excluded under Rules 401, 402, 403, 801 and 803) and II.B. (Plaintiffs' Experts Should Be Barred from Providing Opinions at Trial That Were Not Timely Disclosed). AbbVie further objects to the testimony of this witness to the extent it is duplicative and cumulative of other expert witnesses being proffered by Plaintiff.</p>
<p>4. Peggy Pence, PhD, RAC, FRAPS (will call – live) Symbion Research International, Inc. 1533 Mirimar Drive Newport Beach, CA 92661</p>	<p>AbbVie objects to this witness's testimony on the grounds set forth in AbbVie's motions <i>in limine</i> I.H. (Evidence Regarding General Criticisms of the FDA That Are Not Tied to the Facts at Issue Should Be Excluded under Rules 401, 402, 403, 801 and 803) and II.B. (Plaintiffs' Experts Should Be Barred from Providing Opinions at Trial That Were Not Timely Disclosed). AbbVie further objects to the testimony of this witness to the extent it is duplicative and cumulative of other expert witnesses being proffered by Plaintiff.</p>

Plaintiffs' Witness	Objection
<p>5. B. Burt Gerstman, PhD (may call – live) San Jose State University Department of Health Science One Washington Square San Jose, CA 95192-0052</p>	<p>AbbVie objects to this witness's testimony on the grounds set forth in AbbVie's motion <i>in limine</i> II.B. (Plaintiffs' Experts Should Be Barred from Providing Opinions at Trial That Were Not Timely Disclosed). AbbVie further objects to the testimony of this witness to the extent it is duplicative and cumulative of other expert witnesses being proffered by Plaintiff.</p>
<p>6. David J. Handelsman, MB BS, FRACP, PHO, FAHMS (may call – live) ANZAC Research Institute Hospital Road (gate #3) Sydney NSW 2139 AUSTRALIA</p>	<p>AbbVie objects to the testimony of this witness to the extent it is duplicative and cumulative of other expert witnesses being proffered by Plaintiff.</p>
<p>7. Martin T. Wells, PhD (may call – live) Cornell University 1190 Comstock Hall Ithaca, NY 14853</p>	<p>AbbVie objects to the testimony of this witness to the extent it is duplicative and cumulative of other expert witnesses being proffered by Plaintiff.</p>
<p>III. Third-Party Generic Witnesses</p>	
<p>1. Alanna Keeley Boswell (may call – live or via deposition) Edelman 200 East Randolph Street, 63rd Floor Chicago, IL 60601</p>	<p>AbbVie objects to this witness being proffered by deposition as she is within the subpoena power of the Court and does not meet any of the exceptions for unavailability.</p>
<p>2. Representative (may call – live or via deposition) Edelman 200 East Randolph Street, 63rd Floor Chicago, IL 60601</p>	<p>AbbVie object to this witness as unidentified and untimely. AbbVie has not been provided with notice of the topics or scope of the testimony anticipated by this unnamed witness. Further, fact discovery related to third-party Edelman closed on February 7, 2017 per Case Management Order No. 36.</p>

Plaintiffs' Witness	Objection
3. Jennifer Weissmann (may call – live or via deposition) 1491 High Street Boulder, CO 80304	
4. William Best (may call – via deposition) Endo Pharmaceuticals, Inc. 1400 Atwater Drive Malvern, PA 19355	AbbVie objects to this witness's testimony pursuant to Rules 401, 402, and 403 as the testimony relates solely to another manufacturer who is not a defendant in this case and to a product not used by Plaintiff in this case. Further, this witness's testimony covers the time period 2013-2016, which post-dates the time period relevant to this case. AbbVie also objects to this witness's testimony as his deposition was taken after the fact discovery deadline set for this case of February 7, 2017 by Case Management Order No. 36. AbbVie further objects to this witness's testimony for the reasons set forth in AbbVie's motion <i>in limine</i> I.D. (Evidence, Testimony and Argument Regarding Other Drugs and Other Manufacturers Should Be Excluded under Rules 401, 402 and 403 and 404(b)).

Plaintiffs' Witness	Objection
<p>5. Kathryn Broderick (may call – via deposition) Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285</p>	<p>AbbVie objects to this witness's testimony pursuant to Rules 401, 402, and 403 as the testimony relates solely to another manufacturer who is not a defendant in this case and to a product not used by Plaintiff in this case. Further, this witness's testimony covers the time period 2013-2016, which post-dates the time period relevant to this case. AbbVie further objects to this witness's testimony for the reasons set forth in AbbVie's motion <i>in limine</i> I.D. (Evidence, Testimony and Argument Regarding Other Drugs and Other Manufacturers Should Be Excluded under Rules 401, 402 and 403 and 404(b)).</p>
<p>6. Adrian Dobs, MD, MHS (may call – via deposition) Division of Endocrinology, Diabetes and Metabolism The Johns Hopkins University School of Medicine 1830 E. Monument St, Suite 333 Baltimore, MD 21287</p>	<p>AbbVie objects to this witness's testimony on the grounds set forth in AbbVie's motion <i>in limine</i> II.A. (Plaintiffs Should Not Be Permitted to Convert Expert Deposition Testimony into Fact Testimony to Be Used at Trial).</p>

Plaintiffs' Witness	Objection
<p>7. Laura Grablutz (may call – via deposition) Auxilium Pharmaceuticals, Inc. 640 Lee Road Wayne, PA 19087</p>	<p>AbbVie objects to this witness's testimony pursuant to Rules 401, 402, and 403 as the testimony relates solely to another manufacturer who is not a defendant in this case and to a product not used by Plaintiff in this case. AbbVie further objects to this witness's testimony on the grounds set forth in AbbVie's motion <i>in limine</i> I.D. (Evidence, Testimony and Argument Regarding Other Drugs and Other Manufacturers Should Be Excluded under Rules 401, 402 and 403 and 404(b)).</p>
<p>8. Martin Miner, MD (may call – via deposition) Miriam Hospital 164 Summit Avenue Providence, RI 02906</p>	<p>AbbVie objects to this witness's testimony on the grounds set forth in AbbVie's motion <i>in limine</i> II.A. (Plaintiffs Should Not Be Permitted to Convert Expert Deposition Testimony into Fact Testimony to Be Used at Trial).</p>
<p>9. Kristin (Vitanza) Squires (may call – via deposition) Endo Pharmaceuticals, Inc. 1400 Atwater Drive Malvern, PA, 19355</p>	<p>AbbVie objects to this witness's testimony pursuant to Rules 401, 402, and 403 as the testimony relates solely to another manufacturer who is not a defendant in this case and to a product not used by Plaintiff in this case. AbbVie further objects to this witness's testimony on the grounds set forth in AbbVie's motion <i>in limine</i> I.D. (Evidence, Testimony and Argument Regarding Other Drugs and Other Manufacturers Should Be Excluded under Rules 401, 402 and 403 and 404(b)).</p>

Plaintiffs' Witness	Objection
IV. AbbVie Corporate Witnesses	With respect to the AbbVie witnesses below, AbbVie objects to their testimony to the extent it is cumulative of any other witness at trial.
1. James Hynd (may call – live or via deposition) 741 E Sunnyside Ave. Libertyville, IL 60048	
2. Frank Jaeger (may call – live or via deposition) 1900 W. Larchmont, #2 Chicago, IL60103	
3. Rita Jain (may call – live or via deposition) 1720 Maple Ave., # 2740 Evanston, IL 60201	
4. Michael Miller (may call – live or via deposition) 1835 S. Matthew Ct. Libertyville, IL 60048	
5. Linda Scarazzini (may call – live or via deposition) 2235 W. Belden Av. Chicago, IL 60647	
6. Steven Wojtanowski (may call – live or via deposition) 643 Sheridan Rd. Evanston, IL 60202	
7. Brenda Day Blair (may call – via deposition) 1000 Old Sinking Creek Rd. Greenback, TN 37742	
8. Marty Comer (may call – via deposition) 3375 Indian Hills Dr. Marietta, GA 30068	
9. Melanie Blanchard (may call – via deposition) MediTech Media 2 Ravinia Drive, Suite 605 Atlanta, GA 30346	
10. Christian Conradt (may call – via deposition) Brookstone Rd. Grayslake, IL 60030	
11. Darryl Doebler (may call – via deposition) 1010 Mulford St. Evanston, IL 60202	
12. Michael Gautsch (may call – via deposition) 689 Valley Park Dr. Libertyville, IL 60048	
13. James Hannasch (may call – via deposition) 990 Wynmont Dr. Marietta, GA 30062	

Plaintiffs' Witness	Objection
14. Nader Khan (may call – via deposition) 2508 Hastings Ln. Gurnee, IL 60031	
15. Ronald Robison (may call – via deposition) AbbVie Inc. 1 North Waukegan Road Building AP-34 North Chicago, IL 60064	
16. Andrew Storey (may call – via deposition) 188 Whistler Rd. Highland Park, IL 60035	
17. Tracey (Rockney) Ward (may call – via deposition) 200 Fox Run Rd. Libertyville, IL 60048	

Schedule B

SCHEDULE B TO FINAL PRETRIAL ORDER
ABBVIE WITNESS LIST IN KONRAD

AbbVie's Witness	Objection
I. Case-Specific Witnesses	
1. Jennifer Morrow, MD (will call via deposition) Stern Cardiovascular Center PA 8060 Wolf Rivre Blvd. Germantown, TN 38138	Plaintiffs incorporate by reference Plaintiffs' Omnibus Motion In Limine, including, among other things, their objection to expert testimony by a treating physician where he or she was not disclosed as an expert and/or where there is no foundation for such expert opinions.
2. Steven Todd Overby, MD (will call via deposition) Internal Medicine Baptist Medical Group 8040 Wolf River Blvd., Suite 200 Germantown, TN 38138	Plaintiffs incorporate by reference Plaintiffs' Omnibus Motion In Limine, including, among other things, their objection to expert testimony by a treating physician where he or she was not disclosed as an expert and/or where there is no foundation for such expert opinions.
II. Expert Witnesses	
3. M. Laurentius Marais, Ph.D. (will call -- live) William E. Wecker Associates, Inc. 270 E. Simpson Avenue Jackson, WY 83001	Plaintiffs incorporate by reference Plaintiffs' Omnibus Motion In Limine, including, among other things, their objection to expert testimony beyond the scope of disclosed opinions.
4. Mohit Khera, MD, MBA, MPH (will call -- live) Baylor College of Medicine Medical Center 7200 Cambridge, 10th Floor, Suite B Houston, TX 77030	Plaintiffs incorporate by reference Plaintiffs' Omnibus Motion In Limine, including, among other things, their objection to expert testimony beyond the scope of disclosed opinions.
5. William J. French, MD (will call -- live) Harbor-UCLA Medical Center 1000 West Carson Street Torrance, CA 90509	Plaintiffs incorporate by reference Plaintiffs' Omnibus Motion In Limine, including, among other things, their objection to expert testimony beyond the scope of disclosed opinions.

6. Janet B. Arrowsmith, MD, FACP, FACE (will call -- live) Arrowsmith Consulting, LLC 81B N. Shining Sun Santa Fe, NM 87506	Plaintiffs incorporate by reference Plaintiffs' Omnibus Motion In Limine, including, among other things, their objection to expert testimony beyond the scope of disclosed opinions.
7. Helena Rodbard, MD, FACP, MACE (will call - live) Endocrine and Metabolic Consultants Suite 250 3200 Tower Oaks Blvd. Rockville MD 20852	Plaintiffs incorporate by reference Plaintiffs' Omnibus Motion In Limine, including, among other things, their objection to expert testimony beyond the scope of disclosed opinions.
III. Third-Party Generic Witnesses	
8. Jennifer Weissmann (will call via deposition) 1491 High Street Boulder, CO 80304	
IV. AbbVie Corporate Witnesses	
9. Linda Scarazzini, RPh, MD (will call - live) VP, Global Pharmacovigilance and Patient Safety AbbVie Inc. 1 North Waukegan Road North Chicago, IL 60064	Plaintiffs incorporate by reference Plaintiffs' Omnibus Motion In Limine, including, among other things, their objection to undisclosed expert testimony from fact witnesses.
10. James Hynd (may call -- live) 741 E. Sunnyside Ave. Libertyville, IL 60048	Plaintiffs incorporate by reference Plaintiffs' Omnibus Motion In Limine, including, among other things, their objection to undisclosed expert testimony from fact witnesses.
11. Steven Wojtanowski (may call – live) 643 Sheridan Rd. Evanston, IL 60202	Plaintiffs incorporate by reference Plaintiffs' Omnibus Motion In Limine, including, among other things, their objection to undisclosed expert testimony from fact witnesses.

AbbVie also reserves the right to call in its own case, live or via deposition, any witness called by Plaintiffs. Plaintiffs object to AbbVie's blanket reservation of rights to call any witness called by Plaintiffs.

Schedule C

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

Plaintiffs' General Liability Exhibits

Trial Ex No	Bates Range	Doc Date	Doc Description	Objection Basis	Objection Code
0001	ABBVIE-00020517 - ABBVIE-00020519	2000	"Grow The Market, Grow Your Bonus" internal representative document	401/403	2
0002	ABBVIE-FST00301150 - ABBVIE-FST00301161	4/12/2000	2 Letters; FDA Correspondence: DDMAC Response to Proposed Introductory Promotional Materials, April 12, 2000		
0003	ABBVIE-00016545 - ABBVIE-00016548	2001	2001 Market Plan Summary AndroGel		
0004	ABBVIE-00031999 - ABBVIE-00032021	2001	Module 7: Selling Androgel	401/403	2
0005	ABBVIE-00001177 - ABBVIE-00001180	2001	Questions and Answers Regarding Testosterone Replacement Therapy (TRT)	401/403	2
0006	ABBVIE-FST15258548 - ABBVIE-FST15258711	3/21/2001	AndroGel Training Modules	401/403	2
0007	ABBVIE-00012276 - ABBVIE-00012276	4/8/2001	AndroPause Consensus 2001		
0008	ABBVIE-00022000 - ABBVIE-00022038	4/26/2001	AndroGel Introduction		2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0009	ABBVIE-00109225 - ABBVIE-00109321	6/13/2001	Strategic Overview - Unimed Pharmaceuticals, Inc., Specialized Markets		
0010	ABBVIE-00460193 - ABBVIE-00460193	6/18/2001	AndroGel SMU Presentation		2
0011	ABBVIE-00015219 - ABBVIE-00015228	11/19/2001	EDU-Medical Management, Inc. 2002 Physician Speaker Facilitator Workshops	401/403, Foundation	2 10
0012	ABBVIE-00008555 - ABBVIE-00008556	2002	TOP TEN TOPICS ABOUT TESTOSTERONE REPLACEMENT THERAPY (TRT) - By Unimed Pharmaceuticals; 2002	401/403	2
0013	ABBVIE-00257492 - ABBVIE-00257504	3/12/2002	Outline for 3rd Annual Andropause 2002 Meeting: Standardization of Laboratory Testing & Values	401/403	2
0014	ABBVIE-00315440 - ABBVIE-00315464	10/1/2002	Inter-Office Memorandum re "Interview with Le Figaro re: Marketing of AndroGel in the US"	401/403, 802	2
0015	ABBVIE-00020564 - ABBVIE-00020564	10/28/2002	Permission to Adapt Summary from Consensus Meeting	401/403	2
0016	ABBVIE-FST10840554 - ABBVIE-FST10840626	12/2002	AndroGel 1% CII 2003 POA 1 December 2002		
0017	ABBVIE-00586352 - ABBVIE-00586682	2003	2003 Summer Projects for AndroGel Including Patient and Prescriber Profiles and First-time Prescriber Research Study	401/403	2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0018	ABBVIE-FST08688750 - ABBVIE-FST08688755	6/5/2003	TESTIM, 1% testosterone gel, Marketed by Auxilium Pharmaceuticals, INC, Advertising/Promotional Material, 05 June 2003	401/403	7
0019	ABBVIE-FST01309167 - ABBVIE-FST01309191	1/2004	Review of Long-Term Safety of Testosterone Replacement and Response to the Institute of Medicine Report: "Testosterone and Aging: Clinical Research Direction"		
0020	ABBVIE-00477662 - ABBVIE-00477731	2/24/2004	2004 Primary Care SE Region Business Plan and Executive Summary		
0021	ABBVIE-00632071 - ABBVIE-00632078	8/2004	Pre-IND Meeting Minutes from August 2004 re Pre-IND 69,413		
0022	ABBVIE-00623460 - ABBVIE-00623461	8/12/2004	FDA AndroGel Meeting Synopsis		
0023	ABBVIE-00526570 - ABBVIE-00526579	9/3/2004	Memorandum of Meeting Minutes from August 1, 2004 Type B, Pre-IND		
0024	ABBVIE-00632058 - ABBVIE-00632065	9/3/2004	Meeting Minutes from August 11, 2004 Pre-IND Meeting with FDA regarding seeking combination use with PDE-5; Investigational NDA for AndroGel 1%		
0025	ABBVIE-FST17591913 - ABBVIE-FST17591928	9/7/2004	AndroGel core team draft minutes from 9/1/2004		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0026	ABBVIE- FST14636863 - ABBVIE- FST14636887	9/21/2004	Life Cycle Management Committee Quarterly Project/Product Review		
0027	ABBVIE- FST00041632 - ABBVIE- FST00041638	4/1/2005	Teleconference Meeting Minutes from March 30, 2005 Meeting		
0028	ABBVIE- FST09292410 - ABBVIE- FST09292474	4/4/2005	NIA Request for Information, w/ attachment "Testosterone Supplementation Compilation final version.doc"		
0029	ABBVIE- FST13300783 - ABBVIE- FST13300786	7/26/2005	Pre-Guidance Standby Statement for Review, w/ attachment "Standby Statement for Solvay Review.doc" - with Redline comments	401/403	2 10
0030	ABBVIE- FST13300781 - ABBVIE- FST13300782	7/26/2005	Pre-Guidance Standby Statement for Review		
0031	ABBVIE- FST13300790 - ABBVIE- FST13300826	9/16/2005	Resource Binder, w/ attachment "Guidance binder 8.12.05.doc"	401/403, 802	2
0032	ABBVIE- FST13301416 - ABBVIE- FST13301420	10/28/2005	Project AndroDATA, with Redline attachment Project " Andro TestoDATA"		
0033	ABBVIE- FST00384210 - ABBVIE- FST00384214		Promo materials directing patients to TestYourT.com, including "Suddenly Realized You've Lost Your Libido? Find out more at www.testyourt.com". [Electronic	401/403	2 8
0034	ABBVIE- FST01242853 - ABBVIE- FST01242874	6/26/2006	Issue Analysis Summary: Regulatory Issues Surrounding Testosterone Therapy in Aging Males	401/403, 802, Foundation	4 10

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0035	ABBVIE- FST00055313 - ABBVIE- FST00055324	11/16/2006	Memorandum of Meeting Minutes from October 18, 2006 Type B, End-of-Phase 2 Meeting		
0036	ABBVIE- 00289334 - ABBVIE- 00289427	4/6/2007	Implementation Meeting 2007 with "June 6 2006v2.ppt" attached	401/403	2 8
0037	ABBVIE- FST09260068 - ABBVIE- FST09230079	5/21/2007	Gender Hormone Meeting Notes; PowerPoint "Regulatory Challenges, Testosterone Therapy in Aging Males" by Daniel A Shames	403, 802	3
0038	ABBVIE- FST00344399 - ABBVIE- FST00344411	10/30/2007	AndroGel Prescribing Information with Redline Edits (and) Solvay Response to "Approvable Letter"		
0039	ABBVIE- FST09269352 - ABBVIE- FST09269353	11/30/2007	Email initially from FDA with proposed changes to the "Adult 1%" prescribing information" [FDA has withdrawn the andropause language]		
0040	ABBVIE- FST13294948 - ABBVIE- FST13294949	12/3/2007	Androgel Prescribing Information; Wojtanowski sending reference materials to John Kim at FDA in support of retaining symptom language in prescribing information, including fatigue, loss of energy, and mood depression.		
0041	ABBVIE- FST13304023 - ABBVIE- FST13304028	2/14/2008	Long term strategy, not slides	403, 802	
0042	ABBVIE- FST00346656 - ABBVIE- FST00346656	2009	Electronic Advertising/Promotional Material: Low T Quiz - A Quiz For Men Only I just don't feel like myself.	401/403, Foundation	2 10

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0043	ABBVIE- FST06253985 - ABBVIE- FST06253987	9/17/2009	TOP OF MIND: September 2009	401/403	2
0044	ABBVIE- FST06097726 - ABBVIE- FST06097788	2010	Screenshots of IsitLowT.com with Voiceovers	401/403	2
0045	ABBVIE- FST02027739 - ABBVIE- FST02027753	3/24/2010	Warning Letter from FDA-DDMAC to Slate Pharmaceuticals re Testopel	401/403, 802, Foundation	7 10
0046	ABBVIE- FST06198443 - ABBVIE- FST06198444	6/18/2010	Calendar Event - Chicago Prep & Endo Guidelines Review		
0047	ABBVIE- FST12131102 - ABBVIE- FST12131107	11/12/2010	Richard's comments on Age Associated Hypogonadism	401/403	1K
0048	ABBVIE- FST02438125 - ABBVIE- FST02438170	11/22/2010	Expired Speaker Bureau Slides w/attachment: "Promo Slides Defining and Diagnosing Low T - Feb 2008.ppt"	401/403	2
0049	ABBVIE- FST09333486 - ABBVIE- FST09333491	12/20/2010	Feedback on AndroGel Visual Aid	401/403	1K
0050	ABBVIE- FST05967587 - ABBVIE- FST05967596	2/14/2011	AndroGel DTC Presentation, w/ attached PowerPoint "AndroGel Direct-to-Consumer Disease Awareness Campaign, 'Motivating Men to get Diagnosed & Treated' Frank Jaeger...on Behalf of the AndroGel Marketing Team"	401/403	1K

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0051	ABBVIE- FST09742568 - ABBVIE- FST09742570	3/11/2011	Upcoming Town Hall Presentations (IMPORTANT -- PLEASE REVIEW)	401/403	1K
0052	ABBVIE- FST14311531 - ABBVIE- FST14311856	3/25/2011	LRP Strategy Review Meeting - April 4- 6 2011, w/ attachment "2011 LRP Strategy Proprietary Products.pdf"	401/403	1K
0053	ABBVIE- FST11262362 - ABBVIE- FST11262393	4/5/2011	AndroGel Unbranded TV Presentation Deck	401/403	1K 2
0054	ABBVIE- FST13278938 - ABBVIE- FST13278981	4/6/2011	AndroGel and [redacted] LRP Strategy Global Pharma LRP Strategy Review Presented by Metabolics & GI Care	401/403	1K
0055	ABBVIE- FST03393664 - ABBVIE- FST03393665	4/18/2011	AndroGel Weekly Report for Week- Ending 4/8/11	401/403	1K
0056	ABBVIE- FST09091689 - ABBVIE- FST09091692	10/18/2011	Trip Report from Mike Miller w/ attachment "Issues in Gender Hormone Therapy"	403, 802	1K 3
0057	ABBVIE- FST02652346 - ABBVIE- FST02652667	2012	2012 AndroGel 1.62% Business Plan	401/403	1K 13 14
0058	ABBVIE- FST06673474 - ABBVIE- FST06673479	1/26/2012	Re Having T-Pain Perform "All I Do Is Win" Live	401/403	1K 2
0059	ABBVIE- FST10970872 - ABBVIE- FST10970882	2/8/2012	Grow & Transition Strategy	401/403	1K 13 14

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0060	ABBVIE-FST00895225 - ABBVIE-FST00895246	3/2012	Testosterone Replacement Therapy: Past, Present and Future March 2012	401/403, Foundation	1K 7 10
0061	ABBVIE-FST14872619 - ABBVIE-FST14872654	4/23/2012	Brand Topics - Complete Deck, w/ attachment "Consumer Brand Topics and Messaging_4-23-12.ppt"	401/403	1K 2
0062	ABBVIE-FST08802148 - ABBVIE-FST08802153	4/30/2012	Brand Discussion Topics	401/403	1K 2
0063		5/7/2012	Corporate Integrity Agreement ("CIA") between the Office of Inspector General of the Department of Health and Human Services and Abbott Laboratories; Executed	401/403; 408; 410	1K 7
0064		5/7/2012	Justice News "Abbott Labs to Pay \$1.5 Billion to Resolve Criminal and Civil Investigations of Off-label Promotion of Depakote" Department of Justice, Office of Public Affairs (re Corp. Integrity Agreement)	401/403; 408; 410; 802	1K 7
0065		5/7/2012	Plea Agreement between United States and Abbott Laboratories; [Rheinfrank - Ex 3 to Defs' MIL (No. 4); Case No. 1:12-cr-00026-SGW (USDC WDVA)]	401/403; 408; 410	1K 7
0066		5/7/2012	Agreed Statement of Facts in United States vs. Abbott Laboratories [Rheinfrank - Ex 4 to Defs' MIL (No. 4); Case No. 1:12-cr-00026-SGW (USDC WDVA)]	401/403; 408; 410	1K 7
0067	ABBVIE-FST00547665 - ABBVIE-FST00547812	6/12/2012	Global Regulatory Strategic and Tactical Plan - AndroGel 1% and 1.62% - Phase 4 - US Only - Canada and Mexico-EPD/Abbott	401/403	1K 13 14

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0068	ABBVIE- FST02393218 - ABBVIE- FST02393245	9/21/2012	2013 AndroGel 1.62% Brand Plan	401/403	1K 13 14
0069	ABBVIE- FST02564644 - ABBVIE- FST02564649	11/7/2013	Testosterone Therapy and CV Risk (Following JAMA Article)	401/403	1 2
0070	ABBVIE- FST02448056 - ABBVIE- FST02448058	1/30/2014	Heart Risk Issue brought up by Sales Reps in the field	802	1
0071	ABBVIE- FST08645657 - ABBVIE- FST08645657	2/5/2014	Testosterone Publication (Original email in string)		
0072	ABBVIE- FST08645658 - ABBVIE- FST08645659	2/5/2014	RE Testosterone Publication (further along in email string)		
0073	ABBVIE- FST02249331 - ABBVIE- FST02249340	7/25/2014	Men's Health Advisory Board July 25, 2014	401/403, Foundation	1 10
0074	ABBVIE- FST02020014 - ABBVIE- FST02020028	8/2014	AndroGel Update Aug 2014	401/403; 802	1
0075	ABBVIE- FST06149563 - ABBVIE- FST06149567	8/7/2014	FW: Briefing Book; w/ attached "TRT Ad Com BB DRAFT MASTER"	401/403	1
0076	ABBVIE- FST02415194 - ABBVIE- FST02415204	8/18/2014	Aug 18 Time Article on TRT	401/403; 802	1 12

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0077	ABBVIE- FST03767426 - ABBVIE- FST03767489	2/10/2015	FDA Letter for AndroGel Team Review	401/403	1
0078		3/3/2015	FDA Drug Safety Communication: Cautions about TRT use for low testosterone due to aging; Requires labeling change re possible increased risk of heart attack and stroke	401/403	1 2
0079	ABBVIE- FST13265040 - ABBVIE- FST13265051	4/16/2015	FDA Call on AndroGel PMR	401/403	1
0080	ABBVIE- FST08687599 - ABBVIE- FST08687600	5/19/2011	Men's Health Awareness PR Campaign	401/403	1K 2
0081	ABBVIE- FST00343814 - ABBVIE- FST00343823		Electronic Advertising/Promotional Material: "He may not be telling you everything that's bothering him"	401/403	2 8
0082	ABBVIE- FST14979754 - ABBVIE- FST14979824		Marty Trent Comer National Sales Director Cardio-Metabolic Specialty & Gastroenterology	401/403	1 5
0083	ABBVIE- FST13208187 - ABBVIE- FST13208211		Lyrics for T-Pain's "All I Do Is Win" performance with AndroGel-related lyric substitutions	401/403	1K 2
0084	ABBVIE- FST02567236 - ABBVIE- FST02567239		<u>Author</u> : Tracy Rockney Ward <u>CreateDate</u> : 9/10/2014 <u>FileName</u> : Strategic QAs TR draft	401/403	1 13 14
0085	ABBVIE- FST01077066 - ABBVIE- FST01077077		Signal Evaluation Report - Step 2 Report Number: S06_TEST_Thromboembolism_10MA R2007_Step2		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0086	ABBVIE- FST01076952 - ABBVIE- FST01077030		Signal Evaluation Report - Step 2 Report Number: S12_TEST_MYOCARDIAL ISCHEMIA_02MAR2010		
0087	ABBVIE- FST01076761 - ABBVIE- FST01076951		Signal Evaluation Report - Step 2 Report Number: S15_TEST_ArterialThromboembolism _22OCT2010		
0088	ABBVIE- FST14633846 - ABBVIE- FST14633848				
0089	ABBVIE- 00445219 - ABBVIE- 00445264		EDU-MEDICAL MANAGEMENT, INC. Medical Education Transition	401/403, 802	2
0090	ABBVIE- 00301105 - ABBVIE- 00301108	9/10/2001	8/20/01 Check Request Form; 11/3/00 Letter to Shalender Bhasin re Study of Testosterone on Physical Function and Atherosclerosis Progression in Older Males		
0091	ABBVIE- 00050490 - ABBVIE- 00050513	8/26/2002	IMPORTANT! AndroGel - CBeck Programs	401/403	2
0092	ABBVIE- 00098352 - ABBVIE- 00098358	12/14/2004	2004 Media Highlights and Outreach Programs		
0093	ABBVIE- FST15551742 - ABBVIE- FST15551752	6/28/2011	Fully-executed Contract Notification: Contract #46335 with Glenn R Cunningham	401/403	1K 2
0094	ABBVIE- FST06093253 - ABBVIE- FST06093272	2/2014	Promo Material: "let's be clear there's a reason it's worth looking for and accurately diagnosing hypogonadism his name is Dave"	401/403	1 2 13 14

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0095	ABBVIE-FST11224843 - ABBVIE-FST11224855	8/18/2014	Email with Professional Services Agreement (Consulting Agreement) between AbbVie and Shalender Bhasin re assisting and preparing for, and presenting at Advisory Committee Meeting	401/403	1 2
0096	ABBVIE-00576915 - ABBVIE-00576989	12/01/2002	Androgel 1% - 2003 Business Plan		
0097	ABBVIE-00111163 - ABBVIE-00111186	2005	2005 Objectives Solvay Pharmaceuticals		2
0098	ABBVIE-FST06271893 - ABBVIE-FST06271896	3/29/2010	Solvay Field Contact Report Dr. Smith	401/403	2
0099	ABBVIE-FST02420553 - ABBVIE-FST02420559	11/2012	The Consumer's Low-T Journey	401/403, Foundation	1K 2 10
0100	ABBVIE-FST06534319 - ABBVIE-FST06534385	9/21/2012	Cardiovascular Care AndroGel 1.62% Training: Guest Trainer Preparation; w/ <u>Materials</u> : AndroGel CV Care Leaders' Guide Grow Awareness Message Map Disease State Education Guidelines AndroGel 1.62% PI Label Change Highlight Model Messaging Messaging Guidelines iPad Seek and Find Transition Call Flashcard Competitor Clinical Snapshots AndroGel 1.62% Validation Sheet	401/403	1K 13 14

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0101	ABBVIE- FST08856415 - ABBVIE- FST08856422		Brand Discussion Topics April - November 2012	401/403	1K 2
0102	ABBVIE- FST12493386 - ABBVIE- FST12493387	1/28/2014	RM Webex Follow-Up (Communication Points) sent to Comer for his Review	401/403	1 5
0103	ABBVIE- FST08651246 - ABBVIE- FST08651260	4/30/2014	Important Drug Information Slide Deck and Sales Force FAQ Documents - FOR MANAGERS ONLY	401/403	1 4
0104	ABBVIE- FST00345964 - ABBVIE- FST00345965	1/9/2009	Screenshots of website pages from Is it Low T.com	401/403	2
0105	ABBVIE- 00243022 - ABBVIE- 00243044	4/20/2006	AndroGel 1% CIII Overview, Draft PowerPoint by Jim Hynd	401/403	2 8
0106	ABBVIE- FST08694885 - ABBVIE- FST08694887	8/20/2013	Waterfall Data Notes Final, from meeting with Snabes, w/ attachment "Waterfall Data Med Review and GMA Notes"	401/403	1 2 10
0107	ABBVIE- 00120049 - ABBVIE- 00120050	9/4/2007	RE I-Detail Update	401/403	2
0108	ABBV-PERS- 011362 - ABBV- PERS-011366		Curriculum Vitae of Ronald O Robison		
0109	ABBVIE- 00465272 - ABBVIE- 00465286	3/30/2001	2000 SMU Marketing Awards	401/403	2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0110	ABBVIE-FST00000929 - ABBVIE-FST00000932	4/25/1997	Letter from DDMAC to David Riggs re March 31, 1997 News Release "Unimed Begins Pivotal Clinical Trial For Innovative Testosterone Gel" in Violation of the FD&C Act.	401/403	2
0111	ABBVIE-FST01270323 - ABBVIE-FST01270326	8/16/2002	RE: Prevent Disease.com - NEWS - Prevention - Wellness - Health - Exercise - Fitness	401/403	2
0112	ABBVIE-FST00896934 - ABBVIE-FST00896977		Testosterone - Cardiology, Hematology and Nephrology Made Rediculously Simple 101 Michael G Miller, PharmD	401/403	13 14
0113	ABBVIE-FST00377387 - ABBVIE-FST00377391	4/29/2005	Approvable Letter for NDA 21-015 Supplement 011 from Shames, FWD by John C. Kim to "Regulatory Submissions" re NDA Supplement to include labeling language re "A Long-Term Study of the Safety and Effectiveness of Testosterone-Gel for Hormonal Replacement in Hypogonadal Men"		
0114	ABBVIE-FST00045011 - ABBVIE-FST00045345	9/9/2005	Attachment C to "The Safe Use of Testosterone Replacement Therapy in Hypogonadal Men". White Paper, Vol 6		
0115	ABBVIE-FST00008733 - ABBVIE-FST00009080	9/15/2006	General Correspondence: Type-B Meeting Briefing Book		13 14
0116	ABBVIE-00509542 - ABBVIE-00509588	9/5/2007	Blue Ocean Analysis	401/403	2 5 8
0117	ABBVIE-FST00013091 - ABBVIE-FST00013487	7/14/2008	AndroGel 1% and 1.62% Annual Report to FDA	401/403 (redaction)	13 14

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0118	ABBVIE-FST01029831 - ABBVIE-FST01029849		Signal Evaluation Report - Step 2 Report Number: S15_TEST_ArterialThromboembolism_22OCT2010		
0119	ABBVIE-FST01730935 - ABBVIE-FST01731173	11/7/2013	Urgent Literature Search Request for AndroGel w/ Attached AbbVie Library Search Results	401/403	1
0120	ABBVIE-FST02262776 - ABBVIE-FST02262869	1/31/2006	Appropriate Treatment of Male Hypogonadism of Any Etiology		
0121	ABBVIE-FST01467669 - ABBVIE-FST01467687		Signal Evaluation Report - Step 2 Report Number: S14_TEST_VenousThromboembolism_22OCT2010		
0122	ABBVIE-FST01469866 - ABBVIE-FST01469988	7/9/2014	Handwritten Notes	401/403	1
0123	ABBVIE-00165270 - ABBVIE-00165296	3/24/2003	Letter serving as permission from the Endocrine Society for development and distribution of an adaption for the Summary of the Second Annual Andropause Consensus 2001 meeting.	401/403, Foundation	2 10
0124	ABBV-PERS-000781 - ABBV-PERS-000797		Curriculum Vitae of Michael Gregory Miller, PharmD		
0125	ABBVIE-FST00298337 - ABBVIE-FST00298345	4/10/1999	AndroGel Integrated Summary of Benefits and Risks		
0126	ABBVIE-FST00384458 - ABBVIE-FST00384683	8/16/2006	Inter-Office Memorandum re "AndroGel NDA 21-015 Original NDA Application (Volumes 1-61 of 61; Unimed volumes 1.1-1.61 of 61)"		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0127	ABBVIE-FST00299595 - ABBVIE-FST00299595	10/17/1999	FDA Contact Report re "Androgel - FDA Requests for 1) Electronic PK Information/Data and 2) Change in Protocol UMD-98-035 (Elevated Hematocrit Associated with Secondary Polycythemia)"		
0128	ABBVIE-FST00362623 - ABBVIE-FST00362641	11/8/2002	AndroGel Patient and Physician Package Insert		
0129	ABBVIE-00108170 - ABBVIE-00108170	2/6/2004	FW: IOM Physicians - "some interesting news from an OTL affiliated with the IOM from SLC, Utah.	401/403	2
0130	ABBVIE-FST00912726 - ABBVIE-FST00912751	9/13/2012	Summary of Additional Qualitative Work on the Hypogonadism Impact of Symptoms Questionnaire (HIS-Q): Inclusion of Congenital Hypogonadism Patients and Confirmation of Changes Among Patients with Acquired Hypogonadism	401/403	1K 13 14
0131	ABBVIE-FST09259140 - ABBVIE-FST09259141	10/28/2004	Proposal titled "Androgen Supplementation for the Treatment of Anemia in Patients with Chronic Kidney Disease"	401/403	10 13 14
0132	ABBVIE-FST09277211 - ABBVIE-FST09277212	4/1/2005	Results of the FDA Teleconference; Original email from Scott Segal		
0133	ABBVIE-FST01237048 - ABBVIE-FST01237055		Solvay Pharmaceuticals, Inc. AndroGel Advisory Board Meeting September 25-26, 2005 Chicago, IL - w/ Redline comments		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0134	ABBVIE-FST09257701 - ABBVIE-FST09257707	11/17/2005	SSRB Review (Response/comments ["Recommendations for Consideration"] to recently issued Endocrine Society's Draft Guidelines for Testosterone Replacement)		
0135	ABBVIE-FST09248133 - ABBVIE-FST09248133	1/30/2006	Canadian Revisions of the AndroGel White Papers (Tx and Safety)	401/403	2 4
0136	ABBVIE-FST00301150 - ABBVIE-FST00301161	4/12/2000	Letter from DDMAC in response to Unimed 3/21/2000 request for comments on proposed introductory promotional materials for AndroGel		
0137	ABBVIE-FST00344410 - ABBVIE-FST00344411	10/30/2007	Solvay "Response to Approvable Letter" with "A summary of changes proposed by Solvay are as follows"		
0138	ABBVIE-FST02403206 - ABBVIE-FST02403208	7/8/2014	RE Advisor Update	401/403	1
0139	ABBVIE-FST09083993 - ABBVIE-FST09083994	7/11/2012	Question re: AndroGel 1.62% History ("Following the approval of Testim (2003 or 04) and AndroGel (2000), the FDA no longer considered clinical endpoints such as mood, sexual desire, BMD, etc...for inclusion in labels for testosterone replacement therapies.")	401/403	1K 2 13 14
0140	ABBVIE-FST00009094 - ABBVIE-FST00009102	10/16/2006	IND 50,377 testosterone gel 1.62% - FDA's draft responses to Solvay's EOP2 meeting questions (Also sent via Facsimile directly to Steven Wojtanowski)		
0141	ABBVIE-FST13809327 - ABBVIE-FST13809339	7/7/2015	Final 2016 AndroGel 1.62% Strategic Plan	401/403	1 13 14

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0142	ABBVIE- FST13810811 - ABBVIE- FST13810818	5/13/2015	2016 Strategic Plan Draft Document for Tomorrow's IBT Workshop	401/403, Foundation	1 10 13 14
0143	ABBVIE- FST00864346 - ABBVIE- FST00864356	7/27/2014	Ad Board Notes	401/403	1
0144	ABBVIE- FST08845609 - ABBVIE- FST08845624	8/13/2014	TRT Advisory Committee Q&A Prep - Ad/Promo, etc. - Part 2	401/403	1 2
0145	ABBVIE- FST02273772 - ABBVIE- FST02273780	9/11/2014	AbbVie/Testosterone Sponsor Group	401/403, 802	1
0146	ABBVIE- FST06111804 - ABBVIE- FST06111807	9/18/2014	Testosterone FDA Advisory Committee, Summary	401/403	1
0147	ABBVIE- FST02242341 - ABBVIE- FST02242344		Promo w/ Gas Gauge "Low Testosterone is associated with sexual dysfunction and depressed mood"	401/403, Foundation	2 10
0148	ABBVIE- FST02243029 - ABBVIE- FST02243036	8/2013	HCP Promo Materials - Starting the Conversation: Talking to your patients about male hypogonadism A guide for nurse practitioners and physician assistants	401/403	1 2
0149	ABBVIE- FST00346361 - ABBVIE- FST00346362	5/2009	HCP Promo Materials - Recharge Testosterone Levels with the #1- Prescribed TRT What your patients do next is up to them	401/403	2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0150	ABBVIE-FST08782398 - ABBVIE-FST08782405	2011	Electronic Advertising/Promotional Material: Screenshots of T-Talk Tune Up website pages - Abbott	401/403	1K 2
0151	ABBVIE-FST00346806 - ABBVIE-FST00346806		Electronic Advertising/Promotional Material: Screenshot of Solvay AndroGel website page "Treating Low T may help improve his Low T symptoms"	401/403, Foundation	2 8 10
0152	ABBVIE-FST00383506 - ABBVIE-FST00383517	4/20/2006	Electronic Advertising/Promotional Material: "See what he can regain from your prescription choice"	401/403	2 8
0153	ABBVIE-FST00378322 - ABBVIE-FST00378329		Electronic Advertising/Promotional Material: "Get him above the line and help him regain what he's lost"	401/403	2
0154	ABBVIE-FST00345992 - ABBVIE-FST00345999	1/2009	Electronic Advertising/Promotional Material: "Why Low T should be on your radar"	401/403	2 8
0155	ABBVIE-FST00346087 - ABBVIE-FST00346089	1/20/2009	Electronic Advertising/Promotional Material: "Is it Low T?"	401/403, Foundation	2 10
0156	ABBVIE-FST13794894 - ABBVIE-FST13794898		Abbott - Story Outline for Innovation Summit Story: Challenger Rep; Storyteller: Rob Kunis AndroGel MESSAGING GUIDELINES Rep training document [852-963901]	401/403, Foundation	2 10 13 14
0157	ABBVIE-FST13801236 - ABBVIE-FST13801257	4/2/2015	April AndroGel IBT Overview and Action Items - 2016 Strategic Brand Planning	401/403	1 13 14

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0158	ABBVIE- FST05971342 - ABBVIE- FST05971373	1/28/2011	Public Affairs Documents - Scenario Planning and 1.62% Playbook	401/403	1K 2 13 14
0159	ABBVIE- FST15013236 - ABBVIE- FST15013244	5/16/2011	Final 1.62% Sales Aid/Visual Aid	401/403	1K 2 8 13 14
0160	ABBVIE- FST06346158 - ABBVIE- FST06346202	7/2/2014	Important Drug Information Letter Deck and Supporting Documents; Including Electronic Version of Letter and Communication Plan	401/403	1
0161	ABBVIE- FST08633252 - ABBVIE- FST08633261	1/20/2011	Wallstreet Journal Today w/ attachment "2010 AndroGel Speaker Analysis_1 20 11"	401/403	1K 2
0162	ABBVIE- FST05982199 - ABBVIE- FST05982240	2/28/2013	Men's Health 2013 KOL Plan FINAL and KOL Plan Tracker FINAL	401/403	1 2
0163	ABBVIE- FST02430117 - ABBVIE- FST02430121	2/6/2014	Today's NYT op-ed (Overselling Testosterone, Dangerously) is even worse	401/403, 802	1 12
0164	ABBVIE- FST10970530 - ABBVIE- FST10970532	5/18/2013	Urgent KOL Request	401/403	1 2
0165	ABBVIE- FST08649005 - ABBVIE- FST08649006	10/1/2010	Low Testosterone SMT Update	401/403	1K 2 8
0166	ABBVIE- FST02441623 - ABBVIE- FST02441626	10/22/2010	Hypogonadism and Epidemiology, Section	401/403, foundation	2 10

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0167	ABBVIE-FST02535397 - ABBVIE-FST02535452	1/3/2013	Boost App Plan for 2013 w/ attachment "AndroGel 1.62% Brand Plan Presentation Hynd FINAL_8 23 12.ppt"	401/403	1 13 14
0168	ABBVIE-FST02534968 - ABBVIE-FST02534991	3/5/2013	RE: Can you send me the most current approved DSA slide deck? Thanks. EOM w/ attachment "852- 729515 Androgel Unbranded Speaker Slide Kit w Disclosure - Modified <u>1 11 12 LCK.ppt</u> "	401/403	1 2
0169	ABBVIE-FST02436130 - ABBVIE-FST02436151	1/4/2013	Summit Nomination Files - AbbVie Commercial Summit All Star Awards - AndroGel 1.62% FINAL_1 2 13.docx 2012 Summit Submission - AndroGel 1.62% & Men's Health FINAL_1 2 13.ppt	401/403	1 13 14
0170	ABBVIE-FST02428448 - ABBVIE-FST02428459	5/2011	The Restoration Program What is Low Testosterone?	401/403	1K 2
0171	ABBVIE-FST06071896 - ABBVIE-FST06071922	8/15/2011	AndroGel 1.62% Acceleration Strategy - Need Feedback ASAP	401/403	1K 5 13 14
0172	ABBVIE-FST06583028 - ABBVIE-FST06853055	11/13/2011	Q4 '11 Metabolic IC Plan and SPIFF (AndroGel Launch Incentive Plan) Documents	401/403	1K 2 5 13 15
0173	ABBVIE-FST05969864 - ABBVIE-FST05969865	10/15/2010	AndroGel Planning Meeting Update	401/403	1K 2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0174	ABBVIE-FST06274802 - ABBVIE-FST06274803	9/24/2010	AndroGel Q4, 2010 District Meeting Information and Material, w/ attachments " 851-449503 DSA Patient Type Flashcard Rep Ed FINAL_9 23 10.ppt", "AndroGel District Meeting Leader's Guide & Agenda_Q4 2010.pdf", "AndroGel District Meeting Leader's Guide POA_Q4 2010.pdf", and "AndroGel District Meeting FAQs_Q4 2010.pdf"	401/403	1K 2
0175	ABBV-PERS-004841 - ABBV-PERS-004844		Curriculum Vitae of Tracy D. Rockney, JD		
0176	ABBVIE-FST08711132 - ABBVIE-FST08711132		Football Psych-up Sales Force Video re "All In" and "Not in This House/Protect This House" with Marty Comer as Coach of 1.62% Team; [Length - 1:53] <u>FileName:</u> <i>Protect_This_House_FINAL.wmv</i>	401/403	2 13 14
0177	ABBVIE-FST06002237 - ABBVIE-FST06002237		Do you feel like a Shadow of Your Former Self? (Disease Awareness) Commercial (Basketball); [Length - 0:32] <u>FileName:</u> <i>NEW Is it Low T</i>	401/403	2M
0178	ABBVIE-FST08781943 - ABBVIE-FST08781943		June is Men's Health Awareness Month (Racing/NASCAR Theme) - T Talk Tune Up Commercial with Terry Labonte and Dr. Fisch; [Length - 0:57] <u>FileName:</u> <i>AndroGel_MensHealth_Labonte_video.wmv</i>	401/403	2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0179	ABBVIE- FST08704201 - ABBVIE- FST08704201		Interview with Dr. Harry Fisch on WSFA News 12 Alabama Live "Get your guy to the doc!" Discusses "risks" for having low testosterone, plugs his book "The Male Biological Clock"; [Length - 4:36] FileName: <i>SMT2_9_27_10.wmv</i>	401/403	2
0180	ABBVIE- FST00345927 - ABBVIE- FST00345927	12/16/2008	DTC Patient Targeting Commercial - "If you're a male with Diabetes"; [Length - 1:30] FileName: <i>Diabetes Health Network Video.mov</i>	401/403	2 8
0181	ABBVIE- FST13171591 - ABBVIE- FST13171595	7/12/2013	July 2013 National Call	401/403, 408, 410	1 7 13 14
0182	ABBVIE- FST12051278 - ABBVIE- FST12051288		Is Low T Making Your Patient Feel Like a Shadow of His Former Self?	401/403	1K 2
0183	ABBVIE- FST08970250 - ABBVIE- FST08970302	9/23/2014	2015 Tactical Plan Presentation	401/403	1 13 14
0184	ABBVIE- 00009520 - ABBVIE- 00009522	10/10/2003	Cunningham Slide Sets		
0185	ABBVIE- FST02535397 - ABBVIE- FST02535452	1/3/2013	Annual AndroGel Sales Figures: 2001 - 2012	401/403	5 13 14
0186	ABBVIE- FST08642938 - ABBVIE- FST08642988	4/19/2011	Annual AndroGel Sales Figures: 2010	401/403	1K 13 14

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0187	ABBVIE-FST08648133 - ABBVIE-FST08648135	6/6/2012	Annual AndroGel Sales Figures: 2011		1K 8
0188	ABBVIE-FST15700742 - ABBVIE-FST15700903	1/11/2016	Annual AndroGel Sales Figures: 2014 - 2015	401/403	1 5
0189	ABBVIE-FST09885363 - ABBVIE-FST09885366	4/11/2013	2013 04 11-Sidetracked by CIA	401/403; 408; 410	1 7
0190	ABBVIE-FST09402257 - ABBVIE-FST09402260	4/1/2013	2013 04 01-Admin Burden Overwhelming	401/403; 408; 410	1 2 7
0191	ABBVIE-FST10717291 - ABBVIE-FST10717292	4/28/2011	2011 04 28-Launch Meeting Ideas Email	401/403	1K 13 14
0192	ABBV-PERS-004553 - ABBV-PERS-004554		Curriculum Vitae of Marty Comer		
0193	ABBVIE-FST05326754 - ABBVIE-FST05327018		Annual AndroGel Sales Figures: 2012 - 2013	401/403	1 5
0194	ABBV-PERS-004840 - ABBV-PERS-004840	2/16/2012	APEX Results for 2011 and Incentive Plan Payment	401/403	1K 5
0195	ABBV-PERS-004835 - ABBV-PERS-004835	2/14/2013	APEX Results for 2012 and Incentive Plan Payment	401/403	1K 5
0196	ABBV-PERS-004836 - ABBV-PERS-004837		2013 Annual Rewards Summary for Marty Comer	401/403	1 5

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0197	ABBVIE-00583770 - ABBVIE-00583837		AndroGel 2001 Media Analysis	401/403, Foundation	2 10
0198	ABBVIE-00303229 - ABBVIE-00303243	3/2003	AndroGel Strategic Product Guidelines March 2003		
0199	ABBVIE-FST06007700 - ABBVIE-FST06007711	2012	Title: "For patients with hypogonadism, AndroGel 1.62% is designed with a man in mind" Doc Name: 852-840939 HCP Leave Behind 2012	401/403	1K 2 13 14
0200	ABBVIE-FST15052822 - ABBVIE-FST15052881	9/15/2014	Promotion and Education Slide Deck	401/403	1 2
0201	ABBVIE-FST11262909 - ABBVIE-FST11262915	7/1/2011	FINAL 2012 AndroGel 1.62% Brand Plan	401/403	1K 13 14
0202	ABBVIE-FST05966966 - ABBVIE-FST05966983	9/11/2014	TRT AdComm Meeting ESC Slides w/ Mock 1 Summary for Final Review	401/403	1 10
0203	ABBVIE-FST12046664 - ABBVIE-FST12046665	11/7/2013	Objection Handler Talking Points for Representatives [852-1327110]	401/403	1 2
0204	ABBVIE-FST15261304 - ABBVIE-FST15261304	11/21/2014	"A thought" email for brainstorming	401/403	1
0205	ABBVIE-FST12167101 - ABBVIE-FST12167124	4/28/2011	AndroGel DTC Exemption w/ Memo	401/403	1K 13 14

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0206	ABBVIE-FST14305251 - ABBVIE-FST14305263	6/2/2013	Embargoed: JAMA Internal Medicine, w/ attached articles and Review Policies via "Backgrounder"	401/403	1
0207	ABBVIE-FST08781176 - ABBVIE-FST08781184	6/2011	AndroGel Business Review June 2011	401/403	1K 8
0208	ABBVIE-FST13396229 - ABBVIE-FST13396231	4/16/2015	Executive Labeling Committee ("ELC") - Meeting Minutes	401/403	1
0209	ABBVIE-FST08777495 - ABBVIE-FST08777526	6/24/2011	AndroGel Business Review - 2012 AndroGel 1.62% Brand Planning Update by Michael Gautsch	401/403	1K 13 14
0210	ABBVIE-00000710 - ABBVIE-00000725	3/2004	"In the Treatment of Low Testosterone (Low T) What does his body language say to you?" - "Listen Up for Low T" [Print Ad].	401/403	2
0211	ABBVIE-FST01459642 - ABBVIE-FST01459690		Draft Question and Response reference slides, primarily emphasizing proper responses to TRT Benefits questions		
0212	ABBVIE-FST15447087 - ABBVIE-FST15447122		AndroGel US Advertising & Promotion Regulatory History Document; Version 5 [RAQST-USRH-00002EN]	401/403	1 2
0213	ABBVIE-FST01440058 - ABBVIE-FST01440068	7/27/2014	Ad Board Notes - Draft/compilation notes by Gennadiy and Henri	401/403, 802	1
0214	ABBVIE-FST15736467 - ABBVIE-FST15736550		Men's Health Advisory Board Meeting	L401/403	1

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0215	ABBVIE-FST15742476 - ABBVIE-FST15742579	12/7/2015	Protocol Comments, w/ attachment "MCS on MGM studyTRT CV_- Protocol-description-Draft 1 5 .12.7.15.docx", a DRAFT Clinical Study Protocol Document with Redline comments regarding language/content for TRT Clinical	401/403, Foundation	1 10
0216	ABBVIE-FST01455939 - ABBVIE-FST01455957	9/24/2013	Metabolic CSM Team Meeting NYC Medical Affairs, Men's Health, Michael Snabes	401/403	1 13 14
0217	ABBVIE-FST06175831 - ABBVIE-FST06175834	8/10/2014	Briefing Book; Comments provided by Dr. Janet Wittes of Statistics Collaborative, Inc.	401/403	1
0218	ABBVIE-FST06174907 - ABBVIE-FST06174911	8/7/2014	Briefing Book; Comments provided by Sean Hennessy of the University of Pennsylvania	401/403	1
0219	ABBVIE-FST01906839 - ABBVIE-FST01906892	2/15/2000	Center for Drug Evaluation and Research (CDER); Application No. 21-015 MEDICAL REVIEW		
0220	ABBV-PERS-000003 - ABBV-PERS-000004		Curriculum Vitae of Christian Conradt		
0221	ABBVIE-FST08933744 - ABBVIE-FST08933755	4/15/2010	<u>Title</u> : Pharmacovigilance Safety Signal Process <u>Doc ID</u> : Q-13-07 <u>Doc Type</u> : Process		
0222	ABBVIE-FST11273956 - ABBVIE-FST11273977	12/15/2014	<u>Title</u> : Planning and Generating an Assessment of Benefit-Risk <u>Doc ID</u> : Q-15-01-020 <u>Doc Type</u> : Standard Operating Procedure	401/403	1

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0223	ABBVIE-FST08857086 - ABBVIE-FST08857089	8/14/2013	RE Waterfall Data Notes KVA, w/ attachment "Waterfall Data Notes KVA.MK.doc"; Redline comments by Mary Klema added to Kanika Agrawal's doc	401/403	1 2 10
0224	ABBV-PERS-009781 - ABVV-PERS-009783		Curriculum Vitae of Andrew Storey		
0225	ABBV-PERS-004495 - ABVV-PERS-004505	2015	Curriculum Vitae of Linda J Scarazzini, RPh, MD		
0226	ABBVIE-FST11273389 - ABBVIE-FST11273405	10/18/2015	<u>Doc ID:</u> Q-15-01-002 <u>Doc Type:</u> Standard Operating Procedure <u>Title:</u> Safety Monitoring	401/403	1
0227	ABBVIE-FST11273415 - ABBVIE-FST11273428	6/7/2015	<u>Doc ID:</u> Q-15-01-002-W005 <u>Doc Type:</u> Guideline <u>Title:</u> Safety Surveillance Framework	401/403	1
0228	ABBVIE-FST14754948 - ABBVIE-FST14754958	11/6/2015	<u>Doc ID:</u> Q-15-01-002-W008 <u>Doc Type:</u> Guideline <u>Title:</u> Case Series Analysis	401/403	1
0229	ABBVIE-FST00859316 - ABBVIE-FST00859606	12/16/2013	Androgel, with Testosterone Gel 1.62% Summary of Clinical Safety attached; "summary-clin-safety_1.62%.pdf"	401/403	13 14
0230	ABBVIE-FST01468985 - ABBVIE-FST01468987	11/13/2013	Potential Signal Identification and Investigation Report - (Step 1) [Q-15-01-002-F01]; Executed by Robert Reder on November 13, 2013	401/403	1

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0231	ABBVIE-FST00859004 - ABBVIE-FST00859040	2/4/2014	AndroGel 1% and AndroGel 1.62% "Association of Testosterone Therapy with Mortality, Myocardial Infarction, and Stroke in Men with Low Testosterone Levels" (Systematic Review following Vigen et al.) [Review Approved by Linda J Scarazzini]		
0232	ABBVIE-FST02255293 - ABBVIE-FST02255310		Signal Evaluation Report - Step 2 Report Number: S14_TEST_VenousThromboembolism_22OCT2010		
0233	ABBVIE-FST13973073 - ABBVIE-FST13973307	11/7/2013	Suspect Adverse Reaction Report CIOMS Forms (AERs returned for SMQ query described on P.1)	401/403	1
0234	ABBVIE-FST13033494 - ABBVIE-FST13033658	11/7/2013	Suspect Adverse Reaction Report CIOMS Forms (AERs returned for SMQ query described on P.1)	401/403	1
0235	ABBV-PERS-004987 - ABBV-PERS-004994	2002	2002 Exempt Performance Appraisal, Core and Functional Competency Review - Part I, for Steven Wojtanowski	401/403	4 5 7
0236	ABBV-PERS-004845 - ABBV-PERS-004849		Curriculum Vitae of Steven A. Wojtanowski, RPh, MPH		
0237	ABBVIE-FST15872903 - ABBVIE-FST15872909	8/12/2000	(Letter Via Facsimile) RE NDA 21-015 AndroGel; DDMAC comments in response to introductory promotional materials submitted by Unimed		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0238	ABBVIE-FST00377392 - ABBVIE-FST00377395	4/29/2005	Letter from FDA to Solvay in response to supplemental application submission proposing changes to product labeling to reflect study "A Long-Term Study of the Safety and Effectiveness of Testosterone-Gel for Hormonal Replacement in Hypogonadal Men"		
0239	ABBVIE-FST14618379 - ABBVIE-FST14618385	4/21/2005	Working Action Plan - Class Labeling, with Testosterone Class-Labeling ("CL") Response Team Working Action Plan, 21 April 2005 attached		
0240	ABBVIE-FST14633926 - ABBVIE-FST14633932	6/28/2005	Testosterone Class-Labeling Response Team Working Action Plan, 28 June 2005; meeting summary		
0241	ABBVIE-FST13279885 - ABBVIE-FST13279885	9/12/2014	Malaysia; re AndroGel White Paper	401	4
0242	ABBVIE-FST14633933 - ABBVIE-FST14633939	7/5/2005	Testosterone Class-Labeling Response Team Working Action Plan, 05 July 2005; meeting summary		
0243	ABBVIE-FST14633831 - ABBVIE-FST14633835	1/3/2006	Testosterone Class-Labeling Response Team Working Action Plan, 03 January 2006; meeting summary		
0244	ABBVIE-FST13298790 - ABBVIE-FST13298790	5/13/2005	Final Draft Outlines	Foundation	10
0245	ABBVIE-FST13300973 - ABBVIE-FST13300974	7/5/2005	Snapshot of OTL comments so far, w/ Native Excel spreadsheet printed to PDF	802	

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0246	ABBVIE- FST13290666 - ABBVIE- FST13290666	4/20/2010	RE Warning Letter	401/403	2 8
0247	ABBVIE- FST08802326 - ABBVIE- FST08802359	3/24/2010	FDA Warning Letter Re Testopel Pellets (Printed via FDA.gov) and "Reclaim Your Life" Testopel product brochure	401/403, 802, Foundation	7 10
0248	ABBVIE- 00010854 - ABBVIE- 00010854	2001	Doctor leave behind "For many hypogonadal men CLINICAL PERFORMANCE IN A PACKET"	401/403	2
0249	ABBVIE- 00010892 - ABBVIE- 00010892		HIV/AIDS-Targeted promo material "When you hear low testosterone, answer with AndroGel"	401/403, Foundation	2 8 10
0250	ABBVIE- 00296224 - ABBVIE- 00296225	3/27/2007	AndroGel Class-Labeling		
0251	ABBVIE- FST00304607 - ABBVIE- FST00304619	10/22/2007	"Approvable Letter" from FDA following Solvay supplemental NDA(s) submitted 4/17/2007, 4/18/2007, and 8/30/2007, with approvable product labeling enclosed		
0252	ABBVIE- FST13279415 - ABBVIE- FST13279451	2010	Pharmaceutical Products Group 2010 Long Range Plan	401/403	4 5
0253	ABBVIE- FST13278936 - ABBVIE- FST13278936	3/8/2011	Product Priority for 2011		
0254	ABBVIE- FST02279925 - ABBVIE- FST02280060	3/1/2000	Re: AndroGel; General Correspondence - Proposed Introductory Promotional Materials		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0255	ABBVIE-FST13284504 - ABBVIE-FST13284538	11/13/2009	TA Hormones, w/ attachment "HRM_Global_TA Strategy_Overview_11-12-09_FINAL for ABBOTT.zip"	401/403	2 5
0256	ABBVIE-FST13284338 - ABBVIE-FST13284341	3/9/2010	Follow up from AndroGel promotional material discussion	401/403	7 9
0257	ABBVIE-FST15115674 - ABBVIE-FST15115674		AndroGel 1.62% MESSAGING GUIDELINES; Sales Representative Training Document <u>852-963901</u>	401/403	1K 2 13 14
0258	ABBVIE-FST15121653 - ABBVIE-FST15121666	3/2013	Representative Education Material re "Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men published in the New England Journal of Medicine in July 2010" [852-1098905] (includes copy of article)	401/403	1 2
0259	ABBVIE-FST06027578 - ABBVIE-FST06027583	6/26/2014	FDA Teleconference - Testosterone Advisory Committee	401/403, 802	1
0260	ABBVIE-FST15803219 - ABBVIE-FST15803229	7/1/2014	DRAFT Consulting Agreement between AbbVie and 3D Communications, LLC	401/403, Foundation	1 10
0261	ABBVIE-FST08645002 - ABBVIE-FST08645004	8/8/2014	TRT BB Comments, w/ attachment "Comments on the BB.DOCX"	401/403	1
0262	ABBVIE-FST02566444 - ABBVIE-FST02566489	9/4/2014	TRT FDA Ad Comm Update Sep 5 2014 v4.pptx, w/ attachment [same name as subject]	401/403, Foundation	1 10

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0263	ABBVIE-FST02566219 - ABBVIE-FST02566303	9/5/2014	presentations, w/ attachments "2_-_CORE_-_Hypogonadism_-_Treatment_Guidelines_-_Benefit_C2[1].pptx", "3_-_CORE_-_Potential_CV_Risk_C3[1].pptx", and "4_-_CORE_-_Overall_Summary_and_Recommendations_C4[2].pptx"	401/403, 802, Foundation	1 10
0264	ABBVIE-FST13265053 - ABBVIE-FST13265057	2/12/2015	AndroGel	401/403	1 2
0265	ABBVIE-FST13265091 - ABBVIE-FST13265092	2/10/2015	AndroGel	401/403	1
0266	ABBVIE-FST08853007 - ABBVIE-FST08853021	2/21/2014	FDA Advisory Committee for Testosterone Products: Lessons Learned	40/1403	1 7
0267	ABBVIE-FST00020630 - ABBVIE-FST00020659	12/18/1992	AndroGel NDA Volume Table of Contents; Clinical Expert Report (UMB-98-045) "Androgen Treatment of Abdominally Obese Men"		
0268	ABBV-PERS-004485 - ABBV-PERS-004494		Curriculum Vitae of Rita Jain, MD		
0269	ABBVIE-FST12139903 - ABBVIE-FST12139904	11/7/2013	Scott Brun's Direct Staff Meeting at AP30-3-B	401/403	1
0270	ABBVIE-FST12139921 - ABBVIE-FST12139955		Clinical Developments and Acceptable Practices	401/403; 407; 410	1 7

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0271	ABBVIE- FST12141870 - ABBVIE- FST12141870	7/25/2012	Final AndroGel Portfolio Presentation	401/403	1K
0272	ABBVIE- FST12141871 - ABBVIE- FST12141895	7/2012	2013 Plan GPRD/GHEOR Portfolio Review Portfolio and Strategy Overview - AndroGel July 2012	401/403	1K 2 10 13 14
0273	ABBVIE- FST00433266 - ABBVIE- FST00433274	2/27/2013	Request for Type C Patient Reported Outcomes Meeting AndroGel IND 50,377 February 27, 2013	401/403	1
0274	ABBVIE- FST02245776 - ABBVIE- FST02245783	9/8/2014	Mock 1 Summary, w/ attachment "AbbVie Mock 1 Summary Notes.docx"	401/403	1
0275	ABBVIE- FST02245777 - ABBVIE- FST02245783	9/8/2014	AbbVie/Testosterone Sponsor Group Mock 1 Summary 9/8/2014	401/403	1
0276	ABBVIE- FST09068165 - ABBVIE- FST09068170	8/17/2014	Testosterone Replacement Therapy (TRT) Advisory Committee Meeting	401/403	1
0277	ABBVIE- FST12143723 - ABBVIE- FST12143723	3/24/2011	LRP Slides	401/403	1K 7
0278	ABBVIE- FST12143728 - ABBVIE- FST12143770	4/6/2011	AndroGel and [redacted] LRP Strategy Global Pharma LRP Strategy Review Presented by Metabolics & GI Care Franchise	401/403	1K 5 7 8 13 14

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0279	ABBVIE- FST02553510 - ABBVIE- FST02553517	9/3/2014	FDA Briefing Document: Key Points	401/403	1
0280	ABBVIE- FST02553513 - ABBVIE- FST02553517		FDA Briefing Document: Key Points	401/403	1
0281			Drug Utilization, Industry Recommendations, and Conclusions (Presented by Rita Jain, MD; VP, Global Pharmaceutical R&D Abbvie)	401/403	1
0282	ABBVIE- FST13250481 - ABBVIE- FST13250558	3/24/2014	Context for Tomorrow w/ Ron	401/403	1
0283	ABBVIE- FST14307191 - ABBVIE- FST14307242	5/24/2012	AEM Slide Deck - Please review by 5/29	401/403	1K
0284	ABBVIE- FST09072847 - ABBVIE- FST09072848	1/22/2004	Summary Points from NIA Meeting on Jan 21		
0285	ABBVIE- FST09292923 - ABBVIE- FST09292926	9/27/2006	Funding for NIA Study of Androgel		
0286	ABBVIE- FST02378325 - ABBVIE- FST02378334	7/7/2011	Professional Services Agreement (Consulting Agreement) between Abbott and Abraham Morgentaler re "SLV361 (Oral T) development program" for \$49,500.00.	401/403	1K 7
0287	ABBVIE- FST10400522 - ABBVIE- FST10400606	5/6/2009	Material Transfer Provider Agreement between Solvay and Peter J Snyder for National Institute on Aging Testosterone Trial [U01 AG030644] for \$15,000,000.00		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0288	ABBVIE-FST09176792 - ABBVIE-FST09176801	1/13/2012	KOLs and HEOR Database Work, w/ attachment "Suggested KOLs List for Database Work.doc"	401/403	1K 2
0289	ABBVIE-FST09292833 - ABBVIE-FST09292911	8/7/2006	No Subject-10.EML, w/ attachments "TTrial-Appl-Master.v.19.4.pdf" and "TTrial-Solvay.pdf"	802	
0290	ABBVIE-FST14916703 - ABBVIE-FST14916741	5/23/2012	Additional materials for our 1:1 tomorrow, w/ attachment "AndroGel 1.62% KOL Plan V5.ppt"	401/403	1K 2
0291	ABBVIE-FST09416820 - ABBVIE-FST09417043	9/12/2014	do you have the famous white papers? From back in the day	401/403	1
0292	ABBVIE-FST09680737 - ABBVIE-FST09680740	9/13/2007	NIA Study Group Update (RFI NOT-AG-05-005 Update)		
0293	ABBVIE-FST01311134 - ABBVIE-FST01311137	6/11/2008	9-June-08 NIA Study Group Update (RFI NOT-AG-05-005)		
0294	ABBV-PERS-011393 - ABBV-PERS-011396	2015	Performance Assessment -- 2015 for Ronald O Robison	401/403	1 7
0295	ABBVIE-FST15358174 - ABBVIE-FST15358199	6/28/2013	Jun QBR - Commercial Presentation, with slide deck "AndroGel 1.62% Update Frank Jeager, June 24, 2013	401/403	1 2 5 13 14
0296	ABBV-PERS-005207 - ABBV-PERS-005208		Curriculum Vitae of Frank A Jeager		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0297	ABBVIE-FST14911675 - ABBVIE-FST14911677	10/13/2011	Androgel 1.62%	401/403	1K 13 14
0298	ABBVIE-FST09067798 - ABBVIE-FST09067799	3/14/2011	Androgel Weekly Report for week-ending 3/4/11	401/403	1K
0299	ABBVIE-FST09276419 - ABBVIE-FST09276421	3/11/2004	Speaking Engagement - TRT	401/403	2
0300	ABBVIE-FST15352653 - ABBVIE-FST15352693	6/3/2013	Update pre-conference call at 3:00, with AUA CME "Testosterone Therapy and Prostate Health, Examining Barriers to Treatment of Hypogonadism" and "PPD AbbVie Grant Management PD20" FINAL DRAFT attachments	403, 802	1
0301	ABBVIE-FST08782434 - ABBVIE-FST08782445	5/2011	T Talk Tune-Up PPT Slide Deck "Low T Disease Awareness Campaign, Strategic Overview, May 2011"	401/403	1K 2
0302	ABBVIE-FST08649007 - ABBVIE-FST08649008	9/23/2010	Low Testosterone Satellite Media Tour	401/403	1K 2 8
0303	ABBVIE-FST09062194 - ABBVIE-FST09062195	6/1/2013	Our Recommendations	403, 802	1
0304	ABBVIE-FST05967764 - ABBVIE-FST05967777	2/2011	Is Low T (low testosterone) making Your Patient Feel Like a Shadow of His Former Self? IDENTIFY THE SYMPTOMS. DIAGNOSE HYPOGONADISM.	401/403	1K 2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0305	ABBVIE- FST06099614 - ABBVIE- FST06099642	2011	T Talk Tune-Up/AndroGel website screenshots featuring Terry Labonte and Harry Fisch	401/403	1K 2
0306	ABBVIE- FST15926897 - ABBVIE- FST15926901	11/11/2010	AndroGel Brand topic grid	401/403	1K
0307	ABBVIE- FST15011367 - ABBVIE- FST15011367	11/17/2010	Medical Summary	401/403	1K
0308	ABBVIE- FST09071869 - ABBVIE- FST09071871	11/21/2000	AndroGel and The TRT Market		
0309	ABBVIE- FST09072884 - ABBVIE- FST09072915	8/28/2001	Unimed Franchise 2002 Marketing Plans, w/ attachment "AndroGel 2002 Business Plan" by Kate Robertson and Tim Hatke		
0310	ABBVIE- FST09072063 - ABBVIE- FST09072090	5/1/2002	Position Paper, w/ attachment "DRAFT - Position Statement - Androgen Replacement for Male Hypogonadism"	401	
0311	ABBVIE- FST09072130 - ABBVIE- FST09072145	8/14/2002	AndroGel '03 Planning Meeting Summary (for meeting July 30, 2002)		
0312	ABBVIE- FST09072166 - ABBVIE- FST09072179	6/10/2003	AndroGel DTC TV Pilot Program - for PMC Meeting 6/10/03	401/403	2
0313	ABBVIE- FST08688805 - ABBVIE- FST08688847	12/12/2003	Final Version of Men's Health (Proposal for Franchise Development)	401/403	2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0314	ABBVIE-00500228 - ABBVIE-00500229	11/2/2007	Commercial Organization	401/403	2
0315	ABBVIE-FST09067829 - ABBVIE-FST09067830	2/2/2011	Androgel Weekly Report for week-ending 1/21	401/403	1K 5
0316	ABBVIE-FST03390243 - ABBVIE-FST03390244	5/23/2011	Androgel Weekly Report for week-ending 5/13/11	401/403	1K 5
0317	ABBVIE-FST08687596 - ABBVIE-FST08687598	6/8/2011	FOR APPROVAL: Men's Health Awareness Campaign Launch Press Release	401/403 , Foundation	1K 2 10
0318	ABBVIE-FST03387905 - ABBVIE-FST03387906	6/13/2011	Androgel Weekly Report for week-ending 6/3/11	401/403	1K 5
0319	ABBVIE-FST09067286 - ABBVIE-FST09067287	9/26/2011	Androgel Weekly Report for week-ending 9/16/11	401/403	1K 5
0320	ABBVIE-FST09063076 - ABBVIE-FST09063096	6/8/2012	REVISED AndroGel Blue Plan, w/ attachment "2012 AndroGel 1.62% Blue Plan Request, June 8, 2012"	401/403	1K 2 5
0321	ABBVIE-FST02421066 - ABBVIE-FST02421071		Commercial Summit All Star Award Nomination - AndroGel 1.62% and Men's Health	401/403	1 13 14
0322	ABBVIE-FST02390709 - ABBVIE-FST02390711	4/24/2013	CEO Rick Gonzalez Visits Sites in Europe	401/403	1 2 4

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0323	ABBVIE- FST12271843 - ABBVIE- FST12271848	4/3/2013	Clear and Present Danger	401/403	1 2 13 14
0324	ABBVIE- FST06336055 - ABBVIE- FST06336062	7/2013	2014 AndroGel 1.62% Business Plan "Providing a Hypogonadal Roadmap"	401/403, Foundation	1 2 10 13 14
0325	ABBVIE- FST06394075 - ABBVIE- FST06394083	6/4/2014	2015 AndroGel 1.62% Strategic Narrative_6 4 14	401/403	1 2 13 14
0326	ABBVIE- FST02385691 - ABBVIE- FST02385700	7/11/2014	Update: Q2 Earnings Preparation	401/403	1 2 5
0327	ABBVIE- FST02385217 - ABBVIE- FST02385219	9/15/2014	Arrangments for meeting between Jim Hynd, Pablo Hernandez, and Michael Gautsch at College Park Marriott Hotel and Conference Center in Hyattsville, MD	401/403	1
0328	ABBVIE- FST03289231 - ABBVIE- FST03289232	10/7/2013	AndroGel Weekly Report for Week- ending 09/27/2013	401/403	1 5
0329	ABBVIE- FST15821312 - ABBVIE- FST15821323	12/10/2014	Key call JRS review	401/403	1 5 7
0330	ABBVIE- FST15817409 - ABBVIE- FST15817414	3/3/2015	DSC Just Posted--AndroGel and TRT	401/403	1
0331	ABBVIE- FST15815169 - ABBVIE- FST15815174	4/9/2015	Questions for Webex	401/403	1 7

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0332	ABBVIE-FST13801085 - ABBVIE-FST13801088	4/10/2015	F/U AndroGel IBT Strategy Meeting - DRAFTED SWOT & 2016 Strategies	401/403	1
0333	ABBVIE-FST13811331 - ABBVIE-FST13811338	4/30/2015	Public Affairs Q1 in Review	401/403	1 2 7
0334	ABBV-PERS-002899 - ABBV-PERS-002900		Curriculum Vitae of James Hynd		
0335	ABBVIE-00640461 - ABBVIE-00640466	2003	"Considerations for older male patients" brochure	401/403	2
0336	ABBV-PERS-005145 - ABBV-PERS-005153	2006	Critical Success Factors - 2006 Part III - Exempt Performance Appraisal for Jim Hynd	401/403	2 5 7
0337		11/17/2015	AMA News Room article "AMA Calls for Ban on Direct to Consumer Advertising of Prescription Drugs and Medical Devices"	401/403, 802	1 12
0338	ABBV-PERS-005205 - ABBV-PERS-005206	2015	Annual Rewards Summary for 2015 for Jim Hynd	401/403	1 5
0339	ABBVIE-00354277 - ABBVIE-00354280	1/1/2006	Project Exhibit 5 For Master Relations Agreement between Solvay and Daniel J Edelman, Inc. Effective January 1, 2004 (Date used in "Doc Date" field is beginning of Project Exhibit Term)	401/403	2 8
0340	ABBVIE-00357802 - ABBVIE-00357809	3/6/2003	Amendment No. 2 to Public Relations Agreement between Solvay and Daniel J Edelman, Inc.		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0341	ABBVIE- FST10001649 - ABBVIE- FST10001650	2/2/2012	Androgel 2012 Update sales	401/403	1K
0342	ABBVIE- FST09955441 - ABBVIE- FST09955442	1/20/2013	Carlos Request - [Redacted] - AndroGel DTC/DA	401/403, Foundation	1 2 13 14
0343	ABBVIE- 00070428 - ABBVIE- 00070437	6/13/2002	CME Payment; Endocrine Society Continuing Medical Education Services Package on "Aging Male: Audio Conferences", w/ Invoice	401/403, Foundation	2 10
0344	ABBVIE- FST17098921 - ABBVIE- FST17098961	3/5/2002	Business Plan	401/403	2
0345	ABBVIE- FST17070667 - ABBVIE- FST17070680	7/15/2002	Summary/Recommendations		
0346	ABBVIE- 00224871 - ABBVIE- 00224881	6/1/2004	\$35k Clinical Research Award Grant		
0347	EDEL0001806 1 - EDEL0001806	5/24/2006	Shawn Micheel on FOX Memphis	401/403, 802	2
0348	EDEL0009920 6 - EDEL0009925 6	7/21/2005	2006 SMK/PC Business Planning Meeting Minutes and Path-forward w/attachments: "2006 Explore Team Business Plan Template.ppt; 2006 SMK Business Planning Session Minutes.doc"	401/403	2
0349	ABBVIE- FST17063517 - ABBVIE- FST17063536	1/25/2002	AndroGel PR Recommendations w/attachment: "AndroGel 2002 Recs FINAL.doc"		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0350	ABBVIE- FST17064714 - ABBVIE- FST17064722	3/24/2003	FYI - Support Materials for Speaker Training Messages and Q&A w/attachments: "FieldFAQfinal.doc; Standby Statement FINAL - IOM NIA Task Force.doc; Swerdloff Abstract.doc; Harbor-UCLA FINAL RELEASE.doc"	401/403	2
0351	ABBVIE- FST09441566 - ABBVIE- FST09441578	8/9/2002	2003 Business Plan Summaries		
0352	ABBVIE- FST17063504 - ABBVIE- FST17063516	1/7/2002	2001 Media Results w/attachments: "Transitionmtg 2.ppt; 2001 results.ppt"	401/403	2
0353	ABBVIE- FST16928952 - ABBVIE- FST16928960	5/11/2005	AndroGel Class Labeling w/attachment: "C-L Response Team Working Action Plan 5-10-05.doc"		
0354	ABBVIE- FST13297641 - ABBVIE- FST13297642	4/15/2005	Testosterone Class Labeling Response Team		
0355	ABBVIE- FST13297648 - ABBVIE- FST13297651	4/15/2005	Class Labeling Responses		
0356	EDEL0000119 3 - EDEL0000119	3/8/2004	U.S. News and World Report	401/403, 802	2
0357	ABBVIE- 00199959 - ABBVIE- 00200060	5/5/2002	Andropause Consensus 2002		
0358	ABBVIE- FST14633868 - ABBVIE- FST14633869				

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0359	ABBVIE- FST14633954 - ABBVIE- FST14633960			401/403	2 5
0360	ABBVIE- FST00378449 - ABBVIE- FST00378458	9/9/2005	Response to Teleconference 3/30/2005		
0361	ABBVIE- FST01352951 - ABBVIE- FST01352953	6/25/2010	TRT and CV Risk Article	802	
0362	ABBVIE- FST09700526 - ABBVIE- FST09700528	7/6/2010	Some Insight on Hct		
0363	ABBVIE- FST09622789 - ABBVIE- FST09622792	11/29/2007	TEST SMT Minutes of September 14, 2007 Meeting		
0364	ABBV-PERS- 013667 - ABBV- PERS-013668		Curriculum Vitae of Darryl Doebler		
0365	ABBV-PERS- 013669 - ABBV- PERS-013669	2012	2012 Setting Goals/Expectations for Darryl K Doebler	401/403	1K 2 5
0366	ABBVIE- FST18686296 - ABBVIE- FST18686359	11/1/2012	Regulatory Affairs Standard Operating Procedure Doc ID: Q-60-03-004 Title: Guidance for the Development and Approval of PPD US Promotional and Non-Promotional Materials		
0367	ABBVIE- FST02540704 - ABBVIE- FST02540706	9/12/2013	Endocrine Guidelines Request from AbbVie	401/403	1 2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0368	ABBVIE-FST02540707 - ABBVIE-FST02540749	4/2012	Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline	401/403	1K 2
0369	ABBVIE-FST02540750 - ABBVIE-FST02540781	9/23/2013	Selected Excerpts from the 2010 Endocrine Society Guidelines: Clinical Practice Guidelines for Hypogonadal Adult Men: An Endocrine Society Clinical Practice Guideline	401/403	1 2
0370	ABBV-PERS-004549 - ABBV-PERS-004552	8/26/2015	Curriculum Vitae of Nader Sultan Ahmed Khan, MD		
0371	ABBVIE-FST01464029 - ABBVIE-FST01464129	5/1/2014	Handwritten Notes of Nader Khan; page one dated 5/1/2014	401/402	1
0372	ABBVIE-FST01799255 - ABBVIE-FST01799255	7/17/2014	TRT ADCOM BB Draft; Benefits Document	401/403	1
0373	ABBVIE-FST01799256 - ABBVIE-FST01799321	7/17/2014	Core Briefing Book Components and Executive Summary of Risk vs. Benefit and Who Uses TRT	401/403, Foundation	1 10
0374	ABBVIE-FST01705713 - ABBVIE-FST01705719	10/9/2013	Response to Today's Comments re Slides for 10 October 2013 testosterone knowledge forum	401/403	1
0375	ABBVIE-FST01705720 - ABBVIE-FST01705752	10/9/2013	AndroGel Knowledge Forum: Adverse Events [attachment to AbbVie P1.1199/Khan 08]	401/403	1
0376	ABBVIE-FST01469086 - ABBVIE-FST01469112	12/18/2013	Presentation to the SRB Annual Post-Marketing Product Safety Review: AndroGel Nader Khan - PST Lead [See also <u>AbbVie P1.0225</u>]		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0377	ABBVIE- FST01431263 - ABBVIE- FST01431264	2/25/2014	Slides for CV risks with Hypogonadism		
0378	ABBVIE- FST01431265 - ABBVIE- FST01431272	2/25/2014	[attachment to <u>AbbVie P1.1207/Khan 15</u>]		
0379	ABBVIE- FST01431275 - ABBVIE- FST01431298			401/403, Foundation	1 10
0380	ABBVIE- FST01812128 - ABBVIE- FST01812137	11/11/2013	20131106 AndroGel AdHoc MM (NK), w/ attachment - Ad Hoc - Product Safety Team Minutes, Testosterone Gel (Q-15-01-001-T04)	401/403	1
0381	ABBVIE- FST01812129 - ABBVIE- FST01812137	11/6/2013	Ad Hoc - Product Safety Team Minutes, Testosterone Gel (Q-15-01-001-T04)		
0382	ABBVIE- FST02867332 - ABBVIE- FST02867333	11/12/2013	Potential Signal Identified for Testosterone	401/403	1
0383	ABBVIE- FST01728680 - ABBVIE- FST01728680	11/7/2013	Draft AndroGel Action Plan for JAMA article (06NOV2013)	401/403, Foundation	1 2 10
0384	ABBVIE- FST01728681 - ABBVIE- FST01728681	11/6/2013	AndroGel Action Plan [attachment to <u>AbbVie P1.1214/Khan 23</u>]	401/403	1
0385	ABBVIE- FST01467898 - ABBVIE- FST01467924	2/4/2014	White Paper - Association of Testosterone Therapy with Mortality, Myocardial Infarction, and Stroke in Men with Low Testosterone Levels; Review Period 1/1/1990 - 9/30/2013 (Q-15-01-002-T02)		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0386	ABBVIE-FST11180223 - ABBVIE-FST11180231	5/13/2015	AndroGel 1.62% TTRT Market Growth SPIFF, 2013	401/403	1 13 14
0387		1/28/2015	AndroGel Product Monograph, Control No. 178980 - BGP Pharma ULC	401/403	1 4
0388			Curriculum Vitae of Melanie A Blanchard, BS, RN, CNN, CMPP		
0389	ABBVIE-FST17496217 - ABBVIE-FST17496222		Curriculum Vitae of James D Hannasch, MD		
0390	ABBV-PERS-013701 - ABBV-PERS-013706	2010	2010 Performance Appraisal for James Hannasch		
0391	ABBVIE-FST16944304	9/24/2004	Follow up on AndroGel White Paper w/attachment: "Review of Long-Term Safety of TRT and Response to IOM.pdf"		
0392	ABBVIE-FST17937292 - ABBVIE-FST17937315	2/9/2010	Presentation to Abbott	401/403	7
0393	ABBVIE-FST17529123 - ABBVIE-FST17529129	5/28/2010	TRT and CV Risk Article...		
0394	ABBVIE-FST17529022 - ABBVIE-FST17529029	6/15/2010	TRT and CV Risk Article...	401/403	11
0395	ABBVIE-FST17532929 - ABBVIE-FST17532932	4/8/2011	JH transition plan w/attachment: "Marietta Transition Plans__JH_04082011.doc"	401/403	1K

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0396	ABBVIE- FST17534144 - ABBVIE- FST17534144	7/13/2011	Androgel RMP	401/403	1K 13 14
0397	ABBVIE- FST01350007 - ABBVIE- FST01350010	5/17/2010	Peer Review S361.1.001 Amendment 2		
0398	ABBVIE- FST17954234 - ABBVIE- FST17954240	9/13/2010	Disc due to increase hematocrit or hemoglobin - help needed	401/403	1K
0399	ABBVIE- FST17529317 - ABBVIE- FST17529324	11/2/2010	IDT for NEJM- Testosterone w/attachments: "Appendix 1-1% placebo controlled CV data.doc; Appendix 2- 1.62% placebo controlled CV data.doc; AndroGel- Placebo Group Comparison of CV risks.doc"	401/403	1K
0400	ABBVIE- FST16090150 - ABBVIE- FST16090155	11/3/2010	IDT- Testosterone and CV risk, placebo-controlled trials w/attachments		
0401	ABBVIE- FST09340052 - ABBVIE- FST09340569	4/23/2008	AndroGel Annual Periodic Safety Update Report 28 February 2007 through 27 February 2008		
0402	ABBVIE- FST17534711 - ABBVIE- FST17534711	4/15/2008	Step 2 Signal Report - Androgel and Thromboembolism		
0403	ABBVIE- FST01150938 - ABBVIE- FST01151787	4/22/2010	Letter with attachments re NDA 21- 015 PSUR 8		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0404	ABBVIE- FST01077025 - ABBVIE- FST01077030		Signal Evaluation Report- Step 1 Report Number: S12_TEST_MYOCARDIAL ISCHEMIA_01MAR2010		
0405	ABBVIE- FST01249598 - ABBVIE- FST01249710	10/30/2006	Investigator's Brochure Edition No.: IB-176.00	401/403	13 14
0406	ABBVIE- FST01873070 - ABBVIE- FST01873982	4/22/2011	Letter with attachments re NDA 21- 015 PSUR 9		
0407	ABBVIE- FST00121401 - ABBVIE- FST00121861	4/4/2007	ECRF Audit Trail History	Foundation, 802, 401/403	10
0408	ABBVIE- FST17915725 - ABBVIE- FST17915762	10/21/2009	New Signal Evaluation Report Templates and Instruction Guide		
0409	ABBVIE- FST17507884 - ABBVIE- FST17507907	6/3/2008	Dr. Hill Luncheon Presentation	401/403	7
0410	ABBVIE- FST19483050 - ABBVIE- FST19483052	1/15/2004	DSS Case Review Meeting		
0411	ABBVIE- FST19514232 - ABBVIE- FST19514233	2/28/2006	Medical Review Meeting (No. 132) - Meeting Minutes	401/403, 802	13 14
0412	ABBVIE- FST19496894 - ABBVIE- FST19496922		Testosterone Update	401/403	13 14

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0413	ABBVIE- FST19538261 - ABBVIE- FST19538263	3/28/2006	SIGNAL EVALUATION REPORT - Step 1 (Report No. S01_TEST_29MAR2006)		
0414	ABBVIE- FST18652484 - ABBVIE- FST18652511	9/20/2002	15-Day Alert Report - Manufacturer Report Number: TEST00202002306	401/403, 802	13 14
0415	ABBVIE- FST00322316 - ABBVIE- FST00322465	4/22/2005	Solvay Periodic Safety Update Report (PSUR) for AndroGel, Feb 28, 2000 - Feb 27, 2005; Report No. TEST 03		
0416	ABBVIE- FST18653058 - ABBVIE- FST18653157	8/19/2004	15-Day Alert Report - Manufacturer Report Number: TEST00204002653	401/403, 802	13 14
0417	ABBVIE- FST16089240 - ABBVIE- FST16089240	6/3/2010	Recent Publication of Interest		
0418	ABBVIE- FST18652378 - ABBVIE- FST18652407	7/15/2003	15-Day Alert Report - Manufacturer Report Number: TEST00203001801	401/403, 802	13 14
0419	ABBVIE- FST19090054 - ABBVIE- FST19090078	11/25/2003	15-Day Alert Report - Manufacturer Report Number: TEST00203003262	802	
0420	ABBVIE- FST19090635 - ABBVIE- FST19090659	11/24/2003	15-Day Alert Report - Manufacturer Report Number: TEST00203003216	802	
0421	ABBVIE- FST19089068 - ABBVIE- FST19089095	3/27/2001	15-Day Alert Report - Manufacturer Report Number: TEST00201004957	802	

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0422	ABBVIE- FST18652235 - ABBVIE- FST18652333	6/9/2004	15-Day Alert Report - Manufacturer Report Number: TEST00204001537	802	
0423	ABBVIE- FST01170388 - ABBVIE- FST01170946	4/23/2007	Solvay Periodic Safety Update Report (PSUR) for AndroGel, Feb 28, 2006 - Feb 27, 2007; Report No. TEST 05		
0424	ABBVIE- 00343553 - ABBVIE- 00343586	1/24/2001	Advertising and Promotional Labeling submission to FDA for AndroGel		2
0425	EDEL0010486 8 - EDEL0010489	8/20/2004	DRAFT: 2005 Plan for Review, w/ attachments "Expand the Market" and "SWOT Tune-Up Only"	401/403, Foundation	2 8 10
0426	EDEL0010042 0 - EDEL0010042	8/3/2005	Action Needed - Identify OTLs who may have an interest in speaking with the media	401/403	2
0427	EDEL0010279 0 - EDEL0010279	6/9/2005	Q&A to share with Bill, w/ attachment "Final SMT Key Messages and Q&A"	401/403, Foundation	2 10
0428	EDEL0002114 5 - EDEL0002114	10/24/2006	NY Times "Andropause" Article	401/403, 802, Foundation	10
0429	ABBVIE- 00152340 - ABBVIE- 00152347	8/8/2003	PR Recommendations for Institute of Medicine Final Report	401/403, 802	2 10
0430	EDEL0000278 4 - EDEL0000279	11/12/2003	IOM Update 11/12/03	401/403, 802	2
0431	EDEL0011879 0 - EDEL0011879	12/18/2006	AndroGel PR Budget, w/ attachment "AndroGel Estimated 2007 Budget 12.06.06 for Brian"	401/402, 802,	2 5 8
0432	EDEL0012462 4 - EDEL0012468	8/29/2007	Public Relations Recommendations Presented by Edelman	401/403. 802, Foundation	2 10

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0433		12/6/2016	Expert Report of Adrian Dobs, MD, MHS	401/403, 802, Case dismissed	13 14
0434	ABBVIE-FST13333133 - ABBVIE-FST13333144	7/10/2003	Long-Term Testosterone Replacement Therapy - Overview of IOM Activities		
0435	ABBVIE-FST17092732 - ABBVIE-FST17092733	8/26/2002	CBS Evening News transcript and summary	401/402, 802	2
0436	ABBVIE-FST17064513 - ABBVIE-FST17064513	1/10/2003	IOM Task Force -- Dr. Dobs	802	
0437	ABBVIE-FST17096273 - ABBVIE-FST17096274	11/12/2002	Dobs/Oyung Proposals	401, 802	
0438	ABBVIE-FST00461066 - ABBVIE-FST00461088	5/15/1996	IND 50,377: Response to Request for Modification of Informed Consent and Investigator's Brochure for Phase I Testosterone-Gel Study in Hypogonadal Men		
0439		12/6/2016	Expert Report on Testosterone Therapy (AndroGel) Jesse Mitchell v AbbVie Inc, et al Martin Miner, MD	401/403, 802	
0440		12/6/2016	Expert Report on Testosterone Therapy (AndroGel) Jeffrey Konrad v AbbVie Inc, et al Martin Miner, MD	401/403, 802	
0441		8/2016	Curriculum Vitae of Martin Morris Miner, MD	401/403, 802	
0442		1/2017	Updated Curriculum Vitae of Martin Morris Miner, MD	401/403, 802	

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0443			AUA (American Urological Association) University - "Testosterone: Diagnosis and Management of the Hypogonadal Male"	401/403, 802	
0444		4/23/2014	Letter from Abraham Morgentaler to Margaret Hamburg	401/403, 802	1
0445	ABBVIE-FST00035624 - ABBVIE-FST00035664	11/30/2000	AndroGel NDA 21-015 Labeling Supplement: Proposed Changes to Patient and Physician Package Inserts		
0446	ABBVIE-FST15022026 - ABBVIE-FST15022034	12/12/2001	FDA Correspondence: Approvable Letter for S-004 Labeling Supplement		
0447	ABBVIE-00308973 - ABBVIE-00309057	2002	Consultant Advisory Session on Testosterone	401/403	2
0448	ABBVIE-00021844 - ABBVIE-00021893	3/29/2007	AndroGel 2005 Business Plan		2
0449	ABBVIE-FST18687217 - ABBVIE-FST18687220	8/27/2010	Androgel Sales Aid 8-27-2010 - Medical Comments	401/403, Foundation	1K 10
0450	ABBVIE-FST00918991 - ABBVIE-FST00919026	8/16/2010	Letter enclosing Meeting Minutes from August 16, 2010 meeting re PRO	401/403	1K
0451	ABBVIE-FST01057422 - ABBVIE-FST01057428	9/9/2005	Letter re Response to Teleconference March 30, 2005		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0452	ABBVIE- FST14615784 - ABBVIE- FST14615800	10/24/2007	AndroGel SLR 016 w/attachment: "Comparison-102407.doc"		
0453	ABBVIE- FST08749139 - ABBVIE- FST08749261	2003	2003 Business Plan		
0454	ABBVIE- FST17938181 - ABBVIE- FST17938182	4/15/2010	Minutes Meeting - 15Apr2010 - Besins study cases	401/403, Foundation	10 11
0455	ABBVIE- FST17509618 - ABBVIE- FST17509619	6/14/2011	TAD Study results.xls- + PADAM- Besins study cases for AndroGel		
0456	ABBVIE- FST19559825 - ABBVIE- FST19559843	3/27/2008	Steps 1&2 Signals on Thromboembolism for AndroGel, w/ attachments "S06_TEST_Thromboembolism_01M AR2007_Step1.pdf" and "S06_TEST_Thromboembolism_10M AR2007_Step2.pdf"		
0457	ABBVIE- 00164247 - ABBVIE- 00164259	2003	\$330k Grant to Endocrine Society for CMES Practical Clinical Issues in TRT		
0458	ABBVIE- 00308682 - ABBVIE- 00308690	12/10/2002	\$497k Grant to Endocrine Society for Symposia at 1st 3 PRI*MED conferences		
0459	ABBVIE- FST10178492 - ABBVIE- FST10178549	12/1999	Androgel Launch Plan (Attaching email not included)		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0460	ABBVIE-FST01463253 - ABBVIE-FST01463338	7/3/2013	Potential Signal Identification and Investigation Report - (Step 1) [Q-15-01-002-F01] and Product Safety Plan, Edition 3.0 - June 2014		
0461	ABBVIE-FST02254565 - ABBVIE-FST02254568	11/7/2013	JAMA paper	401/403	1
0462	ABBVIE-00221149 - ABBVIE-00221213	11/19/2003	AndroGel 2004 Business Plan	401/403	2
0463	ABBVIE-00457953 - ABBVIE-00457967	2003	2003 Endo/Uro Medical Liaison Business Plan		
0464	ABBVIE-FST06098502 - ABBVIE-FST06098515	2/2011	HCP Marketing piece "Is Low T (low testosterone) making your patient feel like a shadow of his former self?" [851-505310]	401/403	1K 2
0465	ABBVIE-FST01284165 - ABBVIE-FST01284176		Androgens - Class Labeling Guideline		
0466	ABBVIE-FST00541768 - ABBVIE-FST005441796	09/15/2006	Unimed Pharma - 1.62%		
0467	ABBVIE-FST03767438 - ABBVIE-FST03767447	2/09/2015	Labeling Supplement nad PMR Required REMS Modification Notification	401/402	1
0468	ABBVIE-00043639 - ABBVIE-00043645	2/09/2004	VMS (Video Monitoring Services of America, Inc.), Chicago, IL	403, 802	4

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0469	ABBVIE-00632067 - ABBVIE-00632068	8/27/2004	Correspondence regarding Androgel 1% - Pre-IND Type B Meeting, 11-Aug-2004 Meeting Minutes		
0470	ABBVIE-FST09260069 - ABBVIE-FST09260079		Regulatory Challenges, Testosterone Therapy in Aging Males - Daniel A. Shames MD FACS, Deputy Director , Office of Drug Evaluation III, CDER/FDA	403; 802	3
0471	ABBVIE-FST00546230 - ABBVIE-FST00546374	5/16/2012	Global Regulatory Strategic and Tactical Plan - AndroGel 1% and 1.62% - Phase 4	401/403	1K 13 14
0472	ABBVIE-FS00500326 - ABBVIE-FST00500478	12/26/2012	Global Regulatory Strategic and Tactical Plan - AndroGel 1% and 1.62% - Phase 4 - US Only - Canada and Mexico-EPD/Abbott	401/403	1 13 14
0473	ABBVIE-00075499 - ABBVIE-00075623	9/10/1998	Unimed Pharmaceuticals, Inc., 1998 Strategic Plan		
0474	ABBVIE-00605557 - ABBVIE-00605658	1999	Annual report 1999 - Solvay in Action	401/403	5
0475	ABBVIE-00278318 - ABBVIE-00278318	12/20/2001	Re: 2002 AndroGel Strategy Presentation 12-05-01		
0476	ABBVIE-00278319 - ABBVIE-00278371	2002	AndroGel 2002 - Situation Overview Marketing Plan		
0477	ABBVIE-FST11282701 - ABBVIE-FST00282751	3/13/2002	2002 Business Plan		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0478	ABBVIE- FST17063579 - ABBVIE- FST17063605	1/18/2002	Edelman Public Relations Worldwide - AndroGel 2000/2001 Highlights and 2002 Public Relations Recommendations	401/403	2
0479	ABBVIE- FST17105699 - ABBVIE- FST171056700	2002	Endocrinology/Urology Medical Liaison, 2002 Tactical Plan	401/403	2
0480	ABBVIE- FST08702899 - ABBVIE- FST08702938	2011	AndroGel 2011 Tactical Business Plan	401/403	1K
0481	ABBVIE- FST02535399 - ABBVIE- FST02535452	9/21/2012	2013 AndroGel 1.62% Brand Plan	401/403	1K 13 14
0482	ABBVIE- 00460194 - ABBVIE- 00460290		Unimed Specialized Markets - Agenda		
0483	ABBVIE- FST10179487 - ABBVIE- FST10179489	12/2001	Publication Strategy for Unimed Products		
0484	ABBVIE- 00090182 - ABBVIE- 00090188	2001	Part III: Critical Success Factor Review - 2001 - Exempt Performance Appraisal for Sandra Faulkner	401/403	2
0485	ABBVIE- FST17095430 - ABBVIE- FST17095430		(Anderson et al) Perceptions of andropause among the general public and health care professionals		
0486	ABBVIE- FST17095705 - ABBVIE- FST17095708	6/2002	Publication Strategy for Unimed Products		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0487	ABBVIE-00359613 - ABBVIE-00359615	11/11/99	Androgel Association Relations Update	401/403; lacks foundation	2
0488	ABBVIE-00243519 - ABBVIE-00243532	2000	2000 SMU Marketing Award	401/403, Foundation	2 10
0489	ABBVIE-00015159 - ABBVIE-00015159	2001	WH/GI Medical Liaisons 2001 Tractical Plan AndroGel	401/403	2
0490	ABBVIE-00024476 - ABBVIE-00024477	8/23/2001	Outstanding Example of ALERT Program Impact - Dr. Porcase (Please Read)	401/403	2
0491	ABBVIE-00011633 - ABBVIE-00024477	2/05/2004	Speaker Program Report	401/403	2
0492	ABBVIE-FST17784241 - ABBVIE-FST17784241	7/19/2007	Slides	401/403 , Foundation	2 10
0493	ABBVIE-FST17784242 - ABBVIE-FST17784454		Introduction Presentation #1	401/403, Foundation	2 10
0494	ABBVIE-FST17756416 - ABBVIE-FST17756416	8/08/2007	OTL Outline Presentation	401, Foundation	10
0495	ABBVIE-FST18181303 - ABBVIE-FST18181304	9/10/2007	Dr. Hayes presentation	401/403, Foundation	2 10

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0496	ABBVIE-FST18181305 - ABBVIE-FST18181340		Introduction Presentation #1 - Dr. Hayes	401/403, 802, Foundation	2 10
0497	ABBVIE-FST18181036 - ABBVIE-FST18181036	9/13/2007	Promotional Slide Set - Dr. Hayes	401/403, Foundation	2 10
0498	ABBVIE-FST17757249 - ABBVIE-FST17757251	12/20/2007	Teleconference Series: Dr. Hayes Slide Set	401/403, Foundation	2 10
0499	ABBVIE-FST17786627 - ABBVIE-FST17786628	1/07/2008	Slide Set with Notes	401/403, Foundation	2 10
0500	ABBVIE-FST17792596 - ABBVIE-FST17792720	10/21/2008	FW: AndroGel Slide Kit Steering Committee Meeting - Executive Summary and slide set w/attachments: "AGL Slide Kit Steering Committee Executive Summary 10 15 2008.doc; Slide Kit Advisory Board Meeting Slides Final Complete 10 15 2008.pdf"	401/403	2
0501	ABBVIE-FST06201697 - ABBVIE-FST06201746	1/31/2008	OTL Teleconferences Registration and Call in Information w/attachments	401/403	2 8
0502	ABBVIE-FST17160086 - ABBVIE-FST17160200	7/11/2008	New AndroGel Speaker Slide Kits w/attachments: "Defining & Diagnosing Low Testosterone.ppt; Low Testosterone--Prevalence & Comorbidities.ppt; TRT--Treatment, Monitoring & Safety.ppt"	401/403	2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0503	ABBVIE- FST16328618 - ABBVIE- FST16328737	3/26/2009	FW: New AndroGel Speaker Slide Kits w/attachments: "Defining & Diagnosing Low Testosterone.ppt; Low Testosterone--Prevalence & Comorbidities.ppt; TRT--Treatment, Monitoring & Safety.ppt"	401/403	2
0504	ABBVIE- 00147682 - ABBVIE- 00147685	2000	Print Ad Pamphlet "Tired? Low Energy? Losing Strength? Depressed Mood?"	401/403, Foundation	2 10
0505	ABBVIE- FST02027663 - ABBVIE- FST02027663		Video Ad "Stop Living in the Shadows"	401/403, Foundation	2 10
0506	ABBVIE- FST16262796 - ABBVIE- FST16262796		Video Ad "Shadow of Your Former Self" Michael		2M
0507	ABBVIE- FST06097909 - ABBVIE- FST06097930	2010	Testosterone and Hypogonadism in Men's Health		2
0508	ABBVIE- FST06098966 - ABBVIE- FST06098988	2011	Testosterone and Hypogonadism in Men's Health	401/403	1K 2
0509	ABBVIE- FST06104716 - ABBVIE- FST06104752		Hypogonadism in Men's Health	401/403	2 8
0510	ABBVIE- FST02462985 - ABBVIE- FST02463067	11/29/2011	The Low T Patient Journey	401/403, Foundation	1K 2 10
0511	ABBVIE- FST00429327 - ABBVIE- FST00429359	2/28/2000	AndroGel (testosterone gel); NDA 21-015 Response to requested information		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0512	ABBVIE- FST00427190 - ABBVIE- FST00427204	12/16/2007	FW: NDA 21-015 S-016 AP LTR.pdf w/attachment: "NDA 21-015 S-016 AP LTR.pdf"		
0513	ABBVIE- FST08557660 - ABBVIE- FST08557697	11/12/2014	Letter from FDA re Supplemental New Drug Application w/Content of Labeling REMS enclosed	401/403	1
0514	ABBVIE- FST09325501 - ABBVIE- FST09325502	8/3/2011	Conference Call - AndroGel 1.62% Business Review Agenda October 2011	401/403	1K 13 14
0515	ABBVIE- FST17304259 - ABBVIE- FST17304293		Territory Name: Scranton	401/403	1K 13 14
0516	ABBVIE- FST06098037 - ABBVIE- FST06098037	1/2011	Print Ad "Take the Low T quiz"	401/403	1K 2
0517	ABBVIE- FST15430073 - ABBVIE- FST15430164	2015	Draft of Webpage Ads	401/403	1 2
0518	ABBVIE- FST10878637 - ABBVIE- FST10878671	5/11/2015	Correspondence re: Supplement Approval	401/403	1
0519	ABBVIE- 00223478 - ABBVIE- 00223535	9/22/2003	AndroGel 2004 Business Plan	401/403	2
0520	ABBVIE- 00074709 - ABBVIE- 00074724	10/2007	AndroGel 2007 Business Plan	401/403	2 8

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0521	ABBVIE- FST06099435 - ABBVIE- FST06099446	2011	Print Ad "T Talk Tune-Up: Maintenance Guide for Men's Health"	401/403	1K 2
0522	ABBVIE- 00013843 - ABBVIE- 00013871	11/29/2007	AndroGel 2008 Business Plan	401/403	8
0523	ABBVIE- FST10839537 - ABBVIE- FST10839596	11/9/2007	AndroGel 2008 Business Plan	401/403, 802	2 8
0524	ABBVIE- FST08744256 - ABBVIE- FST08744267	11/2008	2009 Executive Summary Forecast	401/403	2 8
0525	ABBVIE- FST06267973 - ABBVIE- FST06267983	2009	Field Sales Representative Performance Appraisal Core and Functional Competency Review for Maria Hernandez	401/403	2 8
0526	ABBVIE- FST06224370 - ABBVIE- FST06224373	3/30/2009	Solvay Field Contact Report Maria Hernandez	401/403	2 8
0527	ABBVIE- FST06098289 - ABBVIE- FST06098289	2/4/2011	Audio Recording with Helena Rodbard discussing men w/diabetes and Low T	401/403, Foundation	1K 2 8 10
0528	ABBVIE- FST16465983 - ABBVIE- FST16465984	2/5/2001	Greetings Mental Health Team!	401/403	2
0529	ABBVIE- FST06091490 - ABBVIE- FST06091520		Drive for Five Slides	401/403	1K 2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0530	ABBVIE-00009858 - ABBVIE-00009861	8/21/2000	Testosterone Replacement Therapy 2001 Medical Education Plan of Action and Topics of Discussion	401/403	2 8
0531	ABBVIE-FST17069401 - ABBVIE-FST17069403	4/30/2002	3rd Taskforce - May 3-5 w/attachments: "Andropause Consensus4-02 ltr.doc; White Paper 4- 26.doc; White Paper Slides 4-26.ppt; 3rd Taskforce Fac and Agenda 4- 26.doc; PROSTATE MONITORING 4- 26.doc"		
0532	ABBVIE-FST17069401 - ABBVIE-FST17069452	4/30/2002	3rd Taskforce - May 3-5 w/attachments: "Andropause Consensus4-02 ltr.doc; White Paper 4- 26.doc; White Paper Slides 4-26.ppt; 3rd Taskforce Fac and Agenda 4- 26.doc; PROSTATE MONITORING 4- 26.doc"	401, 802	2
0533	ABBVIE-FST17070701 - ABBVIE-FST17070702	4/25/2002	Summary Guidelines		
0534	ABBVIE-FST17070703 - ABBVIE-FST17070705	4/25/2002	Summary Guidelines		
0535	ABBVIE-00187333 - ABBVIE-00187356	7/19/2000	2nd Annual Andropause Consensus Meeting: Advances in Testosterone Replacement Therapy		
0536	ABBVIE-00016950 - ABBVIE-00016954	5/10/2001	Consensus Summary: Enduring Material from 2nd Andropause Conference		
0537	ABBVIE-00017047 - ABBVIE-00017053	5/17/2001	2001 Steering Committee Meeting: Evidenced-Based Clinical Guideline Project	401/403, Foundation	

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0538	ABBVIE-00010017 - ABBVIE-00010020	8/17/2001	Status Report as of August 17 w/attachment: "weekly status 8-16-01.rtf" (Unimed Project Status Report as of August 25, 2014 prepared by Michael McCarver)		
0539	ABBVIE-00055316 - ABBVIE-00055317		Draft of Consensus Guidelines	401/403, Foundation	2 10
0540	ABBVIE-00033837 - ABBVIE-00033844	2001	Summary from the Second Annual Andropause Consensus Meeting		
0541	ABBVIE-00017054 - ABBVIE-00017060	12/7/2001	Unimed Project Status Report as of December 7, 2001 prepared by Susan Reinhardt		
0542	ABBVIE-00174739 - ABBVIE-00174745	1/7/2002	Unimed Project Status Report as of January 7, 2002 prepared by Susan Reinhardt		
0543	ABBVIE-FST17069498 - ABBVIE-FST17069500	2/15/2002	A-GEL SUPPORTED 'interium guidelines' w/attachment: "Summary of Conf Call 2-14-02.doc" (Meeting Minutes - Conference Call Summary re Discussion of Endo Society Clinical Affairs Committee Comments on Endorsed Piece)		
0544	ABBVIE-FST17068981 - ABBVIE-FST17068982	3/15/2002	Summary of Teleconference w/attachment: "Summary of Conf Call - 3-14-02.doc" (Meeting Minutes - Conference Call Summary re Discussion of Endo Society Clinical Affairs Committee Comments on Endorsed Piece)		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0545	ABBVIE-FST17068983 - ABBVIE-FST17068987	3/21/2002	EDU Update w/attachment: "Summary of Solvay Meeting 3-20.doc" (Meeting Minutes of Conference Call Summary re Education Initiatives Supported by	401/403	2
0546	ABBVIE-FST17068985 - ABBVIE-FST17068987	3/20/2002	Conference Call Summary re Education Initiatives Supported by AndroGel	401/403, 802, Foundation	2 10
0547	ABBVIE-FST17070700 - ABBVIE-FST17070700	4/23/2002	AndroPause Task force		
0548	ABBVIE-FST17070718 - ABBVIE-FST17070739	6/6/2002	Summary/Recommendations w/attachment: "Summary 6-5.doc" (Summary of the Consensus Session From the Second Annual Andropause Consensus 2001 Meeting)	401/403, Foundation	2 10
0549	ABBVIE-FST17068988 - ABBVIE-FST17068993	3/26/2002	CAST Meetings w/attachment: "STW Invite Copy 3-25.doc" (Draft of Consultant Advocacy & Speaker Training Invite Copy as of March 26, 2002)	401/403	2
0550	ABBVIE-FST17069198 - ABBVIE-FST17069200	4/3/2002	FW: CAST Meetings	401/403	2
0551	ABBVIE-FST17070763 - ABBVIE-FST17070768	6/28/2002	Program Calendar as of June 28, 2002	401/403, Foundation	2 10
0552	ABBVIE-00017071 - ABBVIE-00017082	8/20/2001	2002 Pri*Med CME Breakfast Symposia Series Grant Request		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0553	ABBVIE-00010062 - ABBVIE-00010063	9/25/2001	PRI* MED w/attachment: "Pri-Med Agenda as 9-25.doc"		
0554	ABBVIE-00017320 - ABBVIE-00017320	11/28/2001	Letter from CME to Tim Hatke at Unimed requesting a grant for \$124k		
0555	ABBVIE-FST17071283 - ABBVIE-FST17071285	11/8/2002	Invitation to Breakfast Symposium re CME New Modalities and Emerging Clinical Issues	401/403	2
0556	ABBVIE-00162019 - ABBVIE-00162035	11/8/2002	Testosterone Replacement Therapy: New Modalities and Emerging Clinical Issues CME Ancillary Symposium	401/403	2
0557	ABBVIE-00015294 - ABBVIE-00015294	3/8/2002	Memo to Susan Reinhardt and Melanie Blanchard from CMES re ENDO'02 CMES Program		
0558	ABBVIE-FST06095187 - ABBVIE-FST06095198	2014	Print Ad "His Name is Dave"	401/403	1 2
0559	ABBVIE-00175861 - ABBVIE-00175865	6/21/2002	Letter of Agreement between Melanie Blanchard (Solvay) and EDU-Medical Management, Inc.	401/403, Foundation	2 10
0560	ABBVIE-00168531 - ABBVIE-00168553	6/21/2002	Critical Issues in Male Hypogonadism and Testosterone Replacement Therapy - Endo Society Symposium	401/403, Foundation	2 10
0561	ABBVIE-FST00131070 - ABBVIE-FST00131142	12/16/2008	Clinical Study Report S176.3.104; Study Protocol for "A Multi-Center, Randomized, D-B, P-C Efficacy and Safety Study of T Gel 1.62% for the Treatment of Hypogonadal Men		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0562	ABBVIE-FST00132070 - ABBVIE-FST00134282	12/16/2008	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Testosterone Gel 1.62% for the Treatment of Hypogonadal Men		
0563	ABBVIE-FST01389178 - ABBVIE-FST01389181	6/15/2010	Manuscript 10-1039 Version 1		
0564	ABBVIE-FST14737026 - ABBVIE-FST14737026	1/3/2006	AndroGel Class-labeling Plan	401/403, 802	4
0565	ABBVIE-FST09607711 - ABBVIE-FST09607715	3/21/2006	Canadian Class Labeling Meeting Minutes from February 27, 2006 Meeting with Health Canada	401/403, 802	4
0566	ABBVIE-FST17834089 - ABBVIE-FST17834119	1/2006	Product Monograph -- AndroGel Testosterone USP 1% gel -- Androgenic Hormone		
0567	ABBVIE-FST14736918 - ABBVIE-FST14736921	1/23/2006	Androgel Indication	401/403, 802	4
0568	ABBVIE-FST14616197 - ABBVIE-FST14616201	7/6/2006	Correspondence Re: Androgel 1% Gel, DIN 02245345 and 02245346	401/403, 802, Foundation	4 10
0569	ABBVIE-00054238 - ABBVIE-00054277	8/2002	AndroGel (Testosterone Gel) - Qualitative Evaluation of Diagnosing & Treating Hypogonadism Among IM/FP/GPs	401/403, 802	2
0570	ABBVIE-FST01891268 - ABBVIE-FST01891297		AndroGel (testosterone gel) US Advertising & Promotion Regulatory History Document	401/403	1

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0571	ABBVIE-00310996 - ABBVIE-00311088	2/07/2001	Physician Education Programs	401/403	2
0572	ABBVIE-FST00178492 - ABBVIE-FST00178549	5/15/2006	IND 50,377: Response to Request for Modification of Informed Consent and Investigator's Brochure for Phase 1 Testosterone-Gel Study in Hypogonadal Men		
0573	ABBVIE-FST00228158 - ABBVIE-FST00228310	9/22/2009	Investigation Compound: Testosterone Gel 1.62%, Edition No.: IB-176.01, Edition Date: 22-Sep-2009		
0574	ABBVIE-FST00859318 - ABBVIE-FST00859606		Testosterone gel 1.62% 2.7.4 Summary of Clinical Safety		
0575	ABBVIE-FST01114943 - ABBVIE-FST01115019	12/21/2012	Investigational Product: ABT-SLV176 (AndroGel 1.62% and testosterone gel strengths to be investigated), Generic Name: Testosterone gel, Trade Name: AndroGel, Edition Number: 0, Release Date: 21	401/403; 407	1 13 14
0576	ABBVIE-FST14578283 - ABBVIE-FST14578303	7/01/2009	Global Solvay Pharmaceuticals Operating Procedure -- Pharmacovigilance Risk Identification, Evaluation, Management and Minimization		
0577	ABBVIE-FST13572679 - ABBVIE-FST13572694	10/09/2011	Safety Monitoring		
0578	ABBVIE-FST14753975 - ABBVIE-FST14753990	6/14/2010	Significant Safety Issue Management		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0579	ABBVIE- FST01263536 - ABBVIE- FST01264048	2/2002 - 2/2003	Periodic Safety Update Report -- Androgel		
0580	EDEL0004433 3 - EDEL0004434	5/26/2005	Disease Awareness Campaigns Presented by Edelman	401/403	2
0581	EDEL0008748 2 - EDEL0008748		AndroGel: Balancing the TRT Debate Lannie Keeley Edelman Health Chicago	401/403, 802	2
0582	ABBVIE- FST00303372 - ABBVIE- FST00303398	3/7/2001	Form 2253 Submission for AG112A-M Alert Testosterone Screening Kit for AndroGel		
0583	ABBVIE- FST00302520 - ABBVIE- FST00302524	5/14/2001	Form 2253 Submission for AG99 Primary Care Journal Ad for AndroGel	401/403, Foundation	2 10
0584	ABBVIE- 00008588 - ABBVIE- 00008611	2002	Solvay HCP Marketing piece - For Physicians Treating Low Testosterone "Fatigued?, Depressed Mood? Low Sex Drive? Could be your patient's testosterone is running on empty." - Testosterone Restored [AGL00278]	401/403	2
0585	ABBVIE- FST09070070 - ABBVIE- FST09070084	1/15/2010	[Promotional Materials] 1.62% Detail Aid, w/ attachment "1% 2010 Branded Patient Brochure Final.pdf" and "2010 1% Detail Aid.pdf"	401/403	2 8
0586	ABBVIE- FST00364075 - ABBVIE- FST00364084	4/24/2003			
0587		5/11/2015	PI - AVEED (testosterone undecanoate) injection for intramuscular use. Endo Pharmaceuticals, 2015	401/403	1

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0588	ABBVIE-FST12638789 - ABBVIE-FST12638810	5/21/2014	Addendum to AndroGel 1% and 1.62% White Paper "Association of Testosterone Therapy with Mortality, Myocardial Infarction, and Stroke in Men with Low Testosterone Levels"		
0589	ABBVIE-FST17233414 - ABBVIE-FST17233447	4/15/2002	"His Replacement Therapy" AndroGel - Field Conference Call, Monday April 15, 2002	401/403	2
0590	ABBVIE-FST09326932 - ABBVIE-FST09326934	7/24/2011	FW: Sent on Behalf of Marty Trent Comer, National Sales Director: AndroGel 1.62% Best Practices	401/403	1K 13 14
0591	ABBVIE-00067437 - ABBVIE-00067447		3 Year Clinical Update Continuous Treatment with AndroGel 1% CIII Maintains T Levels and Improves Sexual Function, Mood, and Body Composition in Hypogonadal Men		
0592	ABBVIE-00162930 - ABBVIE-00162933	2001	Print Ad "The Compromised Patient"	401/403, Foundation	2 10
0593	ABBVIE-00000962 - ABBVIE-00000965	2001	Print Ad "Sexual Dysfunction Patient"	401/403, Foundation	2 10 8
0594	ABBVIE-00172703 - ABBVIE-00172718	2001	Print Ad "Is His Mood Related to Low Testosterone?"	401/403, Foundation	2 10
0595	ABBVIE-00031433 - ABBVIE-00031436	2001	Print Ad "The Fatigued Patient"	401/403, Foundation	2 10

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0596	ABBVIE-FST17500988 - ABBVIE-FST17501016	3/10/2007	Signal Evaluation Report Report Number: S06_TEST_Thromboembolism_01MAR2007		
0597	ABBVIE-00018222 - ABBVIE-00018222	2002	Consumer Promo Materials: Questions and Answers Regarding Testosterone Replacement Therapy (TRT)	401/403	2
0598	3rdPARTY_TRT_PSC_PROD00024284 - 3rdPARTY_TRT_PSC_PROD00024287	8/21/2000	AndroGel Planning Meeting, Medical Education. Prepared for Cathryn Robertson and Tim Hatke	401/403, Foundation	2 10
0599	3rdPARTY_TRT_PSC_PROD00024584 - 3rdPARTY_TRT_PSC_PROD00024589	7/24/2002	Dispeling Myths/Clarification Campaign MEMO from EDU-Medical	401/403, 802	2
0600	EDEL00048826 - EDEL0004883	4/9/2006	RE mytestosterone.com	802	2
0601	EDEL00095930 - EDEL0009594	7/25/2003	AndroGelR Planning Meeting Notes from July 15 [2003]; re Specialized Markets 2004 Planning Meeting	401/403	2
0602	EDEL00002737 - EDEL0000273	11/12/2003	Chicago Tribune Email	401/403, 802	2
0603	EDEL00005780 - EDEL0000578	9/17/2004	Poster for AAFP/WONCA		
0604	EDEL00111109 - EDEL0011111	4/2/2004	035 Data Publication Strategy	401/403, Foundation	2 10
0605	EDEL00103038 - EDEL0010304	11/1/2005	Spokespeople, w/ attachment "Doctors Secured for Local Outreach 11.1.05.doc"	401/403	2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0606	DM016608 - DM016613	7/2/2010	NEJM - Testosterone Gel & Cardiovascular Events	401/403, 802, Foundation	7 10
0607	ENDO- PROD0032591 - ENDO- PROD0032616	5/15/2012	Walking the Testosterone Tightrope And Ideal Hands-On Learning Session held in conjunction with The Endocrine Society's 94th Annual Meeting and Expo	401/403	1K 2
0608	ADOBS000030 47 - ADOBS000030 47	11/25/2013	Happy Thanksgiving	401/403, 802	1
0609	ADOBS000023 75 - ADOBS000023 75	5/30/2014	Thank You!	802	1
0610	ADOBS000026 93 - ADOBS000026 93	10/2/2014	comments	401/403; 802	1
0611	EDEL0009486 2 - EDEL0009486	2004	"COULD IT BE LOW T?"; for National Testosterone Tupe-Up 2004 - Print Ad/Flyer	401/403	2
0612	DM015181 - DM015198		What Should the Effective Sales Representative Know About Testosterone Replacement Therapy?, by Morgentaler	401/403	2
0613	DM015590 - DM015614	2/9/2009	AndroGel Recorded Brief, w/ attachment "Treat & Monitor_Healthcare_3_v6.ppt"	401/403	2
0614	EDEL0012789 8 - EDEL0012789	9/10/2007	Take Charge. Talk T.	401/403, 802	2 8
0615	EDEL0009470 4 - EDEL0009470 7	2004	Low Testosterone In Men Fact Sheet (and) Extent and Nature of Testosterone Use Fact Sheet; for National Testosterone Tupe-Up 2004	401/403	2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0616	EDEL0010659 1 - EDEL0010659		Patient Brochure - Take Charge. Talk T. What men with diabetes need to know about low testosterone (AADE)	401/403, Foundation	2 10 8
0617	EDEL0004135 4 - EDEL0004135 8	2004	Brochure - TRT CLEAR & SIMPLE, Basic Facts about Testosterone Replacement Therapy (TRT) for Men; (American Foundation for Urologic Disease, Inc.)		
0618	EDEL0007708 5 - EDEL0007708 5		Tune Up Doctor Contact Memo/Sample Advertisement "Could it be Low T?" for use in local newspapers	401/403	2
0619	ADOBS000020 47 - ADOBS000020 50	6/28/2012	Hypogonadism - DSA PowerPoint Presentation and a Favor	401/403 , 802	1K
0620	ABBVIE- FST02229193 - ABBVIE- FST02229210	2/6/2014	Suspect Adverse Reaction Report & CIOMS Report	401/403	1
0621	ABBVIE- FST12375170 - ABBVIE- FST12375181	10/9/2011	Abbott GPRD SOP - <u>Type</u> : Guideline <u>Title</u> : Signal Evaluation (White Paper) <u>Doc ID</u> : Q-15-01-002-W012		
0622	ABBVIE- FST15405745 - ABBVIE- FST15405812	7/3/2010	The ASR [Affiliate Safety Representative] Handbook (Global Pharmacovigilance)		
0623	ABBVIE- FST14776988 - ABBVIE- FST14777002	3/2/2014	Abbott SOP - <u>Type</u> : Process <u>Title</u> : PPG Global Pharmaceutical Operations and Global Pharmacovigilance Process Overview <u>Doc ID</u> : QSD.06.04.05	401/403	1
0624	ABBVIE- 00114242 - ABBVIE- 00114243	2/27/2003	Agenda or Notes from Conference Call re AndroGel 2/27/2003	401/403	2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0625	ABBVIE-FST18652128 - ABBVIE-FST18652155		Adverse Event Reports	Incomplete files; 802; 401/403: some irrelevant injuries (P1.1977a) or patient on placebo (P1.1977c)	
0626	ABBVIE-FST19090875 - ABBVIE-FST19090876		Adverse Event Reports	Incomplete files; 802; 401/403: different product -- Depo-T (P1.1978a), irrelevant injuries (P1.1978b), and one patient on placebo (P1.1978c)	
0627	ABBVIE-FST08643430 - ABBVIE-FST08643430	10/26/2011	androgel_MensHealth_Plasma FINAL.wmv	401/403	1K 2
0628	ABBVIE-FST06002243 - ABBVIE-FST06002243	6/1/2011	AndroGel_1-62_Launch_On_Site.wmv	401/403	1K 2 13 14
0629	ABBVIE-FST06079974 - ABBVIE-FST06079974	4/14/2011	Is It Low T Commercial_4 21 11.wmv	401/403	1K 2
0630	ABBVIE-FST06097657 - ABBVIE-FST06097657	5/11/2010	398410.PDF	401/403	2
0631	ABBVIE-FST14616561 - ABBVIE-FST14616561	12/19/2008	ANDRO-W2.mp3	401/403	2 8
0632	ABBVIE-00105855 - ABBVIE-00105924	12/22/2004	Androgel Objections, w/ attachment "Objections of AndroGel.ppt"	401/403	2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0633	EDEL0011353 6 - EDEL0011356	4/7/2006	Low T News 4/3-4/7, w/ attachments "Golf World 3.24.06.pdf" and "Weekly Coverage Report 4.3-	401/403, 802	2
0634	ENDO- MDL2545- 00009991 - ENDO- MDL2545- 00009992	8/22/2003	Savient Pharmaceuticals, Inc. Regulatory Submission to FDA for NDA 9-165 - Delatestryl (testosterone enanthate injection, USP) re PRIOR APPROVAL SUPPLEMENT: GERIATRIC LABELING	401/403	7
0635	ENDO- MDL2545- 00054794 - ENDO- MDL2545- 00054803	3/7/2007	FDA Prior Approval Supplement letter to Indevus Pharmaceuticals, Inc. re NDA 9-165/S-030, Delatestryl (testosterone enanthate injection, USP).	401/403, 802, Foundation	7 10
0636	ENDO- MDL2545- 00056666 - ENDO- MDL2545- 00056676	6/2/2005	FDA Prior Approval Supplement letter to Indevus Pharmaceuticals, Inc. re NDA 9-165/S-030, Delatestryl (testosterone enanthate injection, USP).	401/403, 802, Foundation	7 10
0637	ENDO- MDL2545- 00056677 - ENDO- MDL2545- 00056679	7/21/2005	General Correspondence: Response to June 2, 2005 Approvable Letter, re Geriatric Labeling for NDA 9-165/S- 030, Delatestryl (testosterone enanthate injection, USP).	401/403, 802, Foundation	7 10
0638	3rdPARTY_TRT _PSC_PROD00 024908 - 3rdPARTY_TRT _PSC_PROD00 024909		EDU-Medical/EDU-Focus - Unimed Project Status Report (Calendar) with Action Items for EDU and Unimed	401/403	2
0639	ABBVIE- FST18652608 - ABBVIE- FST18652609		Medwatch and CIOMS Forms	401/403, 802	

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0640			AndroGel 1% Package Inserts (PSC A-1 - A-19) [P1.1853 - P1.1871] COMPOSITE COMPONENTS: <u>P1.2008 a - P1.2008 s</u>	L401/403; 407	1
0641			AndroGel 1.62% Package Inserts (PSC B-1 - B-8) [P1.1872 - P1.1879] COMPOSITE COMPONENTS: <u>P1.2009 a - P1.2009 h</u>	401/403, 407	1K 13 14
0642	ABBVIE-FST00000555 - ABBVIE-FST00000556	11/14/1996	Unimed FDA Contact Report RE "General Guidance Re: Phase II/III Study Design"; re Study UMD-96-017 (T-Gel) - Swerdloff et al.		
0643	ABBVIE-FST00000840 - ABBVIE-FST00000842	2/13/1997	Unimed fax to FDA following discussion with list of investigators representing Unimed in trials with AndroGel-T and AndroGel-DHT	401/403	7
0644	ABBVIE-FST00000879 - ABBVIE-FST00000883	3/11/1997	FDA's T-Gel/DHT-Gel Meeting Report (2/18/97)	401/403	7
0645	ABBVIE-00063316 - ABBVIE-00063318	2/1/1999	FDA letter to Unimed re IND 49-483 - Dihydrotestosterone Gel (DHT) - re carcinogenicity of compound and testing	401/403	7
0646	ABBVIE-00038754 - ABBVIE-00038754	3/24/2000	Unimed FDA Contact Report RE "DHT Clinical Development Plans"; Meeting Minutes from Teleconference March 24, 2000	401/403	7
0647	EDEL00087225 - EDEL00087230	7/18/2002	"June 2002 AndroGel Activity Report" summary of public relations activities conducted during June 2002 to support AndroGel	401/403, Foundation	2 10
0648	EDEL00096069 - EDEL00096080	10/13/2003	2004 Plan and Budget, w/ attachments "AndroGel 2004 Budget - Revised 10.13.03.doc" and "AndroGel 2004 Plan in Word - Revised 10.13.03.doc"	401/403, 802	2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0649	EDEL0000188 6 - EDEL0000188	10/11/2004	FYI: Newsday - The Menopausal Male	401/403, 802	2
0650	EDEL0010352 3 - EDEL0010353 1	6/23/2005	FDA Teleconference re: Androgel, w/ attachments "Estimated Budget Revised.doc" and "Timeline for FDA label change.doc"; Memo title: FDA Draft Guidance on Label Change and Potential Advisory Committee Meeting	401/403	2
0651	EDEL0010348 1 - EDEL0010348 3	8/31/2005	Pre-Draft Guidance Media Outreach, w/ attachment "Local Outreach Media Alert for Solvay Review 8.31.05.doc"	401/403	2
0652	EDEL0000606 4 - EDEL0000606	10/28/2005	FYI: Dr. Patrick Knost	401/403	2
0653	ABBVIE- FST15816141 - ABBVIE- FST15816410	3/12/2015	FDA Labeling Response Submissions, w/ attached "final documents submitted to the FDA"	401/403	1
0654	ABBVIE- 00033296 - ABBVIE- 00033298	2000	"Is it part of life or is it low testosterone" Office Poster print ad w/ PI	401/403, Foundation	2 10
0655	ABBVIE- 00000945 - ABBVIE- 00000948	2001	Insert Cards - HCP Print Ads: "Profiles in Hypogonadism - The Compromised Patient" and "For many hypogonadal men-Clinical Performance in Your Practice"	401/403, Foundation	2 10
0656	ABBVIE- 00000952 - ABBVIE- 00000955	2001	Insert Cards - HCP Print Ads: "Profiles in Hypogonadism - The Fatigued Patient" and "For many hypogonadal men-Clinical Performance in Your Practice"	401/403, Foundation	2 10

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0657	ABBVIE-FST00302493 - ABBVIE-FST00302506	6/7/2001	Unimed Form 2253 submission to FDA for AG111 Psych Sales Aid ad for AndroGel; "Is His Mood Related to Low Testosterone?"		2 10
0658	ABBVIE-FST00303325 - ABBVIE-FST00303369	1/5/2001	Promotional Materials submission to FDA - Reprint study: 08/2000 - "Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men", from Journal of Clinical Endocrinology & Metabolism		2
0659	ABBVIE-FST00362657 - ABBVIE-FST00362657	11/4/2002	Could you have low testosterone? Take this quiz	401/403	2
0660	ABBVIE-FST00363449 - ABBVIE-FST00363473	2/19/2003	Unimed form 2253 and submissions to FDA for "AndroGel Leave Behind Brochure for HIV Patients", "AndroGel Leave Behind Brochure for Older Males", and "AndroGel Low T Leave Behind for Physicians"		
0661	ABBVIE-FST00303813 - ABBVIE-FST00303850	3/29/2004	Unimed form 2253 and submissions to FDA for "AndroGel Slim Jim-Leave Behind (AGL00342)" and "AndroGel Detail Aid (AGL00340)"		
0662	ABBVIE-FST11243249 - ABBVIE-FST11243260	3/2006	Print detail ad "See what he can regain from your prescription choice"	401/403	2
0663	ABBVIE-FST02423823 - ABBVIE-FST02423850	4/2007	Reprint for Promo: Urology Times - "Hypogonadism and Testosterone Replacement Therapy: The Controversy and The Evidence" based on a symposium held during Urology Congress April 2007	802, Foundation	10 12

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0664	ABBVIE- FST01902626 - ABBVIE- FST01902641	5/2004	Reprint study: 05/2004 - "Long-Term Testosterone Gel (AndroGel) Treatment Maintains Beneficial Effects on Sexual Function and Mood, Lean and Fat Mass, and Bone Mineral Density in Hypogonadal Men";		
0665	ABBVIE- FST11088922 - ABBVIE- FST11088923	4/2009	Print ad/Brochure - "When the diagnosis is Low T, recharge T levels with AndroGel"	401/403	2
0666	ABBVIE- FST11088933 - ABBVIE- FST11088936	3/2009	Print ad/Brochure - "Recharge T levels with AndroGel"	401/403, Foundation	2 8 10
0667	ABBVIE- FST15864183 - ABBVIE- FST15864188	4/2009	Detailed Leave Behind Brochure - "Before you diagnose ED, make sure it's not Low T"; Make testing for Low T part of your evaluation	401/403	2
0668	ABBVIE- FST02459982 - ABBVIE- FST02459985	3/2010	Brochure - "Identify the symptoms. Diagnose the condition."	401/403	2 8
0669	ABBVIE- FST02269674 - ABBVIE- FST02269689	2/2012	Detail Ad - "Preparing for the road ahead" - "Know these 5 risks to a man's health"	401/403	1K 2
0670	EDEL0011327 7 - EDEL0011328 6	7/20/2005	PR Recommendations, Timeline/List of Deliverables and Budget for AndroGel FDA Guidance on Label Change and Potential Advisory Committee Meeting	401/403, 802	2 3
0671	EDEL0011694 2 - EDEL0011694	12/22/2005	Draft Key Messages in Response to FDA draft guidance re TRT Class relabeling	401/403, Foundation	2 10
0672	EDEL0011297 1 - EDEL0011297	12/22/2005	DRAFT [merge] FORM letter to HCPs re Draft Guidance Changes	401/403, Foundation	2 10

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0673	EDEL0002886 4 - EDEL0002886	6/5/2007	Additional Experience for J&J Diabetes Edelman's Role w Solvay	401/403, 802	2 8
0674	EDEL0009811 3 - EDEL0009812	8/8/2003	PR Recommendations for Institute of Medicine Final Report	401/403, 802	2
0675	EDEL0010486 9 - EDEL0010489 5	8/26/2004	AndroGel Expanding the Market Preliminary 2005 Public Relations Recommendations presented by Edelman	401/403, 802	2
0676	EDEL0010503 3 - EDEL0010503		AndroGel Estimated 2005 Budget	401/403, Foundation	2 10
0677	EDEL0010707 1 - EDEL0010707		AndroGel 2006 Vision - Lead and Expand the TRT Market, draft presentation	401/403, 802, Foundation	2 8 10
0678			Periodic Safety Update Reports - PSUR 1 - PSUR 10 [P1.1882 - P1.1891] COMPOSITE COMPONENTS: <u>P1.2047</u> a - P1.2047 k		
0679		12/15/2016	CV of Laura Grablutz	401, 802, Foundation	7 10
0680	AUXILIUM_M DL_REG_0000 73901 - AUXILIUM_M DL_REG_0000 73926	10/31/2002	Letter from Dan Shames to Diane Myers re Testim 1%	401/403, Foundation	2 7 10
0681	3rdPARTY_TRT _PSC_PROD00 024152 - 3rdPARTY_TRT _PSC_PROD00 024213	2002	EDU-MEDICAL MANAGEMENT, INC. slides on Development and Status of 2002 Programs	401/403, 802, Foundation	2 10

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0682	3rdPARTY_TRT_PSC_PROD00 024895 - 3rdPARTY_TRT_PSC_PROD00 024895	2001	AndroGel Initiatives 2001 - 2002	401/403, 802, Foundation	2 10
0683	3rdPARTY_TRT_PSC_PROD00 024870 - 3rdPARTY_TRT_PSC_PROD00 024873		Local Community Outreach Educational Programs	401/403, 802, Foundation	2 10
0684	3rdPARTY_TRT_PSC_PROD00 024827 - 3rdPARTY_TRT_PSC_PROD00 024829	3/20/2002	Conference Call Summary for Education Initiatives Supported by AndroGel on March 20, 2002		
0685	3rdPARTY_TRT_PSC_PROD00 024412 - 3rdPARTY_TRT_PSC_PROD00 024433	7/19/2001	AndroGel 2001 Plan of Action - Medical Education	401/403, Foundation	2 10
0686	3rdPARTY_TRT_PSC_PROD00 024227 - 3rdPARTY_TRT_PSC_PROD00 024233	8/28/2001	Androgel Client Meeting Agenda to discuss initiatives for 2001-2002	401/403, 802, Foundation	2 10
0687	ABBVIE- 00315482 - ABBVIE- 00315532	3/6/2002	Letter enclosing copies of the Proceedings of The Endocrine Society Andropause Consensus Conferences 2000-2001		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0688	3rdPARTY_TRT_PSC_PROD00024955 - 3rdPARTY_TRT_PSC_PROD00024976	6/6/2002	Summary/Recommendations w/attachment: "Summary 6-5.doc" (Summary of the Consensus Session From the Second Annual Andropause Consensus 2001 Meeting)		
0689	ABBVIE-00039028 - ABBVIE-00039033	11/2/2001	Unimed Project Status Report as of November 2, 2001	401/403, 802, Foundation	2 10
0690	3rdPARTY_TRT_PSC_PROD00024948 - 3rdPARTY_TRT_PSC_PROD00024954	12/7/2001	Unimed Project Status Report as of December 7, 2001 prepared by Susan Reinhardt	401/403, 802, Foundation	2 10
0691	LILLYAX-MDL2545-01989258 - LILLYAX-MDL2545-01989952	7/17/2014	TRT Ad Com - Briefing Book (BB) CV Safety Section, w/ attached "TRT Ad Com BB CV Risk Section draft v2 15 JUL 2014.Lilly consolidated comments.docx" and "Citizen Petition Denial Response from FDA CDER to Public Citizen1.pdf"	401/403, 802	1 10
0692	3rdPARTY_TRT_PSC_PROD00024454 - 3rdPARTY_TRT_PSC_PROD00024502		Male Hypogonadism: Prevalence, Diagnosis, Consequences, and New Treatment Strategies	401/403, 802, Foundation	2 10
0693	3rdPARTY_TRT_PSC_PROD00024602 - 3rdPARTY_TRT_PSC_PROD00024603		Draft letter re St. Louis University sponsoring CME-accredited roundtable programs	401/403, 802, Foundation	2 10

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0694	3rdPARTY_TRT_PSC_PROD00024531 - 3rdPARTY_TRT_PSC_PROD00024546	8/3/2000	Testosterone and Men: Emerging Clinical Issues An Educational CME Roundtable Dinner Series Sponsored by St. Louis Univeristy		
0695	3rdPARTY_TRT_PSC_PROD00025002 - 3rdPARTY_TRT_PSC_PROD00025028	9/28/2000	EDU-Medical Management, Inc. Presentation to Mr. David Knocke of Unimed Pharmaceuticals, Inc. Company on September 28, 2000	401/403, foundation	2 10
0696	3rdPARTY_TRT_PSC_PROD00024917 - 3rdPARTY_TRT_PSC_PROD00024922	10/18/2001	Unimed Project Status Report as of October 18, 2001	401/403, 802, Foundation	2 10
0697	3rdPARTY_TRT_PSC_PROD00024899 - 3rdPARTY_TRT_PSC_PROD00024901		Unimed Project Status Report as of TIME	401/403, 802, Foundation	2 10
0698	ABBVIE-FST08741096 - ABBVIE-FST08741128	12/8/2009	AndroGel Update 12.8.09	401/403	2 5 13 14
0699	ABBVIE-FST10947789 - ABBVIE-FST10947814	2007	The Role of e-Marketing	401/403	2
0700	ABBVIE-FST15349786 - ABBVIE-FST15349877	1/5/2012	Business Plans, w/ attachment "AndroGel 2010 BP_v3_Commercial Ops Exec Team_ATU_Nov.23.ppt"		1K
0701			Curriculum vitae of William Best	401, 802, foundation	7 10

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0702	ENDO- MDL2545- 00042148 - ENDO- MDL2545- 00042186	9/28/2009	FORTESTA PI (NDA 21-463) w/attachments: "REV 2 FORTESTA P1 Sept 28 MARKED.docx; REV 2 FORTESTA P1 Sept 28 CLEAN.docx"	401/403, Foundation	2 7 10
0703	ENDO- MDL2545- 00042187 - ENDO- MDL2545- 00042189	10/1/2009	FDA Telephone Contact Report: October 1, 2009	401/403, Foundation	7 10
0704			PDR reference re AndroGel	401	1K
0705	ABBVIE- FST19408744 - ABBVIE- FST19408826	3/9/2007	Screening Forms Audit	401, 802	13 14
0706	ABBVIE- FST01463780 - ABBVIE- FST01463805	4/22/2010	Summary Bridging Report TESTOSTERONE [Report No.: TEST SBR 02] ATC Code: G03BA03 Period Covered: 28 FEB 2007 - 27 FEB 2010	401, Foundation	10
0707	ABBVIE- 00181201 - ABBVIE- 00181201	1/6/1999	Letter from Unimed to Dobs re: Contact by representatives of Edelman Concerning Experience with Androgen Gels	401	2 7
0708	ABBVIE- 00181203 - ABBVIE- 00181203	1/6/1999	Letter from Unimed to Snyder re: Contact by representatives of Edelman Concerning Experience with Androgen Gels	401	2 7
0709	ABBVIE- 00181204 - ABBVIE- 00181204	1/6/1999	Letter from Unimed to Cunningham re: Contact by representatives of Edelman Concerning Experience with Androgen Gels	401	2 7

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0710	ABBVIE-00216971 - ABBVIE-00216971	1/6/1999	Letter from Unimed to Cunningham re: Contact by representatives of Edelman Concerning Experience with Androgen Gels	401	2 7
0711	ABBVIE-FST18772083 - ABBVIE-FST18772155		AndroGel DTC Campaign Results: Final Analysis Presentation 4/23/09 - 7/31/09	401/403	2
0712	ABBVIE-FST18236641 - ABBVIE-FST18236728	2009	Solvay presentation "AndroGel" Brian Mitchell Business Director, Specialized Markets	401/403	2 7 8
0713		6/19/2014	Axiron FDA Label & Medication Guide	401/403, Foundation	1 7 10
0714	LILLYAX-MDL2545-01511427 - LILLYAX-MDL2545-01511431		Curriculum Vitae of Kathryn Broderick	401, 802, Foundation	7 10
0715	3rdPARTY_TRT_PSC_PROD00024565 - 3rdPARTY_TRT_PSC_PROD00024574	8/21/2000	Testosterone Replacement Therapy: Emerging Clinical Issues		
0716	TD000005 - TD000007		Curriculum Vitae of Kristin Vitanza Squires	401, 802, Foundation	7 10
0717	ENDO-MDL2545-00277401 - ENDO-MDL2545-00277559	2011	FORTESTA 2% Launch Readiness Plan/2011 Tactical Plan	401/403, 802 Foundation	1K 7 10

TRT MDL 2545 (Konrad/Mitchell)

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0718	ENDO- MDL2545- 00114810 - ENDO- MDL2545- 00114827	12/2/2013	Submission of promotional materials	401/403, Foundation	1 2 7 10
0719	ENDO- MDL2545- 00294964 - ENDO- MDL2545- 00295080		Testosterone Replacement Therapy Advisory Council	401/403, 802, foundation	2 7 10
0720	ENDO- MDL2545- 00313277 - ENDO- MDL2545- 00313277	1/7/2011	FORTESTA Gel TRT Advisory Board Meeting Debrief	401, Foundation	1K 7 10
0721	ENDO- MDL2545- 00313278 - ENDO- MDL2545- 00313293	12/11/2010	TRT Advisory Council Executive Summary	401/403, 802, Foundation	1K 7 10
0722	ENDO- MDL2545- 00527634 - ENDO- MDL2545- 00527680	4/8/2013	FORTESTA Gel Behavioral Science Literature Review	401/403, 802, Foundation	1 2 7 10
0723	ENDO- MDL2545- 00282897 - ENDO- MDL2545- 00282932	10/11/2010	Driving Men to Step Up to the Staying Power of FORTESTA	401/403, 802, Foundation	2 7 10

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0724	ABBVIE-00634209 - ABBVIE-00634210	10/20/2005	FDA Contact Report re Psychometric Evaluation of Scales		
0725	ABBVIE-00634206 - ABBVIE-00634208	1/11/2005	FDA Contact Report re Follow-up to Solvay letter requesting info re Psychometric Evaluation of Scales		
0726	ABBVIE-FST00427084 - ABBVIE-FST00427100	4/26/2005	FDA Contact Report re Androgel Label		
0727	ABBVIE-00366744 - ABBVIE-00366745	3/17/2005	FDA Contact Report re Long-term Extension Data Supplement		
0728	ABBVIE-FST13320719 - ABBVIE-FST13320720	10/4/2005	Testosterone Class Labeling Response Team Meeting Minutes	401	2 5
0729	ABBVIE-FST13320721 - ABBVIE-FST13320722	11/1/2005	Testosterone Class Labeling Response Team Meeting Minutes	401	2 5
0730	ABBVIE-FST13320723 - ABBVIE-FST13320730	5/5/2005	Testosterone Class Labeling Response Team Meeting Minutes		
0731	ABBVIE-FST14618380 - ABBVIE-FST14618385	4/21/2005	Testosterone Class Labeling Response Team Meeting Minutes		
0732	ABBVIE-FST14633836 - ABBVIE-FST14633839	1/31/2006	Testosterone Class Labeling Response Team Meeting Minutes	401	2 5

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0733	ABBVIE- FST14633840 - ABBVIE- FST14633842	2/14/2006	Testosterone Class Labeling Response Team Meeting Minutes	401	2 5
0734	ABBVIE- FST14633843 - ABBVIE- FST14633845	2/28/2006	Testosterone Class Labeling Response Team Meeting Minutes	401	2 5
0735	ABBVIE- FST14633849 - ABBVIE- FST14633852	4/11/2006	Testosterone Class Labeling Response Team Meeting Minutes	401	2 5
0736	ABBVIE- FST14633856 - ABBVIE- FST14633858	5/16/2006	Testosterone Class Labeling Response Team Meeting Minutes	401	2 5
0737	ABBVIE- FST14633859 - ABBVIE- FST14633861	6/13/2006	Testosterone Class Labeling Response Team Meeting Minutes	401	2 5
0738	ABBVIE- FST14633862 - ABBVIE- FST14633864	8/8/2006	Testosterone Class Labeling Response Team Meeting Minutes	401	2 5
0739	ABBVIE- FST14633865 - ABBVIE- FST14633867	9/12/2006	Testosterone Class Labeling Response Team Meeting Minutes	401	2 5
0740	ABBVIE- FST14633870 - ABBVIE- FST14633873	11/29/2005	Testosterone Class Labeling Response Team Meeting Minutes	401	2 5
0741	ABBVIE- FST14633874 - ABBVIE- FST14633879	4/14/2005	Testosterone Class Labeling Response Team Meeting Minutes		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0742	ABBVIE- FST14633887 - ABBVIE- FST14633894	5/10/2005	Testosterone Class Labeling Response Team Meeting Minutes		
0743	ABBVIE- FST14633902 - ABBVIE- FST14633909	5/31/2005	Testosterone Class Labeling Response Team Meeting Minutes		
0744	ABBVIE- FST14633910 - ABBVIE- FST14633917	6/14/2005	Testosterone Class Labeling Response Team Meeting Minutes		
0745	ABBVIE- FST14633918 - ABBVIE- FST14633925	6/21/2005	Testosterone Class Labeling Response Team Meeting Minutes		
0746	ABBVIE- FST14633961 - ABBVIE- FST14633967	8/23/2005	Testosterone Class Labeling Response Team Meeting Minutes		
0747	ABBVIE- FST14737781 - ABBVIE- FST14737787	5/17/2005	Testosterone Class Labeling Response Team Meeting Minutes		
0748	ABBVIE- FST02252734 - ABBVIE- FST02252893	9/17/2014	Testosterone Replacement Therapy FDA Advisory Committee Industry Briefing Document		
0749	ABBVIE- FST06144608 - ABBVIE- FST06144616	9/17/2014	FDA CDER Summary Minutes of Advisory Committee Meeting		
0750		9/17/2014	FDA Advisory Committee Meeting materials for attendees	401/403	1

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0751		12/2009	FDA Guidance for Industry "Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims"		
0752	ABBVIE- FST11215659 - ABBVIE- FST11215660	1/31/2014	FDA Drug Safety Communication: FDA Evaluating Risk of Stroke, Heart Attack, and Death with FDA- Approved Testosterone Products	401/403	1
0753	ABBVIE- FST00507025 - ABBVIE- FST00507233	9/17/2014	FDA Background Documents for Advisory Committee		
0754		1/23/2004	Guidance for Industry "Help-Seeking" and Other Disease Awareness Communications by or on Behalf of Drug and Device Firms		
0755		3/22/2005	Guidance for Industry "Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment"		
0756		4/13/2016	CDER Office of Surveillance and Epidemiology Organizational Chart	401/403	1 6
0757		4/2012	Advances in FDA's Safety Programs for Marketed Drugs Establishing Premarket Safety Review and Marketed Drug Safety as Equal Priorities at FDA's Center for Drug Evaluation and Research	401/403, Foundation	1K 10
0758		2012	HIMSS12 Annual Conference & Exhibition EHRs: The New Drug Safety, Liability and Efficacy Battleground	401/403, 802	1K 6
0759			The Use of the WHO-UMC System for Standardised Case Causality Assessment		
0760		7/15/2014	Summary Safety Review - Testosterone Replacement Products Cardiovascular Risk	401/403	1 4

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0761		7/15/2014	Information Update - Possible cardiovascular problems associated with testosterone products	401/403; 802	1 4
0762		3/2001	Guidance for Industry "Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines"		
0763		7/22/2003	FDA Website printout: Regulating Prescription Drug Promotion - Statement of Janet Woodcock, MD		
0764		5/22/2014	Marketed Health Products Directorate, Health Products and Food Branch Health Canada Signal Assessment - Testosterone Containing Products (ANDRODERM, ANDRIOL, ANDROGEL, AXIRON, DELATESTRYL, DEPO-TESTOSTERONE, Testim and Generics) - Cardiovascular Risk	401/403	1 4
0765			Advisory Committee Clinical Background Document - Testosterone Replacement Therapy: Clinical Development and Target	401/403	1
0766		9/30/2004	Regulatory Document - Vioxx (rofecoxib) Sep 2004; FDA Public Health Advisory: Safety of Vioxx	401/403	7
0767		2/17/2016	WBUR Interview of Shalender Bhasin, "Testosterone For Older Men: Major Study Finds Modest Benefits, Mainly Sexual" by Carey Goldberg	401/403; 408	1
0768		4/29/2011	FDA Approval Package: <u>Medical Review(s)</u> AndroGel 1.62%, NDA 22-309		
0769		4/28/2009	FDA Approval Package: <u>Cross-Discipline Team Leader Memo</u> AndroGel 1.62%, NDA 22-309		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

0770	FDA_FOIA_01 8129 - FDA_FOIA_01 8140	5/21/2010	Fatmatta Kuyateh Memorandum		
0771		7/2007	Delatestryl (Testosterone Enanthate Injection, USP), Multiple Dose Vial - Package Insert	401/403, 802	7 10
0772		7/29/2002	Radio Broadcast "Andropause Debate" between Dr. John Morley (Endo Society) and Dr. Jerome Groopman (author of New Yorker "Hormones for Men") via The Connection from WBUR FM Boston and NPR	401/403, 802	2
0773		7/1/2002	Pharmaceutical Research and Manufacturers of America ("PhRMA") Code on Interactions with Healthcare Professionals		
0774		1/1/2009	Pharmaceutical Research and Manufacturers of America ("PhRMA") Code on Interactions with Healthcare Professionals		
0775		10/2007	Viagra (Sildenafil citrate) Product Label; Rev. October 2007	401/403, 802, Foundation	7 10
0776		1/2010	Viagra (Sildenafil citrate) Product Label; Rev. January 2010	401/403, 802, Foundation	7 10
0777	FDA_FOIA_02 9041 - FDA_FOIA_02 9053	12/6/2010	Fatmatta Kuyateh Memorandum		
0778	FDA_FOIA_00 7711 - FDA_FOIA_00 9035	4/29/2011	Approval Package for AndroGel 1.62%		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

Plaintiffs' Medical Literature

Trial Exhibit No.	BatesRange	Author(s)	Source	Title	Doc Date	Objection Basis	Objection Code
Defendants have a standing objection to the use of any medical literature beyond what the Federal Rules of Evidence permits. Specifically, medical literature cannot be admitted as substantive evidence or as an exhibit, and may only be used if the offering party has laid a sufficient foundation under Rule 703 and Rule 803(18).							
1000		Vigen et al	Journal of the American Medical Association	Association of Testosterone Therapy with Mortality, Myocardial Infarction, and Stroke in Men with Low Testosterone Levels	11/20/2013		
1001		Liverman & Blazer	National Academy of Sciences	Testosterone and Aging: Clinical Research Directions	11/1/2003		
1002		Schwartz & Woloshin	JAMA Internal Medicine	Low "T" as in "Template" How to Sell Disease	8/12/2013	802, 401/403	7 12
1003		Wu et al	The New England Journal of Medicine	Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men	7/8/2010		
1004		Braun	JAMA Internal Medicine	Promoting "Low T" A Medical Writer's Perspective	8/12/2013	802, 401/403	12
1005		Baillargeon et al	Annals of Pharmacotherapy	Risk of Myocardial infarction in Older Men Receiving Testosterone Therapy	7/8/2014		
1006		Basaria et al	The New England Journal of Medicine	Adverse Events Associated with Testosterone Administration	7/8/2010		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1007	MR-TAM-000001 - MR-TAM-000239	Liverman & Blazer	Committee on Assessing the Need for Clinical Trials of TRT	Testosterone and Aging: Clinical Research Directions	1/1/2004		
1008		Finkle et al	PLOS One	Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men	1/1/2014		
1009		Xu et al	BMC Medicine	Testosterone Therapy and Cardiovascular Events Among Men: A Systematic Review and Meta-Analysis of placebo-controlled randomized trials	1/1/2013		
1010		Etminan et al	Pharmacotherapy Publications, Inc.	Testosterone Therapy and Risk of Myocardial Infarction: A Pharmacoepidemiologic Study	2015		
1011		Fernandez-Balsells et al	Journal of Clinical Endocrinology & Metabolism	Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis	6/2010		
1012		Guo et al	Endocrinology	The Effects of Short-Term and Long-Term Testosterone Supplementation on Blood Viscosity and Erythrocyte Deformability in Health Adult Mice	3/12/2015		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1013		Perls & Handelsman	Journal of the American Geriatrics Society	Disease Mongering of Age-Associated Declines in Testosterone and Growth Hormone	2015	802, 401/403	4 12
1014		Snyder et al	Clinical Trials	The Testosterone Trials: Seven coordinated trials of testosterone treatment in elderly men	2014	802, 403 (cumulative)	
1015		Sharma et al	European Heart Journal	Normalization of Testosterone Level is Associated with Reduced Incidence of Myocardial Infarction and Mortality in Men	8/6/2015		
1016		Nguyen et al	The New England Journal of Medicine	Testosterone and "Age-Related Hypogonadism" - FDA Concerns	8/20/2015	802, 401/403	12
1017		Goodman et al	American Association of Clinical Endocrinologists [and] American College of Endocrinology	Position Statement on the Association of Testosterone and Cardiovascular Risk	Sep-15		
1018		Basaria et al	JAMA	Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels - A Randomized Clinical Trial	8/11/2015		
1019		Shames et al	Journal of Clinical Endocrinology & Metabolism	COMMENTARY: Guideline for Male Testosterone Therapy: A Regulatory Perspective	Feb-07	802, 401/403	3 12

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1020		Shames et al	The New England Journal of Medicine	TO THE EDITOR: re Risks of Testosterone Replacement	5/6/2004	802, 401/403	3 12
1021	ABBVIE-FST01388782 - ABBVIE-FST01388821	Blazer et al	Institute Of Medicine of the National Academies	Testosterone and Aging: Clinical Research Directions Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy	Nov-03		
1021		Anderson et al	American Journal of Cardiology	Impact of Testosterone Replacement Therapy on Myocardial Infarction, Stroke, and Death in Men With Low Testosterone Concentrations in an Integrated Health Care System	12/13/2015		
1022		Snyder et al	The New England Journal of Medicine	Effects of Testosterone Treatment in Older Men	2/18/2016		
1023		Orwoll	The New England Journal of Medicine	Editorial: Establishing a Framework - Does Testosterone Supplementation Help Older Men?	2/18/2016	802, 401/403	7 12
1024	ABBVIE-FST02413336 - ABBVIE-FST02413371	Bhasin et al	Journal of Clinical Endocrinology & Metabolism	Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline	Jun-10		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1025		Mulligan et al	The International Journal of Clinical Practice	Prevalence of Hypogonadism in Males Aged at Least 45 Years: The HIM Study	Jul-06		
1026		Wallis et al	Lancet Diabetes & Endocrinology	Survival and Cardiovascular Events in Men Treated with Testosterone Replacement Therapy: An Intention-to-treat Observational Cohort Study	5/7/2016		
1027		Chen et al	Mann's Pharmacovigilance, Third Edition	Part II: Pharmacovigilance Systems, Pharmacovigilance in the Americas Ch. 14a. "Spontaneous Reporting and Pharmacovigilance Practice: USA"	4/4/2014		
1028		Cunningham et al	Journal of Clinical Endocrinology & Metabolism	Testosterone Treatment and Sexual Function in Older Men with Low Testosterone Levels	Jun-16		
1029		Corona et al	Expert Opinion on Drug Safety	Cardiovascular Risk Associated with Testosterone-Boosting Medication: A Systematic Review and Meta-Analysis	8/19/2014		
1030		Groopman	The New Yorker	Hormones For Men Is male menopause a question of medicine or of marketing?	7/29/2002	802, 401/403	7 12

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1031		Martinez et al	British Medical Journal	Testosterone treatment and risk of venous thromboembolism: population based case-	11/30/2016		
1032		Albert & Morley	Clinical Endocrinology	Testosterone Therapy, Association with Age, Initiation and Mode of Therapy with Cardiovascular Events: A Systematic Review	5/11/2016		
1033		Cheetham et al	JAMA	Association of Testosterone Replacement With Cardiovascular Outcomes Among Men With Androgen Deficiency	2/21/2017		
1034		Coviello et al	Journal of Clinical Endocrinology & Metabolism	Effects of Graded Doses of Testosterone on Erythropoiesis in Healthy Young and Older Men	12/26/2007		
1035		Hill	Proceedings of the Royal Society of Medicine	Sir Austin Bradford Hill's Address/The Environment and Disease: Association or Causation?	1/14/1965		
1036		Wu et al	Pharmaceutical Development and Regulation	Postmarketing Drug Safety Surveillance- An Overview of Regulatory Issues	2003		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1037	ABBVIE-FST01395623 - ABBVIE-FST01395632	Kenny et al	Journal of the American Geriatric Society	Effects of Transdermal Testosterone on Bone and Muscle in Older Men with Low Bioavailable Testosterone Levels, Low Bone Mass, and Physical Frailty	Jun-10		
1038		Ajayi et al	Circulation	Testosterone Increases Human Platelet Thromboxane A2 Receptor Density and Aggregation Responses	6/1/1995		
1039		Death et al	Endocrinology	Dihydrotestosterone Promotes Vascular Cell Adhesion Molecule-1 Expression in Male Human Endothelial Cells via a Nuclear Factor-kB-Dependent Pathway	Apr-04		
1040		Onasanya et al	Lancet Diabetes & Endocrinology	Association Between Exogenous Testosterone and Cardiovascular Events: An Overview of Systematic Reviews	9/23/2016		
1041		Haddad et al	Mayo Clinic Proceedings	Testosterone and Cardiovascular Risk in Men: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials	Jan-07		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1042		Kaufman et al	Journal of Sexual Medicine	One-Year Efficacy and Safety Study of a 1.62% Testosterone Gel in Hypogonadal Men: Results of a 182-Day Open-Label Extension of a 6-Month Double-Blind Study	Apr-12		
1043		Hartgens & Kuipers	Sports Med	Effects of Androgenic-Anabolic Steroids in Athletes	2004	802, 401/403	12
1044		Angell et al	Sports Med	Anabolic Steroids and Cardiovascular Risk	2012	802, 401/403	12
1045		Sonmez et al	Endocrine Journal	Endothelial Dysfunction, Insulin Resistance and Inflammation in Congenital Hypogonadism, and the Effect of Testosterone	2015		
1046		Alexander et al	American Journal of Medicine	Cardiovascular Risks of Exogenous Testosterone Use Among Men: A Systematic Review and Meta-Analysis	Oct-16		
1047		Tivesten et al	Journal of Clinical Endocrinology & Metabolism	Circulating Estradiol Is an Independent Predictor of Progression of Carotid Artery Intima-Media Thickness in Middle-Aged Men	2006		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1048		Cavasin et al	American Journal of Physiology-Heart and Circulatory Physiology	Estrogen and Testosterone Have Opposing Effects on Chronic Cardiac Remodeling and Function in Mice with Myocardial Infarction	1/30/2003		
1049		Huo et al	PLOS ONE	Treatment of Men for "Low Testosterone": A Systematic Review	9/21/2016		
1050		Matsuda et al	Prostaglandins	Sex Steroid Regulation of Thromboxane A2 Receptors in Cultured Rat Aortic Smooth Muscle Cells	1995		
1051		Matsuda et al	American Physiological Society	Androgen Regulation of Thromboxane A2/Prostaglandin H2 Receptor Expression in Human Erythroleukemia Cells	1993	802, 401/403	7 12
1052		Matsuda et al	American Physiological Society	Testosterone Increases Thromboxane A2 Receptor Density and Responsiveness in Rat Aortas and Platelets	1994		
1053		Schorr et al	European Journal of Clinical Investigation	Testosterone Treatment Enhances Thromboxane A2 Mimetic Induced Coronary Artery Vasoconstriction in Guinea Pigs	1994	802, 401/403	12
1054		Moynihan et al	British Medical Journal	Selling Sickness: The Pharmaceutical Industry and Disease Mongering	4/13/2002	802, 401/403	4 12

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1055		Handelsman	Medical Journal of Australia	Global Trends in Testosterone Prescribing, 2000-2011: Expanding the Spectrum of Prescription Drug Misuse	10/21/2013	802, 401/403	4 12
1056		Bhasin et al	Journal of Andrology	Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan	May-03		
1057		Handelsman	Medical Journal of Australia	Trends and Regional Differences in Testosterone Prescribing in Australia, 1991 - 2001	2004	802, 401/403	4 12
1058		Handelsman	Medical Journal of Australia	Pharmacoepidemiology of Testosterone Prescribing in Australia, 1992 - 2010	2012	802, 401/403	4 12
1059		Handelsman	Asian Journal of Andrology	An Old Emperor Finds New Clothing: Rejuvenation in Our Time	2011	802, 401/403	7 12
1060		Goodman et al	Endocrine Practice	American Association of Clinical Endrocrinologists and American College of Endocrinology Position Statement on the Association of Testosterone and Cardiovascular Risk	9/1/2015		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1061		Halushka et al	Transactions of the American Clinical and Climatological Association	The Gordon Wilson Lecture - Regulation of Thromboxane A2 Receptors by Testosterone: Implications for Steroid Abuse and Cardiovascular Disease	1994	802, 401/403	12
1062		Laughlin et al	The Endocrine Society	Low Serum Testosterone and Mortality in Older Men	Jan-08		
1063		Khaw et al	Circulation	Endogenous Testosterone and Mortality Due to All Causes, Cardiovascular Disease, and Cancer in Men: European Prospective Investigation Into Cancer In Norfolk Prospective Population Study	2007		
1064		Araujo et al	Journal of Clinical Endocrinology & Metabolism	Endogenous Testosterone and Mortality in Men: A Systematic Review and Meta-Analysis	2011		
1065		Oskui et al	Journal of the American Heart Association	Testosterone and the Cardiovascular System: A Comprehensive Review of the Clinical Literature	2013		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1066		Calof et al	Journal of Gerontology	Adverse Events Associated with Testosterone Replacement in Middle-Aged and Older Men: A Meta-Analysis of Randomized, Placebo-Controlled Trials	2005		
1067		Shores et al	Journal of Clinical Endocrinology & Metabolism	Testosterone Treatment and Mortality in Men with Low Testosterone	2012		
1068		Harman et al	Journal of Clinical Endocrinology & Metabolism	Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men	2001		
1069		Baillargeon et al	JAMA Internal Medicine	Trends in Androgen Prescribing in the United States 2001 to 2011	Aug-13		
1070		Maggi et al	International Journal of Clinical Practice	Testosterone Treatment Is Not Associated With Increased Risk of Adverse Cardiovascular Events: Results From the Registry of Hypogonadism in Men (RHYME)	2016		
1071		Wasserstein & Lazar	American Statistician	The ASA's Statement on p-Values: Context, Process, and Purpose	2016		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1072	AUXILIUM_M DL_CUST_001 304393 - AUXILIUM_M DL_CUST_001 304402	Mohr et al	Journal of Clinical Endocrinology	Normal, Bound and Nonbound Testosterone Levels in Normally Aging Men: Results From the Massachusetts Male Ageing Study	2005	802, 401/403	
1073		Burris et al	Journal of Clinical Endocrinology & Metabolism	Gonadotropin Therapy in Men with Isolated Hypogonadotropic Hypogonadism: The Response to Human Chorionic Gonadotropin is Predicted by Initial Testicular Size	1988	401/403	7 13 14
1074		Pitteloud et al	UpToDate	Isolated Gonadotropin- Releasing Hormone Deficiency (Idiopathic Hypogonadotropic Hypogonadism)	8/31/2016		
1075		Adhiyaman et al	Postgraduate Medical Journal	Chronic Subdural Haematoma in the Elderly	2002	802, 401/403	
1076		Deitch & Kirshner	Neurology	Subdural Hematoma After Normal CT	1989	802, 401/403	
1077		Layton et al	JAMA	Association Between Direct-to-Consumer Advertising and Testosterone Testing and Initiation in the United States, 2009- 2013	3/21/2017		
1078		Kravitz	JAMA	Direct-to-Consumer Advertising of Androgen Replacement Therapy	3/21/2017	802, 401/403	12

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1079	ABBVIE-00171305 - ABBVIE-00171308	Anderson et al	Journal of Gerontology	Andropause: Knowledge and Perceptions Among the General Public and Health Care Professionals	2002		
1080		Abramson	Epidemiologic Perspectives & Innovations	WINPEPI updated: computer programs for epidemiologists, and their teaching potential	2011		
1081		Alessi & Juhan-Vague	Thrombosis & Haemostasis	I. Metabolic syndrome, haemostasis and thrombosis	2008		
1082		Altschule & Tillotson	The New England Journal of Medicine	The use of testosterone in the treatment of depressions	1948		
1083		Ambre	JAMA	Medical and Nonmedical Uses of Anabolic-Androgenic Steroids	1990	802, 401/403	12
1084		Anderson et al	JAMA	Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial	2004	802, 401/403	7 12
1085		Andersson et al	Journal of Clinical Endocrinology & Metabolism	Secular decline in male testosterone and sex hormone binding globulin serum levels in Danish population surveys	2007		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1086		Andersson et al	Journal of Clinical Endocrinology & Metabolism	Impaired Leydig cell function in infertile men: a study of 357 idiopathic infertile men and 318 proven fertile controls	2004		
1087		Andrews et al	PloS One	Interventions to influence consulting and antibiotic use for acute respiratory tract infections in children: a systematic review and meta-analysis	2012	802, 401/403	7 12
1088		Anonymous	Lancet	Dr Brown-Sequard's "Elixir of Life"	1890		
1089		Araujo et al	Journal of Clinical Endocrinology & Metabolism	Prevalence of symptomatic androgen deficiency in men	2007		
1090		Araujo et al	Archives of Internal Medicine	Sex steroids and all-cause and cause-specific mortality in men	2007		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1091		Aronow et al	Journal of the American College of Cardiology	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of	2011		
1092		Asthana et al	Journal of Gerontology	Masculine Vitality: Pros and Cons of Testosterone in Treating the Andropause	2004	802, 401/403	12

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1093		Aversa et al	The Journal of Sexual Medicine	Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study	2010		
1094		Aversa et al	Journal of Endocrinological Investigation	Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome	2010		
1095		Bachman et al	The Journals of Gerontology Series A: Biological Sciences and Medical Sciences	Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point	2014		
1096		Bachman et al	Journal of Clinical Endocrinology & Metabolism	Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis	2010		
1097		Barrett-Connor et al	Annual Review Public Health	The rise and fall of menopausal hormone therapy	2005	802, 401/403	12

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1098		Basaria et al	Journal of Clinical Endocrinology & Metabolism	Androgen abuse in athletes: detection and consequences	2010	802, 401/403	12
1099		Basaria et al	The Journals of Gerontology Series A: Biological Sciences and Medical Sciences	Risk factors associated with cardiovascular events during testosterone administration in older men with mobility limitation	2013	802, 401/403 (cumulative)	
1100		Bassil & Morley	Clinics in Geriatric Medicine	Late-life onset hypogonadism: a review	2010		
1101		Bauer et al	British Journal of Pharmacology	Pathophysiology of isoprostanines in the cardiovascular system: implication of isoprostane-mediated thromboxane A2 receptor activation	2014		
1102		Behre et al	Clinical Endocrinology	Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7–10 years	1999		
1103		Belanger et al	Journal of Clinical Endocrinology & Metabolism	Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men	1994		
1104		Berkman et al	Annals of Internal Medicine	Emotional support and survival after myocardial infarction: a prospective, population-based study of the elderly	1992	802, 401/403	12 13 14

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1105		Bhasin et al	Nature Clinical Practice Endocrinology & Metabolism	Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging	2006		
1106		Bojesen et al	Journal of Clinical Endocrinology & Metabolism	Increased mortality in Klinefelter syndrome	2004		
1107		Bojesen et al	Journal of Clinical Endocrinology & Metabolism	Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study	2003		
1108		Bolona et al	Mayo Clinic Proceedings	Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo- controlled trials	2007		
1109		Borell	Journal of the History of Biology	Organotherapy, British physiology, and discovery of the internal secretions	1976		
1110		Borst et al	BMC Medicine	Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis	2014		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1111		Borst et al	American Journal of Physiology- Endocrinology & Metabolism	Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial	2017	401/403	12
1112		Boyle et al	BJU International	Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate specific antigen (PSA): a meta-analysis	2016		
1113		Brand et al	International Journal of Epidemiology	Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies	2014		
1114		Bremner	The New England Journal of Medicine	Testosterone Deficiency and Replacement in Older Men	2010	802, 401/403	7 12
1115		Budoff et al	JAMA	Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone	2017		
1116		Bush et al	American Journal of Cardiology	Even minimal symptoms of depression increase mortality risk after acute myocardial infarction	2001	802, 401/403	12 13 14

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1117		Carlin	Statistics in Medicine	Meta-analysis for 2 x 2 tables: a Bayesian approach	1992		
1118		Carnes & Dech	International Journal of Andrology	Effects of dihydrotestosterone on cardiac inward rectifier K(+) current	2002		
1119		Carney et al	American Journal of Cardiology	Major depressive disorder in coronary artery disease	1987	802, 401/403	12 14
1120		Carosa et al	Clinical Endocrinology (Oxf)	Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels	2004	802, 401/403	7 12 13 14
1121		Case et al	JAMA	Living alone after myocardial infarction	1992	802, 401/403	12 13 14
1122		CDC	Centers for Disease Control and Prevention: https://www.cdc.gov/diabetes/statistics/incidence/fig5.htm	Incidence of Diagnosed Diabetes per 1,000 Population Aged 18-79 Years, by Sex and Age, United States, 1997-2014	2015		
1123		Charbit et al	American Journal of Cardiology	Effects of testosterone on ventricular repolarization in hypogonadic men	2009		
1124		Çınar et al	American Journal of Hypertension	Effect of hematocrit on blood pressure via hyperviscosity	1999		
1125		Coffee et al	American Journal of Human Genetics	Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA	2009	802, 401/403	12 13 14
1126		Cohen	American Psychologist	The earth is round ($p < .05$)	1994		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1127		Cohen et al	Advances in Pharmacology	TP receptors and oxidative stress: hand in hand from endothelial dysfunction to atherosclerosis	2010	802	
1128		Colwell et al	Medical Clinics of North America	Platelet function in Diabetes Mellitus	1978		
1129		Corona et al	The Journal of Sexual Medicine	Testosterone and metabolic syndrome: a meta-analysis study	2011		
1130		Cowan et al	Cardiovascular Drugs & Research	Importance of blood rheology in the pathophysiology of atherothrombosis	2012		
1131		D'Agostino et al	Circulation	General cardiovascular risk profile for use in primary care the Framingham Heart Study	2008		
1132		D'Ascenzo et al	Toxicology Letters	Detrimental effects of anabolic steroids on human endothelial cells	2007	802, 401/403	12
1133		Davi & Patrono	The New England Journal of Medicine	Platelet activation and atherothrombosis	2007		
1134		Davi et al	Circulation	Increased Thromboxane Biosynthesis in Type IIa Hypercholesterolemia	1992		
1135		Davi et al	JAMA	Platelet activation in obese women: role of inflammation and oxidant stress	2002	802, 401/403	12 13 14

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1136		Davis-Bruno & Halushka	Advances in Drug Research	Molecular pharmacology and therapeutic potential of thromboxane A2 receptor antagonists	1994		
1137		DerSimonian & Laird	Control Clinical Trials	Meta-analysis in clinical trials	1986		
1138		Deslypere & Vermeulen	Journal of Clinical Endocrinology & Metabolism	Aging and tissue androgens	1981		
1139		Dorn et al	Circulation	Increased platelet thromboxane A2/prostaglandin H2 receptors in patients with acute myocardial infarction	1990		
1140		Kunnas et al	Preventative Medicine	Hematocrit and the risk of coronary heart disease mortality in the TAMRISK study, a 28-year follow-up	2009		
1141		Yarnell et al	Circulation	Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies	1991		
1142		Funk & Fitzgerald	Journal of Cardiovascular Pharmacology	COX-2 inhibitors and cardiovascular risk	2007	802, 401/403	7 12 13 14

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1143		Zhang et al	American Journal of Epidemiology	Sex-steroid hormones and electrocardiographic QT-interval duration: findings from the third National Health and Nutrition Examination Survey and the Multi-Ethnic Study of Atherosclerosis	2011		
1144		Giannarelli et al	Thrombosis & Haemostasis	Prostanoid and TP-receptors in atherothrombosis: is there a role for their antagonism?	2010		
1145		Fulop et al	Acta Physiologica (Oxford, England)	Effects of sex hormones on ECG parameters and expression of cardiac	2006	802	
1146		Marchioli et al	The New England Journal of Medicine	Cardiovascular events and intensity of treatment in polycythemia vera	2013	802, 401/403	12 13 14
1147		Ferenchick & Adelman	American Heart Journal	Myocardial infarction associated with anabolic steroid use in a previously healthy 37-year-old weight lifter	1992	802, 401/403	12
1148		Nottin et al	American Journal of Cardiology	Cardiovascular effects of androgenic anabolic steroids in male bodybuilders determined by tissue Doppler imaging	2006	802, 401/403	12

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1149		Fitzgerald et al	The Journal of Clinical Investigation	Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo	1986		
1150		Yeap	Current Opinion in Endocrinology, Diabetes and Obesity	Androgens and cardiovascular disease	2010		
1151		Liu et al	Endocrine Reviews	Androgens and cardiovascular disease	2003	802, 401/403	12
1152		Frasure-Smith et al	JAMA	Depression following myocardial infarction: impact on 6-month survival	1993	802, 401/403	12 13 14
1153		Eyben et al	European Journal of Epidemiology	All-cause mortality and mortality of myocardial infarction for 989 legally castrated men	2005	802, 401/403	12 13 14
1154		Kawachi et al	Journal of Epidemiology and Community Health	A prospective study of social networks in relation to total mortality and cardiovascular disease in men in the USA	1996		
1155		Makki et al	Circulation	Does Testosterone Therapy Increase Risk of Cardiovascular Event Among Men? A Meta-Analysis	2014		
1156		Maggio & Basaria	International Journal of Impotence Research	Welcoming low testosterone as a cardiovascular risk factor	2009		
1157		Wu & von Eckardstein	Endocrine Reviews	Androgens and coronary artery disease	2003	802, 401/403	12

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1158		Payne et al	Heart	Cardiac effects of anabolic steroids	2004	802, 401/403	12
1159		Stergiopoulos et al	Vascular Health and Risk Management	Anabolic steroids, acute myocardial infarction and polycythemia: a case report and review of the literature	2008	802, 401/403	12
1160		Schooling et al	Prospero: http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42011001815	Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials	2011	802, 401/403 cumulative	
1161		Jeong et al	Cardiovascular Drugs & Therapy	Cardiovascular risks of anemia correction with erythrocyte stimulating agents: should blood viscosity be monitored for risk assessment?	2010	802, 401/403	7 12
1162		Kalin & Zumoff	Steroids	Sex hormones and coronary disease: a review of the clinical studies	1990	802, 401/403	7 12
1163		Kannel	Journal of Atherosclerosis and Thrombosis	The Framingham Study: ITS 50-year legacy and future	2000		
1164		Kim et al	Journal of Korean Medical Science	Hemoglobin Concentration and Risk of Cardiovascular Disease in Korean Men and Women-The Korean Heart Study	2013	802, 401/403	

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1165		Myerberg et al	Annals of Internal Medicine	Sudden Cardiac Death: Epidemiology, Transient Risk and Interventional Assessment	1993	802, 401/403	12 13 14
1166		Nakao et al	Atherosclerosis	Testosterone inhibits prostacyclin production by rat aortic smooth muscle cells in culture	1981	802, 401/403	
1167		Nettleship et al	Frontiers of Hormone Research	Testosterone and coronary artery disease	2009		
1168		Pesonen et al	European Journal of Endocrinology	Adaptation to acute coronary syndrome-induced stress with lowering of testosterone: a possible survival factor	2016		
1169		Phillips et al	American Journal of Medicine	Association of hyperestrogenemia and coronary heart disease in men in the Framingham cohort	1983		
1170		Prentice et al	American Journal of Epidemiology	Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial	2005	802, 401/403	7 12

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1171		Ridker & Luscher	European Heart Journal	Anti-inflammatory therapies for cardiovascular disease	2014		
1172		Ridker et al	The New England Journal of Medicine	Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men	1997		
1173		Rosenblum et al	Thrombosis Research	Effects in mice of testosterone and dihydrotestosterone on platelet aggregation in injured arterioles and ex vivo	1987		
1174		Ruige et al	Journal of Clinical Endocrinology & Metabolism	Beneficial and adverse effects of testosterone on the cardiovascular system in men	2013		
1175		Ruige et al	Heart	Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis	2010		
1176		Schleifer et al	Archives of Internal Medicine	The nature and course of depression following myocardial infarction	1989	802, 401/403	12 13 14
1177		Smith et al	Cardiovascular Research	The cardiovascular effects of erythropoietin	2003	802, 401/403	12
1178		Smith et al	Circulation	Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly study	2005		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1179		Mozaffarian et al	Circulation	Heart disease and stroke statistics--2015 update: A report from the American Heart Association	2015	802, 401/403	7 12
1180		Frankle et al	Archives of Physical Medicine and Rehabilitation	Anabolic androgenic steroids and a stroke in an athlete: Case report	1988	802, 401/403	12
1181		Wannamethee et al	Journal of Internal Medicine	Haematocrit, hypertension and risk of stroke	1994		
1182		Guo et al	Aging Cell	Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells	2013		
1183		Lapetina	Trends in Pharmacological Sciences	Regulation of arachidonic acid production; The role of phospholipase C and A2	1982		
1184		Lewerin et al	Journal of Clinical Endocrinology & Metabolism	Serum estradiol associates with blood hemoglobin in elderly men: the MrOS Sweden study	2014		
1185		Needleman et al	Annual Review of Biochemistry	Arachidonic acid metabolism	1986		
1186		Penhos et al	Proceedings of the Society for Experimental Biology and Medicine	The role of gonadal steroids in arachidonate-induced mortality in mice (41132)	1981		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1187		Tomasoni et al	Journal of the American Society of Nephrology	Upregulation of Renal and Systemic Cyclooxygenase-2 in Patients with Active Lupus Nephritis	1998		
1188		Wells & Merrill	The Journal of Clinical Investigation	Influence of flow properties of blood upon viscosity-hematocrit relationships	1962		
1189		van Noord et al	American Journal of Epidemiology	2011 Invited commentary: sex-steroid hormones and QT-interval duration	2011		
1190		McCrohon et al	Circulation	Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1	1999		
1191		Zhu et al	Scientific Reports	Ablation of the androgen receptor from vascular smooth muscle cells demonstrates a role for testosterone in vascular calcification	2016		
1192		Hammes et al	Cell	Role of endocytosis in cellular uptake of sex steroids	2005		
1193		Friedl et al	Life Sciences	Testosterone inhibits expression of inducible nitric oxide synthase in murine macrophages	2000	802, 401/403	12

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1194		Mancini et al	Journal of Andrology	Effects of testosterone on antioxidant systems in male secondary hypogonadism	2008		
1195		Valenti et al	International Journal of Andrology	Biphasic effect of nitric oxide on testosterone and cyclic GMP production by purified rat Leydig cells cultured in vitro	1999		
1196		Ferenchick	The New England Journal of Medicine	Are androgenic steroids thrombogenic	1990	802, 401/403	12
1197		Ferenchick et al	American Journal of the Medical Sciences	Androgenic-anabolic steroid abuse and platelet aggregation: A pilot study in weight lifters	1992	802, 401/403	12
1198		Kanayama et al	Hormones & Behavior	Illicit anabolic-androgenic steroid use	2010	802,401/403	12
1199		Karila et al	International Journal of Sports Medicine	Anabolic androgenic steroids produce dose-dependent increase in left ventricular mass in power athletes, and this effect is potentiated by concomitant use of growth hormone	2003	802, 401/403	12
1200		Fitzgerald et al	Federation Proceedings	Thromboxane A2 biosynthesis in human disease	1987		
1201		Graziani et al	American Journal of Cardiology	Thromboxane production in morbidly obese subjects	2011		
1202		Vaduganathan et al	American Heart Journal	Platelet reactivity and response to aspirin in subjects with the metabolic syndrome	2008		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1203		Ly et al	Journal of Clinical Endocrinology & Metabolism	A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency	2001		
1204		Liu et al	Journal of Clinical Endocrinology & Metabolism	A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency	2002		
1205		Merza et al	International Journal of Andrology	Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism	2006		
1206		Kunelius et al	Journal of Clinical Endocrinology & Metabolism	The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study	2002		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1207		Wang et al	Journal of Clinical Endocrinology & Metabolism	Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry	2004		
1208		Kaufman et al	The Journal of Sexual Medicine	Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men	2011		
1209		Wu	Journal of Clinical Endocrinology & Metabolism	Caveat emptor: does testosterone treatment reduce mortality in men?	2012	802, 401/403	12
1210		Ottenbacher et al	Journal of the American Geriatrics Society	Androgen treatment and muscle strength in elderly men: A meta-analysis	2006		
1211		Grossman et al	Current Opinion in Endocrinology, Diabetes and Obesity	Testosterone and type 2 diabetes	2010		
1212		Gascon et al	Geriatric Nephrology and Urology	Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis	1999	802, 401/403	7 12
1213		Herlihy et al	Medical Journal of Australia	The prevalence and diagnosis rates of Klinefelter syndrome: an Australian comparison	2011		
1214		Grundy	Trends in Cardiovascular Medicine	Metabolic syndrome update	2015		
1215		Handelsman	Journal of Clinical Endocrinology & Metabolism	Update in andrology	2007	802, 401/403	7 12

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1216		Kaufman & Vermeulen	Endocrine Reviews	The decline of androgen levels in elderly men and its clinical and therapeutic implications	2005		
1217		Petra et al	The Journal of Steroid Biochemistry and Molecular Biology	Direct effect of sex-steroid binding protein (SBP) of plasma on the metabolic clearance rate of testosterone in the rhesus macaque	1985	802, 401/403	
1218		Gerl et al	Cancer	The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors	2001	802, 401/403	7 12
1219		Egleston et al	Annals of Clinical Biochemistry	Validity of estimating non-sex hormone-binding globulin bound testosterone and oestradiol from total hormone measurements in boys and girls	2010		
1220		Handelsman	The New England Journal of Medicine	Mechanisms of action of testosterone--unraveling a Gordian knot	2013	802, 401/403	12
1221		Fisher	Journal of the Royal Statistical Society	The logic of inductive inference	1935		
1222		Greenland	American Journal of Public Health	Modeling and variable selection in epidemiologic analysis	1989		
1223		Greenland & Neutra	International Journal of Epidemiology	Control of confounding in the assessment of medical technology	1980		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1224		Lehmann	American Statistical Association	The Fisher, Neyman-Pearson Theories of Testing Hypotheses: One Theory or Two?	1993		
1225		Mickey & Greenland	American Journal of Epidemiology	The impact of confounder selection criteria on effect estimation	1989		
1226		Goodman	Annals of Internal Medicine	Toward evidence-based medical statistics. 2: The Bayes	1999		
1227		Goodman	Annals of Internal Medicine	Toward evidence-based medical statistics. 1: The P	1999		
1228		Kramer et al	Journal of Chronic Diseases	Analgesic use, blood dyscrasias, and case-control pharmacoepidemiology . A critique of the International Agranulocytosis and Aplastic Anemia Study	1987	802, 401/403	12
1229		Miettinen	Statistics in Medicine	The need for randomization in the study of intended effects	1983		
1230		Handelsman & Staraj	Journal of Andrology	Testicular size: the effects of aging, malnutrition, and illness	1985		
1231		Ranji et al	Medical Care	Interventions to reduce unnecessary antibiotic prescribing: a systematic review and quantitative analysis	2008	802, 401/403	7 12

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1232		Swerdloff & Wang	Clinical Chemistry	Free testosterone measurement by the analog displacement direct assay: old concerns and new evidence	2008	802, 401/403	12
1233		Swerdlow et al	The Journal of Clinical Endocrinology & Metabolism	Mortality in patients with Klinefelter syndrome in Britain: a cohort study	2005		
1234		Tajar et al	Journal of Clinical Endocrinology & Metabolism	Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study	2010		
1235		Zitzmann	Nature Reviews Endocrinology	Testosterone deficiency, insulin resistance and the metabolic syndrome	2009		
1236		Zitzmann et al	Journal of Clinical Endocrinology & Metabolism	Association of specific symptoms and metabolic risks with serum testosterone in older men.	2006		
1237		Mah & Wittert	Molecular and Cellular Endocrinology	Obesity and testicular function	2010		
1238		Gray et al	Journal of Clinical Endocrinology & Metabolism	Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study	1991		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1239		Maggio et al	Archives of Internal Medicine	Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study	2007		
1240		Layton et al	JAMA Internal Medicine	Comparative Safety of Testosterone Dosage Forms	2015		
1241		Handelsman	JAMA	Editorial: Testosterone and Male Aging: Faltering Hope for Rejuvenation	2017	802, 401/403	7 12
1242		Orwoll	JAMA Internal Medicine	Editorial: Further Elucidation of the Potential Benefits of Testosterone Therapy in Older Men	2017	802, 401/403	12
1243		Schooling et al	JAMA Internal Medicine	Promotion of "low t" and the role of testosterone clinical trials	2014	802, 401/403	7 12
1244		Schwartz & Woloshin	JAMA	Medical communication companies and continuing medical education: clouding the sunshine?	2013	802,401/403	7 12
1245		Gan et al	Clinical Endocrinology (Oxf)	A UK epidemic of testosterone prescribing, 2001-2010	2013	802, 401/403	
1246		Mäkinen & Huhtaniemi	Gerontology	Androgen replacement therapy in late-onset hypogonadism: current concepts and controversies- a mim-review.	2011		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1247		Jasuja et al	Medical Care	Ascertainment of Testosterone Prescribing Practices in the VA	2015	802, 401/403	12 13 14
1248		Layton et al	Journal of Clinical Endocrinology & Metabolism	Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011	2014	802, 401/403	12 13 14
1249		Lundh et al	Cochrane Database System Review	Industry sponsorship and research outcome	2012		
1250		Moore	Southern Medical Journal	An overview of drug development in the United State and current challenges	2003		
1251		Grunewald & Matsumoto	Journal of the American Geriatrics Society	Testosterone supplementation therapy for older men: potential benefits and risks	2003		
1252		van Eenoo & Delbeke	The Journal of Steroid Biochemistry and Molecular Biology	Metabolism and excretion of anabolic steroids in doping control- new steroids and new insights	2006	802, 401/403	12
1253		Kapoor et al	The Journal of Steroid Biochemistry and Molecular Biology	The free androgen index is not valid for adult males	1993		
1254		Ly & Handelsman	European Journal of Endocrinology	Empirical estimation of free testosterone from testosterone and sex hormone-binding globulin immunoassays	2005		
1255		Ly et al	Clinical Endocrinology (Oxf)	Accuracy of calculated free testosterone formulae in men	2010		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1256		Taieb et al	Clinical Chemistry	Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children	2003		
1257		Handelsman et al	European Journal of Endocrinology	Age-specific population centiles for androgen status in men	2015		
1258		Feldman et al	Journal of Clinical Endocrinology & Metabolism	Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study	2002		
1259		Haring et al	Aging Male	Prevalence, incidence and risk factors of testosterone deficiency in a population-based cohort of men: results from the study of health in Pomerania	2010		
1260		Hildreth et al	Journal of Clinical Endocrinology & Metabolism	Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels	2013		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1261		Howell et al	British Journal of Cancer	Fatigue, sexual function and mood following treatment for haematological malignancy: the impact of mild Leydig cell dysfunction	2000	802, 401/403	7 12 13 14
1262		Howell et al	Clinical Endocrinology (Oxf)	The impact of mild Leydig cell dysfunction following cytotoxic chemotherapy on bone mineral density (BMD) and body composition	2000	802, 401/403	7 12 13 14
1263		Howell et al	Clinical Endocrinology (Oxf)	Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy	2001	802, 401/403	7 12 13 14
1264		Hsu et al	Journal of Clinical Endocrinology & Metabolism	The longitudinal relationship of sexual function and androgen status in older men: the Concord Health and Ageing in Men	2015		
1265		Iglesias et al	Journal of Endocrinological Investigation	Hypogonadism in aged hospitalized male patients: prevalence and clinical outcome	2014		
1267		Isidori et al	Clinical Endocrinology (Oxf)	Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis	2005		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1268		Isidori et al	Clinical Endocrinology (Oxf)	Effects of testosterone on sexual function in men: results of a meta-analysis	2005		
1269		Jannini et al	International Journal of Andrology	Lack of sexual activity from erectile dysfunction is associated with a reversible reduction in serum testosterone	1999		
1270		Jenkins	Lancet	The voice of the castrato	1998	401	
1271		Johnson et al	American Journal of Physiology-Heart and Circulatory Physiology	Androgen-mediated sensitivity in platelet aggregation	1977		
1272		Kahn	The Journals of Gerontology Series A: Biological Sciences and Medical Sciences	Regaining lost youth : the controversial and colorful beginnings of hormone replacement therapy in aging	2005		
1273		Kelleher et al	Journal of Clinical Endocrinology & Metabolism	Blood testosterone threshold for androgen deficiency symptoms	2004		
1274		Kessler & Pines	JAMA	The Federal Regulation of Prescription Drug Advertising and Promotion	1990	802, 801/803	6 12
1275		Kessler & Vladeck	Georgetown Law Journal	A Critical Examination of the FDA's Efforts to Preempt Failure-to-Warn Claims	2007	802, 401/403	6 12

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1276		Kinsella et al	Journal of Pharmacology and Experimental Therapeutics	The Human Thromboxane A2 Receptor a Isoform (TP a) Functionally Couples to the G proteins Gq and Gu in Vivo and is Activated by the Isoprostane 8-epi Prostaglandin F2a	1997		
1277		Klotz et al	Chest	Urinary excretion of thromboxane B2 in patients with venous thromboembolic disease	1984		
1278		Kostapanos et al	Current Vascular Pharmacology	Hemostatic factors and the metabolic syndrome	2013		
1279		Liu et al	Cardiovascular Research	In vivo androgen treatment shortens the QT interval and increases the densities of inward and delayed rectifier potassium currents in orchietomized male rabbits	2003		
1280		Millar et al	Canadian Medical Association Journal	Predicting low testosterone in aging men: a systematic review	2016		
1281		Min et al	Current Biology	The lifespan of Korean eunuchs	2012	802, 401/403	12
1282		Morange & Alessi	Thrombosis & Haemostasis	Thrombosis in central obesity and metabolic syndrome: mechanisms and epidemiology	2013		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1283		Morrow et al	Proceedings of the National Academy of Sciences	Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids	1992		
1284		Morrow et al	The Journal of Clinical Investigation	Formation of novel non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in carbon tetrachloride hepatotoxicity. An animal model of lipid peroxidation	1992		
1285		Muraleedharan et al	European Journal of Endocrinology	Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes	2013		
1286		Nabili & Davis	http://www.medicinenet.com/polycythemia_high_red_blood_cell_count/article.htm	Polycythemia (Elevated Red Blood Cell Count)	2016		
1287		Navarro et al	Kidney International	Randomized prospective comparison between erythropoietin and androgens in CAPO patients	2002		
1288		Neyman & Pearson	Philosophical Transactions of the Royal Society of London	IX. On the problem of the most efficient tests of statistical hypotheses	1933		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1289		Nieschlag et al	International Journal of Andrology	Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations	2005		
1290		Nigro & Christ-Crain	Swiss Medical Weekly	Testosterone treatment in the aging male: myth or reality?	2012		
1291		Orwoll et al	Journal of Clinical Endocrinology & Metabolism	Testosterone and estradiol among older men	2006		
1292		Peck & Wechsler	Drug Information Journal	Report of a Workshop on Confirmatory Evidence to Support a Single Clinical Trial as a basis for a New Drug Approval	2002		
1293		Penglis et al	The Journal of Immunology	Differential regulation of prostaglandin E2 and thromboxane A2 production in human monocytes: implications for the use of cyclooxygenase inhibitors	2000		
1294		Pilo et al	Thrombosis & Haemostasis	Testosterone potentiation of ionophore and ADP induced platelet aggregation: relationship to arachidonic acid metabolism	1981		
1295		Poole	American Journal of Public Health	Confidence intervals exclude nothing	1987	802, 401/403	12
1296		Popper	The Logic of Scientific Discovery	N/A	1959		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1297		Pratico et al	Annals of the New York Academy of Sciences (United States)	Cyclooxygenase-dependent formation of the isoprostane 8-epi prostaglandin F2a	1994		
1298		Pratico et al	Trends in Endocrinology & Metabolism	The isoprostanes in biology and medicine	2001		
1299		Resnick et al	JAMA	Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory	2017		
1300		Ridley et al	Journal of Physiology and Pharmacology	Modulation by testosterone of an endogenous hERG potassium channel current	2008		
1301		Roberts & Milne	Journal of Lipid Research	Isoprostanes	2009		
1302		Roddam et al	Journal of the National Cancer Institute	Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies	2008		
1303		Rosen et al	Aging Male	Registry of Hypogonadism in Men (RHYME): design of a multi-national longitudinal, observational registry of exogenous testosterone use in hypogonadal men	2013	401/403	12

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1304		Rossouw et al	JAMA	Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial	2002	802, 401/403	7 12
1305		Roy et al	JAMA Internal Medicine	Association of Testosterone Levels With Anemia in Older Men A Controlled Clinical Trial	2017		
1306		Rubin	Annals of Statistics	Bayesian Inference for Causal Effects: The Role of Randomization	1978		
1307		Santner et al	Journal of Clinical Endocrinology & Metabolism	Comparative rates of androgen production and metabolism in Caucasian and Chinese subjects	1998		
1308		Sartorius et al	Clinical Endocrinology	Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study	2012		
1309		Sartorius et al	Annals of Clinical Biochemistry	Predictive accuracy and sources of variability in calculated free testosterone estimates	2009		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1310		Shi et al	Journal of Clinical Endocrinology & Metabolism	Longitudinal changes in testosterone over five years in community-dwelling men	2013		
1311		Sieveking et al	The Journal of Experimental Medicine	A sex-specific role for androgens in angiogenesis	2010		
1312		Sikaris et al	Journal of Clinical Endocrinology & Metabolism	Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays	2005		
1313		Simmonds et al	Journal of Geriatric Cardiology	Blood rheology and aging	2013		
1314		Snyder et al	JAMA Internal Medicine	Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial	2017		
1315		Spitzer et al	Annals of Internal Medicine	Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial	2012		
1316		Surampudi et al	International Journal of Endocrinology	Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy	2012		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1317		Tracz et al	Journal of Clinical Endocrinology & Metabolism	Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials	2006		
1318		Travison et al	Journal of the American Geriatrics Society	The natural history of symptomatic androgen deficiency in men: onset, progression, and spontaneous remission	2008		
1319		Travison et al	Journal of Clinical Endocrinology & Metabolism	The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men	2007		
1320		Tsujii et al	Proceedings of the National Academy of Sciences	Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential	1997		
1321		Wang et al	American Journal of Physiology	Selective increase of cyclooxygenase-2 expression in a model of renal ablation	1998		
1322		Wang et al	Journal of Andrology	Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations	2008		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1323		Wartofsky et al	Journal of Clinical Endocrinology & Metabolism	Trading one "dangerous dogma" for another? Thyroid hormone treatment of the "euthyroid sick syndrome"	1999	802, 401/403	12
1324		Wolff et al	Archives of Internal Medicine	Prevalence, expnediture and complications of multiple chronic conditions in the elderly	2002		
1325		Women's Health Initiative	JAMA	Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial	2002	802, 401/403	7 12
1326		Wu & Hammond	Journal of Molecular Endocrinology	Naturally occurring mutants inform SHBG structure and function	2014		
1327		Wu et al	Endocrinology	Stimulation of N-terminal truncated isoform of androgen receptor stabilizes human ether-a-go-go-related gene-encoded potassium channel protein via activation of extracellular signal regulated kinase 1/2	2008		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1328		Wu et al	Journal of Clinical Endocrinology & Metabolism	Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study	2008		
1329		Traish et al	Journal of Cardiovascular Pharmacology and Therapeutics	Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease in Men with Hypogonadism: A Real-Life Observational Registry Study Setting Comparing Treated and Untreated (Control)	2/9/2017		
1330		StataCorp LLC	Stata Press	Stata Bayesian Analysis Reference Manual - Release 14	2015		
1331		Gerstman et al	Epidemiology	Use of Subsequent Anticoagulants to Increase the Predictive Value of Medicaid Deep Venous Thromboembolism Diagnoses	Mar-90		
1332		Gerstman et al	Journal of Clinical Epidemiology	A Method of Pharmacoepidemiologic Analysis that Uses Computerized Medicaid	1990		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

1333		Higgins & Green, Cochrane Collaboration	Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0	Chapter 16 Bayesian and hierarchical approaches to meta-analysis, Section 16.8.1 Bayesian Methods	Mar-11		
1334		Kalyani et al	Endocrinology and Metabolism Clinics of North America	Male Hypogonadism in Systemic Disease	2007		
1335		Raivio et al	NEJM	Reversal of Idiopathic Hypogonadotropic Hypogonadism	2007		
1336		Fraietta et al	Clinics	Hypogonadotropic Hypogonadism Revisited	2013		
1337		Annibalini et al	Journal of Endocrinological Investigation	Effects of Sex Hormones on Inflammatory Response in Male and Female Vascular Endothelial Cells	2014		
1338		ABBVIE-FST02020123-125	Endocrine Society	An Endocrine Society Statement - The Risk of Cardiovascular Events in Men Receiving Testosterone Therapy - 2/7/2014	2014		
1339		Institute of Medicine	The Future of Drug Safety: Promoting and Protecting the Health of the Public	N/A	2007	802, 401/403	6 7 12
1340		Rothman et al	Modern Epidemiology, Third Edition (Second ed.)	N/A	2010	NOT PRODUCED	
1341		Melmed et al	Elsevier Health Sciences	Textbook of Endocrinology	2016	NOT PRODUCED, Relevant portion not identified	

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

Plaintiff Jeffrey Konrad's Trial Exhibits

TRIAL EXHIBIT NO.	BATES RANGE	DOC DESCRIPTION	Objection Basis	Objection Code
2000	JKonradPL-ClientDocs-000001 - 000014	AndroGel Patient Support and Savings Program Pamphlet frpm Client	Duplicate of P3.0076	
2001	JKONRADPL-WALGREENS 000001 - 000012	Walgreens Pharmacy		
2002	JKonradPL-Walgreens-000013 - 000090	Walgreens Pharmacy		
2003	JKonradPL-Walgreens-000091 - 000168	Walgreens Pharmacy		
2004	JKonradPL-BMHMemphis FILMRPT-000001 - 000009	Baptist Memorial Hospital - Memphis 07/09/2010 Echo Report & 03/07/2012 Electrophysiology Report		
2005	JKonradPL-BMHMemphis FILMS-000001 000553	Baptist Memorial Hospital - Memphis Diagnostic Images		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2006	JKonradPL-SCFFILMS-000001 - 001072	Stern Cardiovascular Foundation - 11/5/2015 – Transthoracic Echocardiogram		
2007	JKonradPL-SCFFILMRPT-000001 - 000053	Stern Cardiovascular Foundation		
2008	JKonradPL-MethodistLeBonheurFILMS-000001 - 000004	Methodist Le Bonheur Healthcare 04/04/2006 Thallium Treadmill Stress Test		
2009	JKONRADPL-BMH 000001 - 00043	Baptist Memorial Hospital - Memphis		
2010	JKonradPL-BMHCollierville-000001 - 000158	Baptist Memorial Hospital - Collierville		
2011	JKonradPL-SternCardiovascularFoundation-000001 - 000344	Stern Cardiovascular Foundation		
2012	JKonradPL-MethodistLeBonheur-000001 -	Methodist Le Bonheur Healthcare		
2013	JKONRADPL-BMMG 000001 - 000004	Baptist Memorial Medical Group		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2014	JKonradPL-BMMG-000005 - 000148	Baptist Memorial Medical Group		
2015	JKonradPL-HHC-000001 - 000007	Hanissian Health Care (Gina Hanissian, MD)		
2016		Aetna Insurance WILL BE ADDED WHEN RECORDS ARE RECEIVED		
2017		Stern Cardiovascular Foundation WILL BE ADDED WHEN RECORDS ARE RECEIVED		
2018	KONRADJ-23MGR-00001 - 00370	Baptist Memorial Medical Group, Inc		
2019	KONRADJ-11MSA-00001 - 00017	Mike Sandy, MD		
2020	KONRADJ-12JCBR-00001 - 00025	Jackie Brown, DDS		
2021	KONRADJ-13BMHM-00001	Baptist Memorial Hospital - Memphis		
2022	KONRADJ-14BMHM-00002 - 00448	Baptist Memorial Hospital - Memphis		
2023	KONRADJ-15GON-00001 - 00128 and KONRADJ-58GON-00149-159	Gastro One		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2024	KONRADJ-17SCF-00101 - 00456	Stern Cardiovascular Foundation-Medical		
2025	KONRADJ-18BMH-00001	Baptist Memorial Hospital-Medical		
2026	KONRADJ-21BMH-00025 - 00092	Baptist Memorial Hospital-Medical		
2027	KONRADJ-50JCBR-00034 - 00035	Jackie Brown, DDS		
2028	KONRADJ-41GON-00135 - 00145	Gastro One		
2029	KONRADJ-47SCF-00461 - 00492	Stern Cardiovascular Foundation		
2030	JKonradPL-BMHColliervill eBIL-000006 - 000007	Baptist Memorial Hospital - Collierville		
2031	JKonradPL-BMHColliervill eBIL-000001 - 000005	Baptist Memorial Hospital - Collierville		
2032	JKonradPL-SternCardiovascularFoundationBIL-000001 - 000095	Stern Cardiovascular Foundation		
2033	JKonradPL-HHC-BIL-000001 - 000007	Hanissian Health Care (Gina Hanissian, MD)		
2034	KONRADJ-27MGR-00371 - 00373	Baptist Memorial Medical Group, Inc.		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2035	KONRADJ-16SCF-00001 - 00100	Stern Cardiovascular Foundation		
2036	KONRADJ-19BMH-00002	Baptist Memorial Hospital		
2037	KONRADJ-20BMH-00003 - 00024	Baptist Memorial Hospital		
2038	KONRADJ-22BMH-00093 - 00096	Baptist Memorial Hospital		
2039	KONRADJ-25GON-00129 - 00134 and KONRADJ-69GON-00160-162	Gastro One		
2040	KONRADJ-26JCBR-00026 - 00029	Jackie Brown, DDS		
2041	KONRADJ-35BMH-00097 - 00115	Baptist Memorial Hospital		
2042	KONRADJ-49JCBR-00031 - 00033	Jackie Brown, DDS		
2043	KONRADJ-44GON-00146 - 00148	Gastro One		
2044	KONRADJ-46SCF-00457 - 00460	Stern Cardiovascular Foundation		
2045	None	French, William Expert Report re Konrad 12.7.2016	802	
2046	None	French Supplemental Report 03-10-17	802	

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2047	None	Miner, Martin Expert Report re Konrad 12.6.2016	802	
2048	None	Rodbard, Helena Expert Report re Konrad 12.6.2016	802	
2049	None	Phillip Cuculich- Konrad Rpt.-10.31- 16	802	
2050	ABBV- KONRAD- 000110 -	CONFIDENTIAL - Dr. S. Todd Overby - Max Calls	401/403	1 2
2051	ABBV- KONRAD- 000114	CONFIDENTIAL - Dr. S. Todd Overby - iRep Calls	401/403	1 2
2052	None	Defendant Fact Sheet		
2053	None	Amended Defendant Fact Sheet		
2054	ABBV-PERS- 012743 - 012757	05/16/2006 Part III Exempt Performance Appraisal	401/403	2
2055	ABBVIE- FST06325373 - FST06325381	FSR Evaluation - Cardio Metabolic Training Course	401/403	2 7 8
2056	ABBV-PERS- 012759 - 012774	01/01/2007 Part III Exempt Performance Appraisal	401/403	2
2057	ABBVIE- 00291931 - 00291933	03/09/2007 Basic I Evaluation	401/403	2
2058	ABBV- KONRAD- 000003 -	06/03/2003 to 05/26/2010 Call Notes	Duplicate of P3.0085	

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2059	ABBV-PERS-012775 - 012787	2008 Field Leadership Performance Appraisal Core and Functional Competency Review For Chris Buren	401/403	2
2060	ABBVIE-FST18678430 - FST18678433	07/29/2008 Representative Competency Overview and Coaching/Development Plan	401/403	2 8
2061	ABBV-PERS-012687 - 012693	2008 Field Leadership Performance Appraisal Core and Functional Competency Review For Jennie Fields	401/403	2 7 8
2062	ABBVIE-FST18675127 - FST18675131	07/02/2009 Solvay Field Contact Report	401/403	2
2063	ABBVIE-FST18678294 - FST18678296	02/24/2009 and 02/26/2009 Solvay Field Contact Report	401/403	2 7 8
2064	ABBVIE-FST18678239 - FST18678293	07/29/2009 Solvay Field Contact Report	401/403	2 7

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2065	ABBV-PERS-012705 - 012713	2010 Field Sales Representative Performance Appraisal Core and Functional Competency Review For Jennie Fields	401/403	2 7 8
2066	JKonradPL-ClientDocs-000001 - 000014	AndroGel Patient Support and Savings Program Pamphlet	Duplicate of P3.0001	
2067	ABBVIE-FST16161088 - FST16161090	RM/DM Washington, D.C. (Recap of notes from a Regional Manager/District Manager meeting in approximately late 2015)	401/403	1 2
2068	ABBVIE-FST00427107 - FST00427111	04/29/2005 From Johm Kim to Regulatory Submissions with attachment of Approval Ltr	Foundation as to Buren	
2069	ABBV-PERSP012825	2010 to 2015 Chris Buren - Incentive Compensation (Related to AndroGel)	401/403	1 2
2070	ABBV-KONRAD-000001 -	06/03/2003 to 05/26/2010 Call Notes		
2071	ABBV-KONRAD-000007	07/01/2010 Call Note for Jennie Fields		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2072	ABBV-KONRAD-000008 - 000109	09/22/2010 to 09/29/2015 Incentives provided to MD's office (on site meals)	401, 403; Duplicate of P3.0218	1 2
2073	ABBVIE-FST18678427 - FST18678429	02/26/2008 Solvay Field Contact Report	401/403	2 8
2074	AABVIE-FST18678509 - FST18678511	03/21/2008 South-Central WB Update with Attachment Welcome Back Program Stats March 19th ("Everyone please take advantage of this great opportunity to push Androgel")	401/403	2
2075	ABBVIE-FST18678423 - FST18678426	06/23/2008-06/24/2008, Solvay Field Contact Report	401/403	2 8
2076	ABBVIE-FST18678512 - FST18678513	06/24/2008 Welcome Back Update with Attachment Welcome Back Program	401/403	2
2077	ABBVIE-FST16251455- FST16251490	Code on Interactions with Healthcare Professionals		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2078	ABBVIE-FST18678434	02/23/2009 from Christopher Buren Re: High Tricor Writers vs. Androgel TRX's with Attachment High Tricor Docs vs. A-gel.xls	401, 403, Incomplete document	2
2079	ABBVIE-FST18678522 - FST18678524	05/19/2009 - 05/22/2009 Solvay Field Conact Report	401	2
2080	ABBVIE-FST18678289 - FST18678293	7/29/2009 Solvay Field Conact Report	401/403	2 7
2081	ABBV-PERS-012694 - 012704	2009 Field Sales Representative Performance Appraisal Core and Functional Competency Review	401/403	2
2082	ABBVIE-FST06097607	05/11/2010 "If you are starting to notice that he looks like a shadow of himself, it's time to ask if it could be Low T."	401/403	2
2083	ABBVIE-FST06097608	05/11/2010 "Are you developing an unhealthy attachment to your recliner?"	401/403	2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2084	TD007482 - TD007487	Abbott Laboratories Original Call Plan Report - MSS Call Plan for S2 2010 Run Date 06/24/2010	401/403	2
2085	ABBVIE- FST18678470 - FST18678472	06/04/2010 from Jeffrey Bowen Re: PSSP Reports with attachment PSSP 2010May Leaderboard 20100603	401/403	2
2086	ABBVIE- FST18678503 - FST18678504	06/15/2010 Memorandum from Chris Buren to Jennie Fields Re: June Monthly Report	401/403	2
2087	ABBVIE- FST18678323 - FST18678327	2010 Field Representative Mid Year Discussion	401/403	2
2088	TD007436 - TD007442	shows the decile for diabetics, the number the doctors are rated according to if they treat a lot of diabetes or if they treat erectile dysfunction, and then also their total replacement decile and it shows the scripts	401/403	8

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2089	ABBVIE- FST18678243 - FST18678251	2010 Field Sales Representative Performance Appraisal Core and Functional Competency Review	401/403	2
2090	ABBVIE- FST02027662	Androgel Commercial (Shadow of former self - Low Testosterone or Low T...Step out of the shadows)	401/403	2
2091	ABBVIE- FST02027663	Androgel Commercial (Stop Living in the shadows)		
2092	ABBVIE- FST08708256	Androgel Commercial (Shadow of former self - Low Testosterone or Low T...Step out of the shadows)		
2093	ABBVIE- FST18675548 - FST18675558	2006 Field Sales Representative Performance Appraisal Core and Functional Competency Review	401/403	2
2094	ABBVIE- FST18675093 - FST18675099	03/19&20/2007 Solvay Field Contact Report	401/403	2
2095	ABBVIE- 00252057 - 00252064	Little Rock 2006 District Monthly Report	401/403	2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2096	ABBVIE-FST18661491 - FST18661513	Testosterone and Hypogonadism in Men's Health	401/403	2
2097	ABBVIE-FST18661920 - FST18661926	10/18/2009 from Chrisopher Buren RE: American Diabetes Association with attachment ADA Congratulations Letter	401/403	2 8
2098	ABBVIE-FST18661887 - FST18661888	12/17/2009 from Jason Thornton RE: FCR with attachment FCR-Jennie Fields	401/403	2
2099	ABBV-PERS-012738	Jason Thornton Incentive Compenation (Related to Androgel)	401/403	1 2 14
2100	None	Label		
2101	None	Androgel 1% Label 05/2015	401	1
2102	None	Validation of a Screening Questionnaire for Androgen Deficiency in Aging Males	802	
2103	ABBV-KONRAD-000008 -	Steven Todd Overby, MD Expense Report	401/403; Duplicate of 87	1 2
2104	ABBV-KONRAD-000115	CONFIDENTIAL - Dr. Eric Johnson - Financial Data	401/403	1 2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2105	ABBV-KONRAD-000116 - 000119	CONFIDENTIAL - Dr. Gina Hanissian - Financial Data	401/403	1 2
2106	ABBV-KONRAD-000120	CONFIDENTIAL - Dr. Jennifer Morrow - Financial Data	401/403	1 2
2107	None	Steven Todd Overby, MD IMS Data	401, 403, Foundation (no sponsoring witness); 802	1 2 10
2108	None	Interrogatories		
2109	None	Request for Production		
2110	JKonradPL-FamilyPhotos-000001 - 000009	Family Photos	401/403	14
2111	KonradJ-MLBG-00001	Methodist Le Bonheur Germantown Hospital		
2112	KonradJ-60MLBG-00002-3	Methodist Le Bonheur Germantown Hospital		
2113	KONRADJ-71GHA-00001 - 00006	Gina Hanissian, M.D.		
2114	KONRADJ-71GHA-00007 - 00022	Gina Hanissian, M.D.		
2115	ABBV-PERS-012735 - 012736	10/2008, Projected Incentive Payout for Jennie Fields	401/403	2 10

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2116	ABBV-PERS-012737	Jennie Fields - Incentive Compensation (Related to Androgel)	401/403	1K 2 14
2117	ABBVIE-FST18678448 - FST1867850	03/13/2009 from Christopher Buren Re: HIV Physicians DART with attachment ANDL8J0323HIV LeaveBehind	401/403	2 8
2118	ABBVIE-FST18678502	05/27/2010 from Christopher Buren Re: Men's Health Month Initiative with attachment 2010 Monthly Report	401/403	2
2119	ABBVIE-FST11207764 - FST11207766	05/15/2015 Important Drug Warning: Revisions to the Indication Limitations of Use, and new language on the potential for cardiovascular risk...	401/403	1
2120	None	Selling That New-Man Feeling	401/403, 802	12

Plaintiffs reserve the right to supplement their exhibit list with any newly obtained or received medical records.

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

Plaintiff Jesse Mitchell's Trial Exhibits

TRIAL EXHIBIT NO.	Bates Range	Doc Description	Objection Basis	Objection Code
2500	N/A	Adventist Medical Center (updated)	Duplicative of 2070	
2501	MitchellJ-15AMC-00001 - 26	Adventist Medical Center		
2502	MitchellJ-20NWCI-00174-180	Northwest Cardiovascular Institute		
2503	MitchellJ-17RSC-00056-60; MitchellJ-24RSC-00061-62; and MitchellJ-33RSC-00071	Roberts Street Clinic		
2504	MitchellJ-16-RSC-00001-55; MitchellJ-25RSC-00063-70; and MitchellJ-34RSC-00072-78	Roberts Street Clinic		
2505	N/A	Dr. Gordon Canzler (updated)	403, Authentication, Foundation	
2506	N/A	Dr. Nickolas Juliano (updated)		
2507	MitchellJ-18NWCI-00001-78	Northwest Cardiovascular Institute		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2508	N/A	Fred Meyer Pharmacy (updated)		
2509	MitchellJ-18NWCi-00001-78; MitchellJ-19NWCi-00079-173; MitchellJ-27NWCi-00181-213; MitchellJ-28NWCi-00214-238; and MitchellJ-35NWCi-00293-335	Northwest Cardiovascular Institute	Compilation	
2510	N/A	Adventist Medical Center (2)	Duplicative of 2060	
2511	N/A	a - Picture of Plaintiff; b - Picture of Plaintiff and Wife, Kimberly; c - Picture of Plaintiff, son Jesse, grandson Evan, and his father Don "4 generations"; d - Picture of Plaintiff and grandson Evan; e - Picture of Plaintiff		
2512		Resume of Julie Adams	802	

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2513		Mitchell Defendant Fact Sheet-including call notes re: Gordon Canzler, MD		
2514	ABBV- MITCHELL 000003- 000006	Mitchell Meal records re Dr. Canzler's office	401/403	2
2515	ABBV- MITCHELL 000007	Mitchell meal records re Gordon Canzler, MD	401/403	2
2516	ABBVIE-FST 16125343- 16125344	11/21/2008 email from John Rodda re: Harry Fisch interviews	401/403	2
2517	ABBVIE-FST 06211473; 06211475	2/11/2009 Email from Pablo Hernandez re: Agel Reprint Summaries with attachment	401/403	2
2518	ABBVIE-FST 16548618-- 16548628	9/5/2009 email from Geoffrey Nervez re: Oral Boards questions with attachment	401/403	2
2519	ABBVIE-FST 17124271	9/16/2009 email from Bradford Dowden with attached monthly report re Adams and Peet	401/403	2
2520	ABBV-PERS- 012385-12393	2009 Field Sales Representative Performance Appraisal-Adams	401/403	2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2521	ABBV-PERS-012394-12403	2010 Field Sales Representative Performance Appraisal-Adams	401/403	2
2522	ABBVIE-FST 16251455-16251490	2009 PhRMA Code on Interactions with Healthcare Professionals		
2523	ABBVIE-FST00378322-00378329	Sales Aid: "Get him above the line and help him regain what he's	401/403	2
2524	ABBVIE-FST17155608-ABBVIE-FST 17155609	12/19/2008 Email from Sara Lehr re: approved marketing materials for use in field as of Jan 1, 2009	401/403, Incomplete document	2
2525	ABBVIE-00041999	Sales Aid: Prevalence of hypogonadism in males aged at least 45 years: the HIM study	401/403	2
2526	ABBVIE-FST01902612-1902613	Reprint: Wang et al, Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men (2000), Jan 2008	401/403	2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2527	ABBVIE-FST02269784-2269785	Reprint: Prabhakar et al, Frequent occurrence of hypogonadotropic hypogonadism in Type 2 diabetes (2004), Jan 2008	401/403	2
2528	ABBVIE-FST02269840	A quiz for men only, Jan 2008	401/403	2
2529	ABBVIE-FST06084685-06084688	Reprint: Endocrine Society Guidelines for Diagnosing, treating, and monitoring patients with low testosterone (Low T)	401/403	2
2530	ABBVIE-FST00346361-00346362	Sales Aid: Recharge testosterone levels with the #1 prescribed TRT (May 2009)	401/403	2
2531	ABBVIE-FST06097607-06097608	Sales Aid: It could be Low T (May 2010)	401/403	2
2532	ABBVIE-FST16617629-16617630	8/18/2010 Email from Derek Rieder re: Androgel promotional materials	401/403	2
2533	ABBVIE-FST01902546-01902549	Sales Aid: Low T is a common medical condition	401/403	2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2534	ABBVIE-FST02278880-02278887	Reprint: Dhindsa et al, Frequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes (2004)	401/403	2
2535	ABBVIE-FST02425579-02425586	Reprint: Mulligan, et al, Prevalence of hypogonadism in males aged at least 45 years: the HIM study (2006)	401/403	2
2536	ABBVIE-FST02466770-02466779	Sales Aid: Low T is more common than you might think	401/403	2
2537	ABBVIE-FST06274730-06274731	9/20/2010 Email from Debbie Griggs-Smith re: A-List and approved promotional materials	401/403	2
2538	ABBVIE-FST02278857-02278873	Wang et al, Long-Term Testosterone Gel (AndroGel) Treatment Maintains Beneficial Effects on Sexual Function and Mood, Lean and Fat Mass, and Mineral Bone Density in	401, 403, 802	2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2539	ABBVIE-FST02466789-02466819	Reprint: Endocrine Society Guidelines re: Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes	401, 403, 802	2
2540	ABBVIE-FST02668666-02668669	Sales Aid: Millions of Men Aged 45 years or older may have low testosterone (Low T)	401/403	2
2541	ABBVIE-FST02668670-02668677	Sales Aid: Recharge T levels with AndroGel (March 2010)	401/403	2
2542	ABBVIE-FST08754210-08754216	Patient Brochure: Join the AndroGel Patient Support and Savings Program	401/403	2
2543	ABBVIE-FST05912311-05912319	Patient Brochure: the Restoration Program	401/403	2
2544	ABBVIE-FST06102639-06102642	Patient Brochure: Having Trouble Shifting out of Nuetral?	401/403	2
2545	ABBVIE-FST06086958-06086959	Catalog: It's an Amazing Machine Men's Health Toolkit	401/403	2
2546	ABBV-PERS-012939-012947	2001 Field Sales Performance Appraisal-Oliver	401/403	

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2547	ABBV-PERS-012948-012954	2002 Field Sales Performance Appraisal-Oliver	401/403	
2548	ABBV-PERS-012955-012963	2003 Field Sales Performance Appraisal-Oliver	401/403	
2549	ABBVIE-00000685-00000696	Sales Aid: His diabetes is being managed. So why does he feel like he is missing something , Dec 2004	401/403	2 8
2550	ABBVIE-FST01190506-01190559	Selling Skills Primer: Focus on HIM and DM	401/403	2 8
2551	ABBVIE-FST01270772-01270813	Module 3: Selling Skills Primer: Focus on HIM and DM	401/403	2 8
2552	ABBV-PERS-012964-012970	2004 Field Sales Performance Appraisal-Oliver	401/403	
2553	ABBV-PERS-012971-012977	2005 Corp Exempt Performance Appraisal-Oliver	401/403	
2554	ABBVIE-00291534-00291535	1/18/2006 Email from Richard Oliver re: 2006 POA Recap	401/403	
2555		May 2006 Androgel Sales Data	401/403	
2556	ABBVIE-00014257-00014258	9/12/2006 Email from Trisha Merdalo re: McKinley Screener	401/403	

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2557	ABV-PERS-012978-012984	2006 Field Leadership Performance Appraisal-Oliver	401/403	
2558	ABBVIE-00049328-00049329	1/19/2007 Email from Richard Oliver re: Seattle POA Recap	401/403	
2559	ABBVIE-00508213-0050808236	4/5/2007 Email from Richard Oliver re: Seattle Mid POA Recap	401/403	
2560	ABBVIE-FST06199085-06199089	8/18/2007 Email from Debbie Griggs-Smith re: Jump to the Pump Contest (with attachments)	401/403	
2561	ABBVIE-FST06030233-06030234	5/7/2008 Email from Debbie Griggs-Smith re: Welcome Back Program (with attachments)	401/403	
2562	ABBVIE-FST06102639-06102642	Sales Aid: Having Trouble Shifting Out of Neutral (March 2012)	401/403	2
2563	ABV-PERS-011367	Resume of Pamela Peet	802	
2564	ABBVIE-FST06087029-06087106	Module 2: Cardiovascular Disease, 2007	401/403	2
2565	ABBVIE-00000710-00000725	Sales Aid: What does his body language say to you? (March 2004)	401/403	2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2566	ABV-PERS-013092-013093	Resume of Flea Parker	802	
2567	ABBVIE-00025306	9/14/2005 Email from Flea Foley re: signs of Low T	401/403	13
2568	ABBVIE-00044362-0044363	3/4/2001 Email from Flea Foley re: bridging statements	401/403	
2569	ABBV-PERS-013108-013122	2002 Field Sales Performance Appraisal-Foley	401/403	
2570	ABBVIE-00457599-00457608	2003 Field Sales Performance Appraisal-Foley	401/403	
2571	ABBVIE-FST 16195921-16195922	4/7/06 Listing of approved reprints and screener	401/403	2
2572	ABBV-PERS-013145-013149	2006 Field Leadership Performance Appraisal-Parker	401/403	
2573	ABBV-PERS-0131150-ABBV-PERS-013162	2007 Field Leadership Performance Appraisal-Parker	401/403	
2574	ABBVIE-FST 19049690-19049691	Memorandum re: Portland District Strategy	401/403	2 7
2575	ABBVIE-FST 19052442-19052465	4/24/2008 Email from Flea Foley re: Dandona slide deck with attachment	401/403	2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2576	ABBVIE-FST19050148-19050169	6/19/2008 email from Jeff Bowen re: Androgel Speaker Training with attachment re: the relationship between diabetes, obesity and	401/403	2
2577	ABBVIE-FST19058590-19056591	7/15/2008 email by Pamela Peet re: Kaufman speaking engagement in Portland	401/403	2
2578	ABBVIE-FST19050355-19050398	Slide deck: Male Hypogonadism: Diagnosis, Treatment, Diabetes and Prostate Issues for Joel Kaufman, MD	401/403, 802	2
2579	ABBVIE-FST19052152	8/24/2008 Email from Flea Foley re: TRT Dart Tool with attachment	401/403	2, 8
2580	ABBVIE-FST19052337	11/7/2008 email from Flea Foley re: September DART TRT data with attachment	401/403	2, 8
2581	ABBV-PERS-013163-013173	2008 Field Leadership Appraisal-Foley	401/403	
2582	ABBVIE-FST19064654-19064683	2009 Portland District Business Review by Flea Foley	401/403	2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2583	ABBVIE-FST 19066680	3/6/2009 Email by Pamela Peet re: list of doctors interested in attending Androgel March 24 program		
2584		02/23/2001 - 06/12/2007 physician/sales rep call notes	401/403, Duplicate of P1. 2150	
2585	MITCHELLJ-21- PAMC-00001- 00497; MITCHELLJ- 22PAMC- 00498-997; MITCHELLJ-- 23PAMC- 00998-1547; MITCHELLJ-- 26PAMC- 01548-1549; and MITCHELLJ- 32PAMC-	Portland Adventist Med Ctr	Compilation	
2586		Defendants' Responses to Plaintiff's Interrogatories		
2587		Defendants' Responses to Plaintiff's Requests for Production		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2588	ABBV-MITCHELL 000008-000009	Prescribing data for Gordon Canzler, MD	401/403, 802, Foundation	1, 2, 10
2589	ABBV-MITCHELL 000001-000002	Call Notes re: Gordon Canzler, MD		
2590	ABBV-MITCHELL 000010-000016	Call Notes re: Gordon Canzler, MD	401/403, Duplicate of Ex. 2144	
2591	ABBV-MITCHELL 000018	Call Notes re: Gordon Canzler, MD	401/403	1
2592	ABBVIE-00116284-302	11/12/2007 email from Wanda Fitzsimmons to F. Foley, D. Fronk, A. Littlejohn, P. Peet and L. Weiner re Diabetes Modules	401/403, Foundation	2 8
2593	ABBVIE-FST16125559	6/7/2010 email from Tara Keen to S. Pineiro-Garbin re AndroGel Reprints	401/403, Foundation	2
2594	ABBVIE-FST06275165	11/5/2010 email from John Hinckley to D. Griggs-Smith, et al. re Secure Horizons, PacifiCare, UHC/AARP - AndroGel	401/403, Foundation	2

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2595	ABBVIE-00506110-113	04/24/2007 email from Richard Oliver to D. Bradley re Field Contact Report	401/403, Foundation	2
2596	ABBVIE-00506772-776	11/01/2007 email from Richard Oliver to B. Bradley, et al. re Field Contact Report	401/403	2 8
2597	ABBVIE-FST19056573-4	03/2008 Solvay Pharmaceuticals Monthly Activity Sales Report	401/403, Foundation	2 7
2598	ABBVIE-FST19056578-82	03/05/2008 email from Pamela Peet to W. White, F. Foley, etc re AndroGel Talk in Portland	401/403, Foundation	2
2599		Columbia River Surgery Center		
2600	ABBV-PERS-013510	Incentive Compensation for Flea Foley Parker	401/403, foundation	2
2601		Adventist Med Ctr Registration Record 04-20-2015		
2602		NW Cardio Inst. re billing code for imaging 04-20-2015		
2603		11-18-2012 Adventist Med Ctr heart cath		

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2604		11-19-2012 Adventist Med Ctr chest images		
2605		02-25-2013 Adventist Med Ctr chest image		
2606		03-09-2015 Adventist Med Ctr chest image		
2607		04-20-2015 Adventist Med Ctr chest image		
2608		11-20-2012 Adventist Med Ctr chest		
2609		11-21-2012 Adventist Med Ctr chest image		
2610		04-20-2015 Adventist Med Ctr chest image		
2611		11-19-2012 Adventist Med Ctr vascular image		
2612		11-18-2012 Adventist Med Ctr heart cath 01		
2613		11-18-2012 Adventist Med Ctr heart cath 02		
2614		05-23-2014 stress test images		
2615		03-27-2015 stress test images		
2616		02-26-2013 Adventist ultrasound clips (composite)	Compilation	

Schedule C to Final Pretrial Order -- Plaintiffs' Trial Exhibit List with AbbVie's Objections

2617		11-19-2012 Adventist ultrasound clips composite	Compilation	
2618		2012.11.18 Images_films of cardiac catheterization		

Plaintiffs reserve the right to supplement their exhibit list with any newly obtained or received medical records.

Schedule D

AbbVie's General Liability Exhibits

Exhibit Number	Date	Description	Bates	Plaintiffs' Objections
3000	0000.00.00	Uppsala Monitoring Centre, "The use of the WHO-UMC system for standardized case causality assessment"		H, P, R
3001	0000.00.00	AndroGel U.S. Material Review Policies	ABBVIE-FST10970660-70661	H, F, P, R
3002	1972.07.13	1972 Testopel Label		B, P, R
3003	1981.06.23	Androgen Class Labeling Guideline	ABBVIE-FST15685242	NPO
3004	1983.07.01	Davidson JM, et al. Hormonal changes and sexual function in aging men. J Clin Endocrinol Metab. Jul 1983;57(1):71-77		H, R, F
3005	1987.01.01	Tenover JS, Matsumoto AM, Plymate SR, Bremner WJ: The effects of aging in normal men on bioavailable testosterone and luteinizing hormone secretion: response to clomiphene citrate. J Clin Endocrinol Metab 65: 1118-26, 1987.		H, R, F
3006	1991.01.01	Gray A, Berlin JA, McKinlay JB, Longcope C. An examination of research design effects on the association of testosterone and male aging: results of a metaanalysis. J Clin Epidemiol. 44:671-684, 1991.		H, R, F
3007	1992.01.01	Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992;75: 1092-1098.		H, R, F
3008	1993.01.01	de Lignieres B. Transdermal dihydrotestosterone treatment of 'andropause'. Ann Med. 1993;25:235-241.		H, R, F
3009	1993.01.01	Morley JE, Perry HM 3d, Kaiser FE, Kraenzle D et al., Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study, Journal of the American Geriatrics Society (1993)		H, R, F
3010	1994.02.01	Haffner SM, et al., Insulin resistance, body fat distribution, and sex hormones in men. Diabetes. Feb 1994; 43: 212-219		H, R, F
3011	1996.01.01	FDA Consumer, Skin patch replaces testosterone		H, R, P, A, B
3012	1996.01.01	C. Wang et al., <i>Sublingual Testosterone Replacement Improves Muscle Mass and Strength, Decreases Bone Resorption, and Increases Bone Formation Markers in Hypogonadal Men—A Clinical Research Center Study</i> , 1996 J. Clin. Endocrinol. Metab. 81(10): 3654-62.		H, R, F
3013	1996.12.01	Katznelson L, et al. Increase in bone density and lean body mass		H, R, F
3014	1997.01.01	Bhasin S, Storer TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. Feb 1997;82(2):407-413		H, R, F
3015	1997.01.01	Morley JE, Kaiser FE, Perry HM 3rd, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metab. 46:410-413, 1997.		H, R, F
3016	1997.01.01	R. Sih et al., <i>Testosterone Replacement in Older Hypogonadal Men: A 12-Month Randomized Controlled Trial</i> , 1997 J. Clin. Endocrinol. Metab. 82(6): 1661-67.		H, R, F
3017	1997.01.01	Tenover JL: Testosterone and the aging male. J Androl 18:103-106, 1997		H, R, F
3018	1997.03.07	Summary of Unimed/FDA Meeting	ABBVIE-FST00000845-00878	NPO

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

3019	1997.04.04	UMD-96-017 Study Protocol Amendment: Phase III Evaluation of the Safety and Efficacy of Testosterone Gel (T-Gel) for Hormonal Replacement in Hypogonadal Men	ABBVIE-FST00000884-00928	NPO
3020	1997.10.02	UMD-98-044 Phase II Study of the influence of Two Androgen Replacement Treatments on the Vascular Risk Factors in Men Having a Low Total Plasma Testosterone Level	ABBVIE-FST01427802-27879	NPO
3021	1997.11.01	FDA Guidance for Industry relating to programs and activities supported by companies (62 F.R. 64074, 64093-100)		NPO
3022	1997.12.05	FDA Medical Officer Review of Testoderm	ABBVIE-FST01124273	H, R, F
3023	1998.01.01	AACE Clinical Practice Guidelines for the Evaluation and Treatment of Hypogonadism in Adult Male Patients	ABBVIE-FST15874451	H
3024	1998.01.01	Tenover JL 1998 Androgen deficiency in aging men. Abstracts of the First World Congress on The Aging Male. Aging Male I(Suppl I):S07		H, R, F
3025	1998.03.03	UMD-98-035 Study Protocol: A Long-Term Study of the Safety and Effectiveness of Testosterone-Gel for Hormonal Replacement in Hypogonadal Men	ABBVIE-FST00438350-38377	NPO
3026	1998.03.24	UMD-96-017 Study Protocol Amendment	ABBVIE-FST00438378-38411	NPO
3027	1998.07.23	Unimed Response to FDA Request for Information	ABBVIE-FST00001246-01255	H
3028	1998.10.02	Pre-NDA Meeting Briefing Document	ABBVIE-FST00001301-01364	NPO
3029	1998.11.25	Unimed Communication to FDA with Summary Report of Pre-NDA Meeting	ABBVIE-FST00001487-01512	H, R, P
3030	1998.12.01	Tenover, Male Hormone Replacement Therapy Including "Andropause", Endocrinology and Metabolism Clinics of North America, 27(4); 969-987	ABBVIE-FST01388212	H, F
3031	1998.12.07	FDA Communication to Unimed with Pre-NDA Meeting Minutes	ABBVIE-FST00001980-01984	H, P, A
3032	1998.12.16	Statistical Analysis Plan for UMD-96-017	ABBVIE-FST00001985-02072	NPO
3033	1999.01.01	A. Dobs et al., <i>Pharmacokinetics, Efficiency, and Safety of a Permeation-Enhanced Testosterone Transdermal System in Comparison with Bi-Weekly Injections of Testosterone Enanthate for the Treatment of Hypogonadal Men</i> , 1999 J. Clin. Endocrinol. Metab. 84(10): 3469-78.		H, R, F
3034	1999.01.01	Peter Snyder et al., <i>Effects of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age</i> , 1999 J. Clin. Endocrinol. Metab. 84(6): 1966-72.		H, R, F
3035	1999.01.15	Addendum to Revised Statistical Analysis Plan for UMD-96-017	ABBVIE-FST00439180-39187	NPO
3036	1999.08.01	Guidance for Industry: Consumer-Directed Broadcast Advertisements		NPO
3037	1999.09.16	UMD-98-017 Final Study Report Amendment No. 3	ABBVIE-FST00347316-47616	I, F
3038	1999.10.17	Unimed: FDA Contact Report re: Androgel - FDA Requests for 1) Electronic PK Information/Data and 2) Change in Protocol UMD -98 -035 (Elevated Hematocrit Associated with Secondary Polycythemia)	ABBVIE-FST00299595	H
3039	2000.00.00	Wang C, et al., <i>Transdermal testosterone Gel improves sexual function, mood, muscle strength, and body composition parameters in hypergonadal men. J Clin Endocrinol Metab</i> 85;2839:2853, 2000		H, R, F
3040	2000.01.01	Summary of the Consensus Session From the 1st Annual Andropause 2000 Meeting	ABBVIE-00017169	H
3041	2000.01.01	J.E. Morley et al., <i>3rd 2000 Validation of a Screening Questionnaire for Androgen Deficiency in Aging Males</i> , 2000 Metabolism 49(9): 1239-42.		H, R, F
3042	2000.01.24	Unimed Response to 01-21-2000 FDA Request	ABBVIE-FST00034751-34770	H, R, P

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

3043	2000.02.15	NDA 21-015 AndroGel 1% Medical Review	ABBVIE-FST01906839-06892	NPO
3044	2000.02.15	NDA 21-015 Group Leader Memorandum by Daniel Shames	ABBVIE-FST14682040	NPO
3045	2000.02.28	NDA 21-015 AndroGel 1% Approved Draft Labeling	ABBVIE-FST13350382-50410	P, I
3046	2000.02.28	NDA 21-015 AndroGel 1% Approval Letter	ABBVIE-FST14682049-82053	NPO
3047	2000.02.28	1% Med Guide	ABBVIE-FST00300937-00940	NPO
3048	2000.02.28	1% PI	ABBVIE-FST00355125-55130	NPO
3049	2000.03.21	Correspondence from Unimed to FDA re Proposed Introductory Promotional Materials	ABBVIE-FST02279925-80060	NPO
3050	2000.04.12	FDA response to Unimed	ABBVIE-FST12159671-59682	NPO
3051	2000.05.01	Wang C, Swerdloff RS, Iranmanesh A, et al; Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2839-53	ABBVIE-FST06296209	H, R, F
3052	2000.06.07	1% Med Guide & PI	ABBVIE-FST00035567-35576	NPO
3053	2000.08.01	Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85(12):4500-10		H, R, F
3054	2000.08.03	Testosterone and Men: Emerging Clinical Issues	3rdPARTY_TRT_PSC_PROD000024531	H, F, P, R
3055	2000.08.21	Testosterone Replacement Therapy: Emerging Clinical Issues	3rdPARTY_TRT_PSC_PROD000024565-74	H, F, P, R
3056	2001.01.01	S.M. Harman et al., <i>Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men. Baltimore Longitudinal Study of Aging</i> , 2001 J. Clin. Endocrinol. Metab. 86(2): 724-31.		H, R, F
3057	2001.05.01	Basaria S., Dobs AS. Hypogonadism and androgen replacement therapy in elderly men. AM J Med. May 2001; 110(7):563-572		H, R, F
3058	2001.06.27	1% PI	ABBVIE-FST00035605-35610	NPO
3059	2001.09.05	1% Med Guide	ABBVIE-FST00361042-61043	NPO
3060	2001.09.05	1% PI	ABBVIE-FST00362591-62602	NPO
3061	2002.01.01	Summary from the 2nd Annual Andropause Consensus Meeting	ABBVIE-00033837	NPO
3062	2002.01.01	AACE Guidelines	ABBVIE-00218364-18380	H, R, F
3063	2002.01.31	Proceedings of the Endocrine Society Andropause Consensus Conferences 2000-2001	SPI00344397-4446	H
3064	2002.03.14	Conference Call Summary	ABBVIE-FST17068982	H, A, F
3065	2002.05.03	2002 Andropause Consensus - 3rd Annual Andropause Consensus Taskforce	ABBVIE-00199959-00060	NPO
3066	2002.05.29	Letter of Agreement	ABBVIE-00070428-70437	NPO
3067	2002.06.06	Email from Reinhardt re Summary/Recommendations	3rdPARTY_TRT_PSC_PROD000024955-76	H, P, R
3068	2002.07.01	Cunningham Email Exchange	ABBVIE-FST08688418-88422	H
3069	2002.07.01	Matsumoto Email Exchange	ABBVIE-FST08688423	H, R, I, F
3070	2002.10.22	1% PI & Med Guide		NPO
3071	2002.10.28	Email to Melanie Blanchard re Permission to adapt Summary from Consensus	ABBVIE-FST17074449	H, A, F
3072	2002.11.01	American Association of Clinical Endocrinologists, Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients - 2002 Update, Endocr Pract. 2002;8:439-456		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

3073	2003.01.01	Ka Kui Lee et al., <i>A Simple Self-Report Diary for Assessing Psychosexual Function in Hypogonadal Men</i> , 2003 J. Androl. 24(5): 688-98.		H, R, F
3074	2003.03.27	DHCP: Hypogonadism: Diagnosing and Monitoring (Tab 31)	SPI00420936-0937	H, R, P
3075	2003.05.15	Periodic Safety Update Report 2002-2003	ABBVIE-FST00321943-22125 ABBVIE-FST00008555-8556	NPO
3076	2003.06.01	Bhasin S, Singh AB, Mac R, Carter B, Lee MI, Cunningham G, Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan		H, R, F
3077	2003.06.23	Solvay request to FDA re Advertising/Promotional Material	ABBVIE-FST15874519-74530 ABBVIE-FST13285286-85297	H, R, P, F
3078	2003.07.22	Statement of Janet Woodcock, M.D., Director for Center for Drug Evaluation and Research, FDA, before the Senate Special Committee on Aging, 108th Cong.		H, R, P, F
3079	2003.08.07	FDA contact report re Advisory Opinion for AndroGel Television Ad	ABBVIE-FST06112916 ABBVIE-FST15874531	H
3080	2003.09.01	Swerdloff & Wang. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Aging Male. 2003 Sep; 6(3):207-11		H, R, F
3081	2003.11.12	"DIY Guy Dog & Ball" video	ABBVIE-FST08745806	H, B
3082	2004.01.01	Review of IOM Report	ABBVIE-00271343-71367 ABBVIE-FST01309167	NPO
3083	2004.01.01	A.B. Araujo et al., <i>Prevalence and Incidence of Androgen Deficiency in Middle-Aged and Older Men: Estimates from the Massachusetts Male Aging Study</i> , 2004 J. Clin. Endocrinol. Metab. 89(12): 5920-26.		H, R, F
3084	2004.01.01	Draft FDA Guidance for Industry: "Help-Seeking" and other Disease Awareness Communications by or on Behalf of Drug and Device Firms		H, B
3085	2004.01.21	National Institute on Aging Meeting Minutes	ABBVIE-00271368-71370	H
3086	2004.01.29	Snyder, Hypogonadism in Elderly Men - What to Do Until the Evidence Comes, N ENGLJ MED 350;5	EDEL00131472	H, F
3087	2004.02.01	Wojtanowski Email for Ron	ABBVIE-00013460	H, P, I, B
3088	2004.02.12	Andropause on NPR	ABBVIE-FST13282486	H
3089	2004.03.04	Solvay email re: meeting with Snyder to discuss Testosterone Working Group plans	ABBVIE-FST18658227	H
3090	2004.04.16	Periodic Safety Update Report 2003-2004	ABBVIE-FST00322126-22315	NPO
3091	2004.05.01	Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. May 2004;89(5):2085- 2098.		H, R, F
3092	2004.11.19	1% PI & Med Guide		F, B

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

3093	2004.11.23	Bhasin S, Woodhouse L, Casaburi R, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. <i>J Clin Endocrinol Metab.</i> 2005; 90(2):678-88.		H, R, F
3094	2005.03.01	FDA Guidance: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment	ABBVIE-FST15978840	NPO
3095	2005.03.12	TEAAM Protocol		H, R, F
3096	2005.03.17	FDA Contact Report	ABBVIE-FST18028863	H
3097	2005.03.22	Data submission	ABBVIE-FST00041628-41631; ABBVIE-FST18069538	I
3098	2005.03.22	Periodic Safety Update Report 2000-2005	ABBVIE-FST00322316-22465	NPO
3099	2005.04.08	Testosterone Class-Labeling Response Team meeting minutes	ABBVIE-FST14633968-33970	NPO
3100	2005.04.29	Kim email attaching FDA approvable letter for NDA 21-015 supplement 011	ABBVIE-FST00377387-77391	NPO
3101	2005.08.11	FDA Letter to Solvay	ABBVIE-FST00427886-27902	NPO
3102	2005.09.07	Solvay Position Paper	ABBVIE-00631344	H, F
3103	2005.09.09	The Safe Use of Testosterone Replacement Therapy in Hypogonadal Men	ABBVIE-00359725	H, A, I, F, B
3104	2005.09.09	Letter to FDA re: class labeling, response to 3/30/2005 teleconference	ABBVIE-FST01057422-57696	NPO
3105	2005.10.18	Testosterone Class-Labeling Response Team meeting minutes	ABBVIE-FST14633868-33869	NPO
3106	2006.01.01	2006 Endocrine Society Clinical Practice Guideline	ABBVIE-FST01241651-41666	H, R, P
3107	2006.01.19	Solvay Advisory Opinion Review Request to FDA	ABBVIE-FST12159683-59736	H, R, P, F
3108	2006.01.31	Appropriate Treatment of Male Hypogonadism of Any Etiology	ABBVIE-FST02262776-62869	H, P, B
3109	2006.02.01	FDA Draft Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims	ABBVIE-FST10547532-7567	NPO
3110	2006.02.16	FDA Draft Guidance Regarding Testosterone Therapy Class Labeling	ABBVIE-FST17494293-94295	H, I, P, R
3111	2006.03.07	Benesh Email Exchange re NIA Request for Information (AndroGel)	ABBVIE-FST01310804-10805	H, I
3112	2006.03.28	Signal Evaluation Report - Pulmonary Embolism	ABBVIE-FST19538261-38263	NPO
3113	2006.04.20	Wojtanowski email to Baugham re: DDMAC review of DTC material submitted for pre-clearance (DDMAC Tab 11)	ABBVIE-FST15874587	H
3114	2006.04.20	DDMAC Review of DTC Material	ABBVIE-FST00383563	H
3115	2006.04.24	Periodic Safety Update Report 2005-2006	ABBVIE-FST15711294-11762	I
3116	2006.06.01	The Hormone Foundation's Patient Guide to Androgen Deficiency Syndromes in Adult Men	ABBVIE-FST17835098	H, R, P
3117	2006.06.01	Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab.</i> Jun 2006;91(6):1995-2010.		H, R, F
3118	2006.07.01	T. Mulligan, et al., <i>Prevalence of Hypogonadism in Males Aged at Least 45 Years: The HIM Study</i> , 2006 <i>Intl. J. Clin. Pract.</i> 60(7): 762-69.		H, R, F
3119	2006.07.26	Low Testosterone and Men's Health	ABBVIE-FST17835100-35101	H, R, F
3120	2007.03.10	Signal Evaluation Report – Thromboembolism	ABBVIE-FST17663540-63551	NPO
3121	2007.04.23	Periodic Safety Update Report 2006-2007	ABBVIE-FST01881574-82130	NPO
3122	2007.10.22	Letter from FDA re: Approvable Letter for NDA 21-015/S-016	ABBVIE-FST00304607	NPO
3123	2007.10.24	Email from John Kim to Steven Wojtanowski attaching a track change version of the label	ABBVIE-FST14615784	NPO
3124	2007.10.27	Wojtanowski Email re Review FDA Changes to AndroGel 1% Prescribing Information with Attachments	ABBVIE-00048718-48745	H

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

3125	2007.10.30	Wojtanowski Email re Solvay Response to AndroGel SLR	ABBVIE-FST14615745	I
3126	2007.10.30	Solvay response to 10-22-2007 approvable letter	ABBVIE-FST00344410-44411	NPO
3127	2007.11.01	E-mail from Wojtanowski re: AndroGel 1% Label	ABBVIE-FST09622229	H
3128	2007.11.02	Miller Email	ABBVIE-00050152	H
3129	2007.12.03	Email chain with FDA	ABBVIE-FST01259758-59759	H
3130	2007.12.13	FDA Approval Letter	ABBVIE-FST13295000	NPO
3131	2007.12.13	1% PI & Med Guide		NPO
3132	2007.12.27	1% PI & Med Guide		B
3133	2008.01.21	Final Versions of Sales Aid Guides	ABBVIE-FST16098390-98397	NPO
3134	2008.04.23	Periodic Safety Update Report 2007-2008	ABBVIE-FST09340052-40569	NPO
3135	2008.06.11	Lawhorn Email Exchange re 9-June-08 NIA Study Group Update	ABBVIE-FST01311134-11137	H
3136	2008.07.08	SOP, Urgent Safety Notifications for Marketed Products (V.2)	ABBVIE-FST14568340-68351	H, F, P, R
3137	2008.08.12	Emails re: changes to T-Trials protocol based on Basaria study	ABBVIE-FST01311709-11711	H, F
3138	2008.11.01	Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of lateonset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol. Nov 2008;159(5):507-514.		H, R, F
3139	2009.01.00	Testopel Pellets Label	AUXILIUM_MDL_REG_000097603	H, F, P, R
3140	2009.01.01	FDA Guidance for Industry: Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices		B, H, P, R
3141	2009.04.22	FDA Filing Communication	ABBVIE-FST00428002-28006	NPO
3142	2009.04.22	Periodic Safety Update Report 2008-2009	ABBVIE-FST14583934	H
3143	2009.04.24	Material Transfer Provider Agreement btw Solvay Pharma and Trustees of Univ. of Pennsylvania	ABBVIE-FST10400522-00606	F, I
3144	2009.06.00	Instruction Guide, Signal Evaluation Reports (V.4)	ABBVIE-FST17936707-36732	F, H
3145	2009.06.16	FDA email request for information on three subjects in S176.3.104 (one with elevated hemoglobin/hematocrit)	ABBVIE-FST17682035-82036	I
3146	2009.07.14	Solvay response to 4-22-2009, 6-16-2009 FDA requests (response referenced in 4-19-2011 FDA Medical Review(s) upon approval)	ABBVIE-FST00221618-21619	NPO
3147	2009.09.01	Dear HCP Letter re: transfer risk to women and children	ABBVIE-FST00221737-21738	R, I, B
3148	2009.09.18	1% PI & Med Guide		B
3149	2009.09.18	FDA Letter to Auxilium re Testim 1% box warning	AUXILIUM_MDL_CUST_000178652-78687	H, R, A, F
3150	2009.10.00	Instruction Guide, Signal Evaluation Reports (V.5)	ABBVIE-FST17915727-15750	F, H
3151	2009.10.19	Solvay SOP for Marietta PV: Local Procedures for Processing and Reporting Individual and Aggregate FDA Reports	ABBVIE-FST19682964-82977	F, H
3152	2009.11.10	SOP, Guidance for the Development and Approval of Promotional Materials (V.1)	ABBVIE-FST14570259-70304	F, H
3153	2009.12.01	FDA Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims	ABBVIE-FST00419491	NPO
3154	2010.01.01	2010 Endocrine Society Clinical Practice Guideline	ABBVIE-FST06540349	H, R, P, F
3155	2010.01.31	Dear HCP letters re: changes to prescribing information (transfer risk to children)	ABBVIE-FST00051724-51751	R, P

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

3156	2010.02.12	Solvay letter to FDA re: Dear Healthcare Professional letters	ABBVIE-FST00051694-51723	P, R
3157	2010.03.02	Signal Evaluation Report – Myocardial Ischemia	ABBVIE-FST02512049-12121	I
3158	2010.03.12	NDA 22-039 FDA Other Actions Letter(s)	ABBVIE-FST08557472-57477	NPO
3159	2010.04.22	Periodic Safety Update Report 2009-2010	ABBVIE-FST15708407-09307	NPO
3160	2010.05.03	SOP, Urgent Safety Notifications for Marketed Products (V.3)	ABBVIE-FST14568352-68364	F, H
3161	2010.05.21	Testosterone Replacement Therapy and Risk of Cardiovascular Disease	FDA_FOIA_018129-8140	H, P, A, F
3162	2010.05.24	SOP, Significant Safety Issue Management (V.1)	ABBVIE-FST14753975-53990	F, H
3163	2010.06.01	Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. Jun 2010;95(6):2536-2559.		H, R, F
3164	2010.07.08	Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middleaged and elderly men. N Engl J Med. Jul 8 2010;363(2):123-135.		H, R, F
3165	2010.08.01	Consultation with Susan Allen (formerly FDA) re: Basaria study	ABBVIE-FST01955441-55445	H, P
3166	2010.08.09	Key Opinion Leader feedback re: Basaria study	ABBVIE-FST01399026-99028	H, P, R
3167	2010.09.03	SOP, STAR Requirements for Review and Approval of PPD Promotioanl and Educational Material (V.10)	ABBVIE-FST14751369-51389	H, F
3168	2010.10.22	Signal Evaluation Report – Venous Thromboembolism	ABBVIE-FST01029850-29866	I
3169	2010.10.22	Signal Evaluation Report – Arterial Thromboembolism	ABBVIE-FST02084540-84565	H, R, P
3170	2010.11.02	SMT Testosterone, Draft Offline Review Form	ABBVIE-FST01358657-58659	H, R, P, F
3171	2010.11.18	NDA 22-039 Microbiology Review(s)	ABBVIE-FST08557465-57471	NPO
3172	2010.12.06	Testosterone Replacement Therapy and Risk of Cardiovascular Disease by Age Group and Chronic Disease Status	FDA_FOIA_014694-4706	H, P, A, F
3173	2010.12.07	SOP, Safety Monitoring (V.1)	ABBVIE-FST14779897-79911	R, P
3174	2011 - 2014	PADERS - April 29, 2011 – August 27, 2011 PADERS - August 28, 2011 – November 27, 2011 PADERS - February 28, 2012 – May 27, 2012 PADERS - May 28, 2012 – August 27, 2012 PADERS - November 28, 2012 – February 27, 2013 PADERS - February 28, 2013 – May 27, 2013 PADERS - May 28, 2013 – August 27, 2013 PADERS - August 28, 2013 – November 27, 2013 PADERS - November 28, 2013 – February 27, 2014 PADERS - February 28, 2014 – April 27, 2014	ABBVIE-FST01783566 ABBVIE-FST00452648 ABBVIE-FST00453803 ABBVIE-FST02303280 ABBVIE-FST02385081 ABBVIE-FST02379350 ABBVIE-FST02029443 ABBVIE-FST02216834 ABBVIE-FST01789952 ABBVIE-FST01796595	I, C
3175	2011.01.01	1.62% Video	ABBVIE-FST10962043	R, P
3176	2011.01.01	Fortesta Gel Brand Overview	ENDO-MDL2545-00187369-87402	H, R, A, F
3177	2011.02.10	SOP, Significant Safety Issue Management (V.2)	ABBVIE-FST14753991-54006	H, R, P, F
3178	2011.03.10	1% PI & Med Guide		NPO
3179	2011.04.11	NDA 22-039 Risk Assessment & Risk Mitigation Review(s)	ABBVIE-FST08557519-57543	H, R, P
3180	2011.04.19	NDA 22-039 Medical Review(s)	ABBVIE-FST00493278-93775	H, R, P
3181	2011.04.20	Periodic Safety Update Report 2010-2011	ABBVIE-FST15709308-10218	H, R
3182	2011.04.26	NDA 22-039 Statistical Review(s)	ABBVIE-FST00526932-26949	NPO
3183	2011.04.27	NDA 22-039 Chemistry Review(s)	ABBVIE-FST08556932-56966	H, R, P, I
3184	2011.04.28	NDA 22-039 Clinical Pharmacology & Biopharmaceutics Review(s)	ABBVIE-FST01905512-05677	R, P, I, B
3185	2011.04.28	NDA 22-039 Pharmacology Review(s)	ABBVIE-FST01906176-06206	R, P, I, C

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

3186	2011.04.29	NDA 22-039 Other Review(s)	ABBVIE-FST00499125-99181	R, P, I
3187	2011.04.29	NDA 22-039 Summary Review	ABBVIE-FST01906235-06259	NPO
3188	2011.04.29	NDA 22-039 Risk Evaluation & Mitigation Strategy	ABBVIE-FST08557509-57518	NPO
3189	2011.04.29	NDA 22-039 Cross Discipline Team Leader Review	ABBVIE-FST15233704-33750	H, R, P, I, F
3190	2011.04.29	NDA 22-039 Approval Letter	ABBVIE-FST15759646-59651	R, P, I
3191	2011.04.29	1.62% PI		R
3192	2011.04.29	1.62% Med Guide		NPO
3193	2011.05.01	A Navigator to the Maste rVisual Aid (MVA) for Fortesta Gel Sales Professionals	ENDO-MDL2545-00774111-74130	H, R, A, F
3194	2011.06.01	Wang C, Swerdloff RS, Iranmanesh A, et al. Effects of trans-dermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol (Oxf). 2001 Jun; 54(6):739-50		H, R, F
3195	2011.07.01	Kaufman JM, Miller MG, Garwin JL, Fitzpatrick S, McWhirter C, Brennan JJ. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. J Sex Med. Jul 2011;8(7):2079-2089.		H, R, F
3196	2011.09.09	SOP, Safety Monitoring (V.2)	ABBVIE-FST14754565-54580	H, R, P, F
3197	2011.09.21	Product Safety Plan, Testosterone Gel 1% & 1.62%	ABBVIE-FST12601094-01123	H, R, P
3198	2011.09.22	SOP, Requirements for Review and Approval of PPD Promotioanl and Non-Promotional Material (V.11)	ABBVIE-FST14751390-51410	H, R, P, F
3199	2011.10.01	FDA Guidance for Industry: Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products: Content and Format (Oct. 2011)	ABBVIE-FST15685880	R, P
3200	2011.10.28	SOP, PPD Group Consulting (Advisory Board) Meetings (V.2)	ABBVIE-FST14752296-52315	H, R, F
3201	2011.11.01	FDA Guidance: Medication Guides – Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS) (Nov. 2011)		R, P
3202	2011.11.10	Abbott Request for Advisory Comments	ABBVIE-FST01443707-43792	H, R, P, F
3203	2011.11.30	1% PI & Med Guide		NPO
3204	2011.12.01	Wang C, Ilani N, Arver S, McLachlan RI, Soulis T, Watkinson A. Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgendeficient men. Clin Endocrinol (Oxf). Dec 2011;75(6):836-843.		H, F, R
3205	2011.12.08	Annual Post-Marketing Product Safety Review	ABBVIE-FST09556676-56686	H, C, B
3206	2011.12.29	FDA response re NDA 021015, 022309	ABBVIE-FST02280172-80179	R, P, I
3207	2012.01.01	"Turn it Up" Video	ABBVIE-FST10962057	R, P
3208	2012.03.01	Draft FDA Guidance for Industry: Direct-to-Consumer Television Advertisements — FDA DTC Television Ad Pre-Dissemination Review Program		H, R, P
3209	2012.04.01	Kaufman JM, Miller MG, Fitzpatrick S, McWhirter C, Brennan JJ. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day openlabel extension of a 6-month double-blind study. J Sex Med. Apr 2012;9(4):1149-1161.	ABBVIE-FST00487716	H, R, F
3210	2012.04.16	Periodic Safety Update Report 2011-2012	ABBVIE-FST15710219-10770	NPO
3211	2012.07.24	Abbott Request for Advisory Comments on Proposed DTC ad	ABBVIE-FST00415323-15389	H, R, P, F
3212	2012.07.24	Abbott Request for Advisory Comments on Proposed DTC ad	ABBVIE-FST02461642-61706	R, P

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

3213	2012.09.07	1.62% Med Guide	ABBVIE-FST09341115-41122	R, P, B
3214	2012.09.07	1.62% PI		NPO
3215	2012.09.20	1% PI & Med Guide		NPO
3216	2012.09.28	SOP, Requirements for Review and Approval of PPD Promotioanl and Non-Promotional Material (V.12)	ABBVIE-FST14751411-51436	H, F, P, R
3217	2012.10.22	FDA response to 7-24-2012 ad submission	ABBVIE-FST09893926-93929	H, R, P, F
3218	2012.10.22	Email from Kwak to Nayini re: DTC ad submission (1 & 2) (DDMAC Tab 22)	ABBVIE-FST01443933	H, F, P, R
3219	2012.11.01	SOP, Guidance for the Development and Approval of PPD US Promotional and Non-Promotional Materials (V.3)	ABBVIE-FST14570131-70194	H, F, P, R
3220	2012.11.02	SOP, PPG Individual and Group Consulting (V.4)	ABBVIE-FST14590733-90756	H, F, P, R
3221	2012.12.18	Presentation to SRB: Annual Post-Marketing Product Safety Review	ABBVIE-FST12619713-19737	H, F, P, R
3222	2013.05.01	Product Safety Plan, Testosterone Gel 1% & 1.62%	ABBVIE-FST11213397-13437	H, C, B
3223	2013.05.07	FDAAA Section 915 Non-New Molecular Entity (non-NME) Postmarket Safety Summary: AndroGel 1.62%	ABBVIE-FST11221954-21969	H, R, P, I
3224	2013.05.20	1% Med Guide	ABBVIE-FST00534931-34938	R, P, B
3225	2013.05.20	1% PI		NPO
3226	2013.05.20	1.62% PI & Med Guide		R, P
3227	2013.08.07	AndroGel 1.62% DTC Commercial #1 :90	ABBVIE-FST09909567	R, P, I, B
3228	2013.08.15	AbbVie Request for Advisory Comments on Proposed DTC Ad	ABBVIE-FST17850599-50749	R, P
3229	2013.09.18	Email from Nader Khan re AndroGel 1.62% - FDA procedure comprehensive review		H, R, P
3230	2013.12.12	FDA Letter to AbbVie re NDA 22309	ABBVIE-FST01444088-44092	H, R, P
3231	2013.12.16	Presentation to SRB: Annual Post-Marketing Product Safety Review	ABBVIE-FST12619168-19200	H, F, P, R
3232	2014.00.00	Scarazzini et al. Spontaneous Reporting and Pharmacovigilance Practice: USA		H, R, F
3233	2014.00.00	Talking Points re Vigen	ABBVIE-FST15984314	H, F, P, R
3234	2014.00.00	Chen M, et al., Spontaneous Reporting and Pharmacovigilance Practice: USA. Mann's Pharmacovigilance, Third Edition 2014.		H, R, F
3235	2014.01.01	Chen M, et al., Spontaneous Reporting and Pharmacovigilance Practice: USA. Mann's Pharmacovigilance, Third Edition 2014		H, R, F
3236	2014.01.31	Talking Points re Finkle	ABBVIE-FST00534114	H, R, P, F
3237	2014.01.00	Let's be clear - there's a reason it's worth looking for and accurately diagnosing hypogonadism - his name is Dave	ABBVIE-FST06093253-93272	H, R, P
3238	2014.02.04	Association of Testosterone Therapy with Mortality, Myocardial Infarction & Stroke in Men with Low Testosterone Levels	ABBVIE-FST00882465-82501	H, R, P
3239	2014.02.14	Ad Hoc Meeting: CV Risk Assessment Update	ABBVIE-FST02927105-27131	H, R, P, F
3240	2014.03.12	AbbVie Safety Council Meeting Minutes	ABBVIE-FST15750646-50732	H, R, P, F
3241	2014.03.26	FDA Safety Labeling Change Notification	ABBVIE-FST06145227-45230	NPO
3242	2014.03.31	AbbVie Safety Council Meeting Minutes	ABBVIE-FST01791685-91709	H, R, P, F
3243	2014.04.01	Association of Testosterone Therapy with Venous Thromboembolic Events	ABBVIE-FST02254379-54444	R, P
3244	2014.04.14	Periodic Safety Update Report Addendum 2013-2014	ABBVIE-FST01792184-92946	H, R, P, F
3245	2014.04.25	AbbVie Letter to FDA re Safety Label Changes under 404(o)(4) - Rebuttal (Change not Warranted)	ABBVIE-FST08654954-54955; ABBVIE-FST00484819-84827	R, P
3246	2014.04.28	Koev Email Exchange with Dear Prescriber letter re: Important Drug Information regarding AndroGel	ABBVIE-FST01887731-87733	H, R, P

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

3247	2014.05.01	AbbVie response to FDA Request for Information Upon Review of Safety Label Changes under 404(o)(4) - Rebuttal (Change not Warranted)	ABBVIE-FST08654995-54996	R, P
3248	2014.05.21	Addendum to Association of Testosterone Therapy with Mortality, Myocardial Infarction & Stroke in Men with Low Testosterone Levels	ABBVIE-FST12638789	H, R, P, I
3249	2014.05.29	Koev email Exchange re: AndroGel VTE Language	ABBVIE-FST08837978-37981	H, R, P
3250	2014.06.05	Kaleck-Schlinsoog Email Exchange re Nader Will Sign	ABBVIE-FST08660216-60219	H, R, P
3251	2014.06.12	Presentation to SRB: AndroGel Update – CV Risk, VTE Risk, Misuse	ABBVIE-FST00504232-04259	H, R, P, F
3252	2014.06.19	1% PI & Med Guide		R
3253	2014.06.19	1.62% PI & Med Guide		NPO
3254	2014.07.16	FDA Response to Public Citizen Petition	ABBVIE-FST00883321-83336	H, R, P, F
3255	2014.08.12	Introduction Memorandum: Epidemiology	ABBVIE-FST05950018	H, R, P, F
3256	2014.09.12	Pharmacovigilance Review - Myocardial Infarction and Stroke	FDA_FOIA_029131-9179	H, F, P, R
3257	2014.09.17	FDA Advisory Committee Briefing Book	ABBVIE-FST05949997-50205	H, R, P, F
3258	2014.09.17	FDA Advisory Committee slide deck	ABBVIE-FST01859510-59605	NPO
3259	2014.09.17	Advisory Comm. Summary Minutes	ABBVIE-FST06144608-44616	H, R, P
3260	2014.09.17	Ad Comm briefing book, Clinical Background Document		H, R, P, F
3261	2014.09.17	AdComm FDA Briefing Book, Fred Senatore, Clinical Evaluation of the Cardiovascular Risk of Testosterone		H, R, P, A
3262	2014.09.17	Industry Advisory Committee slide deck	ABBVIE-FST15246238-46317	H, R, P, F
3263	2014.09.17	Advisory Committee meeting transcript	ABBVIE-FST13772471-72580	H, R, P, F
3264	2014.09.17	Industry Advisory Committee Briefing Book	ABBVIE-FST02246493-46652 ABBVIE-FST00489476	H, F, P, R
3265	2014.09.29	Dear Healthcare Provider Letter re Venous Thromboembolism	ABBVIE-FST02521407-21409	R, P
3266	2014.10.01	Email from Storey re: AndroGel	ABBVIE-FST08685671-85672	H, R, P, F
3267	2014.11.12	1% PI & Med Guide		NPO
3268	2014.11.14	1.62% PI & Med Guide		NPO
3269	2015.04.14	FDA email response	ABBVIE-FST09375446-75448	H, R, P, F
3270	2015.05.11	1% PI & Med Guide		NPO
3271	2015.05.11	1.62% PI & Med Guide		NPO
3272	2015.08.01	Dear Healthcare Provider Letter re: US Prescribing Information Changes for AndroGel	ABBVIE-FST15726745-26746	NPO
3273	2016.12.06	Arrowsmith Summaries re: Reporting Rate Analyses		R, P, I, C, F, B
3274	2016.12.06	Marais Appendix D		H, R, P, I, C, F, B
3275	2016.12.06	Marais Appendix F		H, R, P, I, C, F, B
3276	2016.12.06	Marais Appendix F		H, R, P, I, C, F, B
3277	2016.12.06	Marais Appendix G		H, R, P, I, C, F, B
3278	2016.12.06	Marais Appendix H		H, R, P, I, C, F, B
3279	2016.12.06	Marais Figure 1		H, R, P, I, C, F, B
3280	2016.12.06	Marais Figure 3		H, R, P, I, C, F, B
3281	2016.12.06	Marais Figure 5		H, R, P, I, C, F, B
3282	2016.12.06	Marais Figure 7		H, R, P, I, C, F, B
3283	2016.12.06	Marais Figure 18		H, R, P, I, C, F, B
3284	2016.12.06	Marais Figure 19		H, R, P, I, C, F, B

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

3285	2016.12.06	Marais Figure 28		H, R, P, I, C, F, B
3286	2016.12.06	Marais Figure 29		H, R, P, I, C, F, B
3287	2016.12.06	Marais Figure 31		H, R, P, I, C, F, B
3288	2016.12.06	Marais Figure 32		H, R, P, I, C, F, B
3289	2016.12.06	Marais Figure 34		H, R, P, I, C, F, B
3290	2016.12.06	Marais Figure 35		H, R, P, I, C, F, B
3291	2016.12.06	Testosterone prescriptions (NPA (updated).xls and NPA_AndroGel TRx NRx EUTRx & sales \$ & IPS_200416.xlsx)		H, R, A, I, C, F, B
3292	2017.03.08	Summary of Data from Budoff (2017) Baseline Coronary Artery Calcium Scores		H, R, A, I, C, F, B
3293	2017.05.10	Marais Figure 2		H, R, P, I, C, F, B
3294	2017.05.10	Marais Figure 15		H, R, P, I, C, F, B
3295	2017.05.10	Marais Figure 16		H, R, P, I, C, F, B
3296	2017.05.10	Marais Figure 17		H, R, P, I, C, F, B
3297	2017.05.10	Marais Figure 30		H, R, P, I, C, F, B
3298	2017.05.10	Marais Figure 33		H, R, P, I, C, F, B

AbbVie's Medical Literature

Exhibit Number	Date	Description	Bates	Plaintiffs' Objections
4000		Friedman G, et al., Cardia: Study Design, Recruitment, and Some Charecteristics of the Examined Subjects. 1988; 41(11): 1105-1116		H, R, F
4001		Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. Oct 1999;84(10):3469- 3478.		H, R, F
4002		Lokshyn S, et al., Atrial fibrillation in coronary artery disease. International Journal of Cardiology. 2000; 72:133-136		H, R, P, F
4003		Yusuf S. et al., Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries. Lancet. 2004; 364: 937-52		H, R, F
4004		Laaksonen DE, et al., Testosterone and sex hormone-binding globulin. Diabetes Care. May 2004; 27(5): 1036-1041		H, R, F
4005		Calof O, et al., Adverse Events Associated With Testosterone Replacement in Middle-Aged and Older Men. Journal of Gerontology. 2005;60A(11):1451-1457		H, R, F
4006		Food and Drug Administration. 2005. "Guidance for Industry: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment." http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126834.pdf .		NPO
4007		Pitteloud N, Hardin M, Dwyer AA, et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J. Clin Endocrinol Metab. May 2005; 90(5): 2636-2641.		H, R, F
4008		Halkin, et al., Prediction of Mortality After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction (the CADILLAC Risk Score), JACC Vol. 45, No. 9, 2005		H, R, F
4009		Lloyd-Jones D, et al., Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age. American Heart Association. Feb 2006;113:791-798		H, R, F
4010		Brambilla, et al., Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men, Clinical Endocrinology (2007) 67, 853-862		H, R, F
4011		Klein I, et al., Thyroid Disease and the Heart. American Heart Association. 2007;116:1725-1735		H, R, F
4012		Haddad R, et al. Testosterone and Cardiovascular Risk in Men. Mayo Clin Proc. 2007;82(1):29-39		H, R, F
4013		O'Donnell, Christopher J., and Roberto Elosua. "Cardiovascular risk factors. Insights from Framingham Heart Study." Revista Espanola de Cardiologia (English Edition) 61.3 (2008): 299-310.		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4014		Somers V, et al., Sleep Apnea and Cardiovascular Disease. Journal of the American College of Cardiology. 2008; 52(8): 686-717		H, R, F
4015		D'Agostino et al. General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study, Circulation. 2008;117:743-753		H, R, F
4016		Girardin JL et al Obstructive Sleep Apnea and Cardiovascular Disease: Role of the Metabolic Syndrome and Its Components... Journal of Clinical Sleep Medicine, 2008 4 (3).		H, R, F
4017		AbbVie DEMAND Study, S176.2.101 (Jun 20, 2008).		P, I
4018		Misra et al. Non-Alcoholic Fatty Liver Disease and Cardiovascular Risk. Curr Gastroenterol Rep. Feb 2009; 11(1): 50–55		H, R, F
4019		Nichols G, et al., Independent Contribution of Diabetes to Increased Prevalence and Incidence of Atrial Fibrillation. Diabetes Care. 2009; 32:1851–1856		H, R, F
4020		Pencina M, et al., Predicting the 30-Year Risk of Cardiovascular Disease. American Heart Association. Jun 2009;119:3078-3084		H, R, F
4021		Bosner S et al. Heartburn or angina? Differentiating gastrointestinal disease in primary care patients presenting with chest pain: a cross sectional diagnostic study. Int Arch Med. 2009; 2: 40		H, R, F
4022		Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. Feb 2010;95(2):639-650.		H, R, F
4023		Fernandez-Balsells M, et al., Adverse Effects of Testosterone Therapy in Adult Men. J Clin Endocrinol Metab. June 2010; 95(6):2560–2575		H, R, F
4024		Basaria S, et al., Adverse Events Associated with Testosterone Administration. NEJM. Jul 8 2010;363(2):109-122		H, R, F
4025		Mottillo S J. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. Am Coll Cardiol. 2010 Sep 28; 56(14):1113-32.		H, R, F
4026		Supariwala A. Synergistic effect of coronary artery disease risk factors on longterm survival in patients with normal exercise SPECT studies. J Nucl Cardiol. 2011 Apr; 18(2):207-14.		H, R, F
4027		Corona G et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011 Jan; 8(1):272-83. Epub 2010 Aug 30		H, R, F
4028		IMS Health National Prescription Audit™. 2011.		P, A, F, B
4029		Sniderman A, et al., A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk. Circ Cardiovasc Qual Outcomes. May 2011;4:337-345.		H, R, F
4030		Bhasin S, et al., Reference Ranges for Testosterone in Men Generated Using Liquid Chromatography Tandem Mass Spectrometry in a Community-Based Sample of Healthy Nonobese Young Men in the Framingham Heart Study and Applied to Three Geographically Distinct Cohors. J Clin Endocrinol Metab. 2011 Aug; 96(8):2430-2439		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4031		Krlev S, et al., Incidence and Severity of Coronary Artery Disease in Patients with Atrial Fibrillation Undergoing First-Time Coronary Angiography. PLoS ONE. Sep 2011; 6(9):e24964		H, R, F
4032		Shores M, et al., Testosterone Treatment and Mortality in Men with Low Testosterone Levels. J Clin Endocrinol Metab. June 2012; 97(6):3A-8A		H, R, F
4033		Bhatia L, et al. Non-alcoholic fatty liver disease. European Heart Journal. 2012; 33: 1190–1200		H, R, F
4034		Muraleedharan V. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. European Journal of Endocrinology. 2013; 169: 725–733		H, R, F
4035		Oskui P, et al. Testosterone and the Cardiovascular System. J Am Heart Assoc. 2013;2:e000272		H, R, F
4036		Ruige J, et al., Beneficial and Adverse Effects of Testosterone on the Cardiovascular System in Men. J Clin Endocrinol Metab. 2013; 98: 0001–0011		H, R, F
4037		Xu L, et al., Testosterone Therapy and Cardiovascular Events Among Men. BMC Medicine. 2013; 11(108): 1-12		H, R, F
4038		Vigen R, et al., Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels. JAMA. 2013;310(17):1829-1836		H, R, F
4039		AAHA CV Risk Calculator, Goff DC et al Circulation 2014; 129 (25 Suppl 2): S49-73		H, R, F
4040		Baillargeon J, et al. Risk of Myocardial Infarction in Older Men Receiving Testosterone Therapy. Annals of Pharmacotherapy. 2014; 1-7		H, R, F
4041		Borst S, et al. Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration. BMC Medicine. 2014; 12:211		H, R, F
4042		Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone boosting medications: a systematic review and meta-analysis. Expert opinion on drug safety. Aug 19 2014:1-25.		H, R, F
4043		Correction. Incorrect Language. 2014:JAMA. 2014;2311(2013):2306. doi:2010.1001/jama.2013.283704. http://jama.jamanetwork.com/article.aspx?articleid=1814192 Accessed April 26, 2014.		H, R, F
4044		Correction. Incorrect Number of Excluded Patients Reported in the Text and Figure. 2014:JAMA. 2014;2311(2019):2967. doi:2010.1001/jama.2014.2444. http://jama.jamanetwork.com/article.aspx?articleid=1835478 Accessed April 26, 2014.		H, R, F
4045		Hirsch MS. FDA Ad Comm Clinical Background Document, Testosterone Replacement Therapy: Clinical Development and Target Population. 2014.		A
4046		Langvik, et al., Symptoms of depression and anxiety before and after myocardial infarction: the HUNT 2 and HUNT 3 study, Psychology, Health & Medicine, 2014		H, R, F
4047		Finkle W, et al., Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men. PLoS ONE. Jan 2014;9(1):e85805.		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4048		Zaman et al. Sudden Cardiac Death Early After Myocardial Infarction. Pathogenesis, Risk Stratification, and Primary Prevention. Circulation. 2014; 129:2426-2435.		H, R, F
4049		Corona, Giovanni, and Mario Maggi. 2015. "Perspective: Regulatory Agencies' Changes to Testosterone Product Labeling." The Journal of Sexual Medicine 12 (8): 1690-93.		H, R, F
4050		Eisenberg MJ, et al., Testosterone Therapy and Mortality Risk. International Journal of Impotence Research. 2014; 27:46-48		H, R, F
4051		Etminan M. et al., Testosterone Therapy and Risk of Myocardial Infarction. Pharmacotherapy 2015; 35(1):72-78		H, R, F
4052		Goodman N. et al. American Association of Clinical Endrocrinologists and American College of Endocrinology position statement on the association of testosterone and cardiovascular risk. Endocr Pract 2015; 21:1066-73		H, R, F
4053		Pastuszak AW, Gomez LP, Scovell JM, Khera M, Lamb DJ, Lipshultz LI. Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen. Sex Med. 2015;3(3):165-173.		H, R, F
4054		Ramasamy R. et al., Association Between Testosterone Supplementation Therapy and Thrombotic Events in Elderly Men. Urology. 2015; 86:283-286		H, R, F
4055		Sharma R, et al., Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. European Heart Journal. Aug 2015; 1-10		H, R, F
4056		Xu I and Schooling C.M., Differential risks in men and women for first and recurrent venous thrombosis. J Thromb Haemost. 2015; 13: 884-6		H, R, F
4057		Li H, et al., Assessment of the Association Between the Use of Testosterone Replacement Therapy (TRT) and the Risk of Venous Thrombotic Events Among TRT-Treated and Untreated Hypogonadal Men. Endocrine Society. Mar 2015		H, R, F
4058		Janmohamed e tal., The Association Between Testosterone Use and Major Adverse Cardiovascular Events (MACE): An Exploratory Retrospective Cohort Analysis of Two Large, Contemporary, Coronary Heart Disease Clinical Trials, Endocrine Society Annual Meeting & = Expo, March7, 2015, Abstract OR 34-4		H, R, F
4059		Bansal N, Prediabetes diagnosis and treatment. World J Diabetes Mar 2015; 6(2): 296-303		H, R, F
4060		Solomon, et al., Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or both, NEJM Vol. 352, No. 25		H, R, F
4061		Forte de Siqueira ER et al. Cardiovascular Disease and NASH. Liver Res Open J. 2015; 1(2): 41-44.		H, R, F
4062		Baillargeon J, et al., Risk of Venous Thomboembolism in Men Receiving Testosterone Therapy. Mayo Clin Proc. Aug 2015; 90(8):1038-1045		H, R, F
4063		Basaria S, et al., Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Lower Low-Normal Testosterone Levels. JAMA. 2015;314(6):570-581		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4064		Albert S, et al., Testosterone therapy, association with age, initiation and mode of therapy with cardiovascular events. Clinical Endocrinology. 2016; 85: 436–443		H, R, F
4065		American Diabetes Association. "8. Cardiovascular disease and risk management." Diabetes Care 39. Supplement 1 (2016): S60-S71.		H, R, F
4066		Anderson J, et al., Impact of Testosterone Replacement Therapy on Myocardial Infarction, Stroke, and Death in Men With Low Testosterone Concentrations in an Integrated Health Care System. Am J Cardiol. 2016;117:794-799		H, R, F
4067		Hackett G. et al., Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes. Int J Clin Pract. March 2016; 70(3): 244–253		H, R, F
4068		Martinez C, et al., Testosterone treatment and risk of venous thromboembolism. BMJ. 2016;355:i5968		H, R, F
4069		Saad F, et al., Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III. International Journal of Obesity. 2016; 40; 162–170		H, R, F
4070		Sharma R, et al., Association Between Testosterone Replacement Therapy and the Incidence of DVT and Pulmonary Embolism. CHEST. 2016; 150(3):563-571		H, R, F
4071		Yassin A, et al. Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men. Clinical Endocrinology. 2016; 84: 107–114		H, R, F
4072		Snyder P, et al., Effects of Testosterone Treatment in Older Men. N Engl J Med. Feb 2016; 374(7): 611-624		H, R, F
4073		Brock G, Heiselman D, Maggi M, et al. Effect of Testosterone Solution 2% on Testosterone Concentration, Sex Drive and Energy in Hypogonadal Men: Results of a Placebo Controlled Study. J Urol. Mar 2016;195(3):699-705.		H, R, F
4074		Le, et al., Current practices of measuring and reference range reporting of free and total testosterone in the United States, The J. of Urology, Vol. 195; 1556-1561		H, R, F
4075		Wallis C, et al., Survival and cardiovascular events in men treated with testosterone replacement therapy. Lancet Diabetes Endocrinol. 2016; 4: 498–506		H, R, F
4076		Haider A. et al., Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy. Vascular Health and Risk Management 2016; 12: 251–261		H, R, F
4077		NHLBI website, Updated Jun 22, 2016 (https://www.nhlbi.nih.gov/health/health-topics/topics/ms)		H, R, P, A, B
4078		Khera M, Broderick GA, Carson CC, 3rd, et al. Adult-Onset Hypogonadism. Mayo Clin Proc. Jul 2016;91(7):908-926.		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4079		Maggi M, Wu FC, Jones TH, et al. Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the Registry of Hypogonadism in Men (RHYME). Int J Clin Pract. Oct 2016;70(10):843-852.		H, R, F
4080		Roy C, et al., Association of Testosterone Levels With Anemia in Older Men. JAMA Intern Med. 2017; 1-11		H, R, F
4081		Snyder P, et al., Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone. JAMA Intern Med. 2017; 1-9		H, R, F
4082		Budoff M. et al., Testosterone Treatment and Coronary Artery Plaque Volume. JAMA. Mar 2017		H, R, F
4083		Cheetham T, et al. Association of Testosterone Replacement With Cardiovascular Outcomes Among Men With Androgen Deficiency. JAMA Intern Med. 2017; 1-9		H, R, F
4084		Resnick S, et al., Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment. JAMA. Feb 2017;317(7):717-727		H, R, F
4085		Alexander G, et al., Cardiovascular Risks of Exogenous Testosterone Use Among Men. The American Journal of Medicine. Mar 2017; 130(3): 293-305		H, R, F
4086		Abbott RD, Launer LJ, Rodriguez BL, et al. Serum estradiol and risk of stroke in elderly men. Neurology. Feb 20 2007;68(8):563-568.		H, R, F
4087		ADVANCE Collaboration Group, Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes, N Engl J Med 2008;358:2560-72		H, F, R
4088		AHA Scientific Statement. Poirier P. Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss: An Update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease From the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Poirier P, et al. Circulation February 14, 2006, Volume 113, Issue 6.		H, R, F
4089		Aichner et al., High cardiovascular event rates in patients with asymptomatic carotid stenosis: the REACH registry, European Journal of Neurology 2009, 16: 902–908		H, F, R
4090		Akishita M, Hashimoto M, Ohike Y, et al. Low testosterone level as a predictor of cardiovascular events in Japanese men with coronary risk factors. Atherosclerosis. May 2010;210(1):232-236.		H, F, R
4091		Ali et al. Effects of Testosterone Supplement Therapy on Cardiovascular Outcomes in Men with Low Testosterone, American College of Cardiology Scientific Session Mar 14, 2015, Abstract 1126M-13		H, F, R
4092		Alkamel, Abdulhakim, Mohammadali Boroumand, and Younes Nozari. "The association between premature coronary artery disease and level of testosterone in young adult males." Archives of Iranian medicine 17.8 (2014): 545.		H, F, R
4093		Allan CA, McLachlan RI. Androgens and obesity. Curr Opin Endocrinol Diabetes Obes. Jun 2010;17(3):224-232.		H, F, R

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4094		Amanatkar HR, Chibnall JT, Seo BW, Manepalli JN, Grossberg GT. Impact Of Exogenous Testosterone On Mood: A Systematic Review And Meta-Analysis Of Randomized Placebo-Controlled Trials. Ann Clin Psychiatry. 2014;26(1):19-32.		H, F, R
4095		Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease. An update. J Am Coll Cardiol. 2004; 43(10):1731-1737		H, F, R
4096		American Diabetes Association. "8. Cardiovascular disease and risk management." Diabetes Care 39.Supplement 1 (2016): S60-S71.		H, F, R
4097		Amiaz R, Pope HG, Jr., Mahne T, et al. Testosterone gel replacement improves sexual function in depressed men taking serotonergic antidepressants: a randomized, placebo-controlled clinical trial. J Sex Marital Ther. 2011;37(4):243-254.		H, F, R
4098		Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. Feb 2004;89(2):503-510.		H, F, R
4099		Arnlov J, Pencina MJ, Amin S, et al. Endogenous sex hormones and cardiovascular disease incidence in men. Annals of internal medicine. Aug 1 2006;145(3):176-184.		H, F, R
4100		Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med. Oct 2010;7(10):3495-3503.		H, F, R
4101		Aversa, Antonio, R. Bruzziches, D. Francomano, G. Spera, and A. Lenzi. 2010. "Efficacy and Safety of Two Different Testosterone Undecanoate Formulations in Hypogonadal Men with Metabolic Syndrome." Journal of Endocrinological Investigation 33 (11): 776–83.		H, F, R
4102		Baillargeon et al. Androgen Therapy and Rehospitalization in Older Men With Testosterone Deficiency. Mayo Clin Proc. 2016 May;91(5):587-95 [2016 Apr 6 Epub ahead of print]		H, F, R
4103		Bang HJ, Yang YJ, Lho DS, Lee WY, Sim WY, Chung BC. Comparative studies on level of androgens in hair and plasma with premature male-pattern baldness. Journal of dermatological science. Feb 2004;34(1):11-16.		H, F, R
4104		Bangalore et al., Beta -Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease, JAMA. 2012;308(13):1340-1349		H, F, R
4105		Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation. Sep 1988;78(3):539-545.		H, F, R
4106		Basaria S. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. J. Androl. Sept. 10 2008; 29(5); 534-539.		H, F, R

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4107		Behre HM, Abshagen K, Oettel M, Hubler D, Nieschlag E. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol. May 1999;140(5):414-419.		H, F, R
4108		Berry et al., Lifetime Risks for Cardiovascular Disease Mortality by Cardiorespiratory Fitness Levels Measured at Ages 45, 55, and 65 Years in Men, J Am Coll Cardiol 2011;57:1604-10		H, R, F
4109		Bhasin S, Travison TG, Storer TW, et al. Effect of testosterone supplementation with and without a dual 5alpha-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. JAMA. Mar 7 2012;307(9):931-939.		H, R, F
4110		Bhasin S, Pencina M, et al. Reference Ranges for Testosterone in men Generated Using Liquid Chromatography Tandem Mass Spectrometry in a Community-Based Sample of Healthy Nonobese Young Men in the Framingham Heart Study and Applied to Three Geographically Distinct Cohorts. J Clin Endocrinol Metab. 2011 Aug; 96(8): 2430-2439.		H, R, F
4111		Bhatt et al., Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis, JAMA. 2010;304(12):1350-1357		H, R, F
4112		Bock, Robert (August 1993). "Understanding Klinefelter Syndrome: A Guide for XXY Males and their Families". NIH Pub. No. 93-3202. Eunice Kennedy Shriver National Institute of Child Health and Human Development.		H, R, A, F
4113		Bond P, Llewellyn W, Van Mol P. Anabolic androgenic steroid-induced hepatotoxicity. Med Hypotheses. Aug 2016;93:150-153.		H, R, F
4114		Braekkan SK, Mathiesen EB, Njolstad I, Wilsgaard T, Hansen JB. Hematocrit and risk of venous thromboembolism in a general population. The Tromso study. Haematologica. Feb 2010;95(2):270-275.		H, R, F
4115		Braunstein. Testes. Basic & Clinical Endocrinology. Samford, CT: Appleton and Lange; 1997:403-433 (additional pages 434 - 452)		H, R, F
4116		Braunwald, E, Bonow, R, Braunwald's Textbook of Heart Disease, 9th ed. 2012		H, R, F
4117		Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab. Jun 1983;56(6):1278-1281.		H, R, F
4118		Camacho EM, Huhtaniemi IT, O'Neill TW, et al. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol. Mar 2013;168(3):445-455.		H, R, F
4119		Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol. Sep 1 2009;54(10):919-927.		H, R, F
4120		Campbell WA, Price WH. Venous thromboembolic disease in Klinefelter's syndrome. Clin Genet. 1981; 19:275-280.		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4121		Canguven O, Talib RA, El-Ansari W, Shamsoddini A, Salman M, Al-Ansari A. RigiScan data under long-term testosterone therapy: improving long-term blood circulation of penile arteries, penile length and girth, erectile function, and nocturnal penile tumescence and duration. Aging Male. Oct 1 2016;1-6.		H, R, F
4122		Cannon CP et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes (PROVE-IT Trial). N Engl J Med 2004; 350:1495-1504.		H, R, F
4123		Carneiro A, Sasse AD, Wagner AA, et al. Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis. World J Urol. 2015;33(9):1281-1289.		H, R, F
4124		Carrero JJ, Qureshi AR, Nakashima A, et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant. Jan 2011;26(1):184-190.		H, R, F
4125		Carrero JJ, Qureshi AR, Parini P, et al. Low serum testosterone increases mortality risk among male dialysis patients. Journal of the American Society of Nephrology : JASN. Mar 2009;20(3):613-620.		H, R, F
4126		Cassar A, Holmes Jr. DR, Rihal CS, Gersh BJ. Mayo Clin Proc. Chronic Coronary Artery Disease: Diagnosis and Management. 2009 Dec; 84(12): 1130–1146.		H, R, F
4127		Cauley JA, Gutai JP, Kuller LH, Dai WS. Usefulness of sex steroid hormone levels in predicting coronary artery disease in men. The American journal of cardiology. Oct 1 1987;60(10):771-777.		H, R, F
4128		Channer KS. Endogenous Testosterone Levels And Cardiovascular Disease In Healthy Men. Heart. 2011;97(11):867-869.		H, R, F
4129		Ciruzzi et al., Frequency of Family History of Acute Myocardial Infarction in Patients With Acute Myocardial Infarction, Am J Cardiol 1997;80:122–127		H, R, F
4130		Citron JT, Ettinger B, Rubinoff H, et al. Prevalence of hypothalamic-pituitary imaging abnormalities in impotent men with secondary hypogonadism. J Urol. Feb 1996;155(2):529-533.		H, R, F
4131		Clarke JH. Nucl Recept Signal. 2006; 4: e023. A critique of Women's Health initiative Studies (2002-2006)		H, R, F
4132		Colangelo LA, Ouyang P, Liu K, Kopp P, Golden SH, Dobs A, Szklo M, Vaidya D, Cushman M, Gapstur SM. Association of endogenous sex hormones with diabetes and impaired fasting glucose in men. Diabetes Care. 2009;32:1049–1051		H, R, F
4133		Comparative Safety of Testosterone Dosage Forms. JAMA Intern Med. 2015; 175(7):1187-1196.		H, R, F
4134		Cornoldi, Alessandra, et al. "Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease." International journal of cardiology 142.1 (2010): 50-55.		H, R, F
4135		Corona et al. High Triglycerides Predicts Arteriogenic Erectile Dysfunction and Major Adverse Cardiovascular Events in Subjects With Sexual Dysfunction. J Sex Med. 2016 Sep;13(9):1347-58		H, R, F
4136		Corona et al. World J Mens Health. 2015 Dec; 33(3): 130–142.		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4137		Corona G, Giagulli VA, Maseroli E, et al. THERAPY OF ENDOCRINE DISEASE: Testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. Mar 2016;174(3):R99-116.		H, R, F
4138		Corona G, Isidori AM, Aversa A, Burnett AL, Maggi M. Endocrinologic Control of Men's Sexual Desire and Arousal/Erection. J Sex Med. Mar 2016;13(3):317-337.		H, R, F
4139		Corona G, Isidori AM, Buvat J, et al. Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med. Jun 2014;11(6):1577-1592.		H, R, F
4140		Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert opinion on drug safety. Aug 19 2014:1-25.		H, R, F
4141		Corona G, Monami M, Boddi V, et al. Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction. J Sex Med. Apr 2010;7(4 Pt 1):1557-1564.		H, R, F
4142		Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A, Forti G, Mannucci E, Maggi M. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl. 2010; 34:528-540.		H, R, F
4143		Corona G, Rastrelli G, Morgentaler A, Sforza A, Mannucci E, Maggi M. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. Eur Urol (2017). Article in press.		H, R, F
4144		Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. The Journal of clinical endocrinology and metabolism. Mar 2008;93(3):914-919.		H, R, F
4145		D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. Jun 10 2007;25(17):2420-2425.		H, R, F
4146		Dean JD, Carnegie C, Rodzvilla J, Smith T. Long-term effects of testim(r) 1% testosterone gel in hypogonadal men. Rev Urol. 2004;6 Suppl 6:S22-29.		H, R, F
4147		Demirbag R, Yilmaz R, Ulucay A, Unlu D. The inverse relationship between thoracic aortic intima media thickness and testosterone level. Endocrine research. 2005;31(4):335-344.		H, R, F
4148		Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes. JAMA. 2006; 295:1288-1299.		H, R, F
4149		Dobrzycki S, Serwatka W, Nadlewski S, et al. An assessment of correlations between endogenous sex hormone levels and the extensiveness of coronary heart disease and the ejection fraction of the left ventricle in males. J Med Invest. 2003;50(3-4):162-9.		H, R, F
4150		Drager LF, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: an emerging risk factor for atherosclerosis. Chest. Aug 2011;140(2):534-542.		H, R, P, F
4151		English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J. 2000; 21:890-894.		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4152		English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. <i>Circulation</i> . Oct 17 2000;102(16):1906-1911.		H, R, P, F
4153		European Medicines Agency. "No consistent evidence of an increased risk of heart problems with testosterone medicines." Nov. 21, 2014. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/11/WC500177618.pdf .		H, R, F
4154		Everson-Rose et al., Chronic Stress, Depressive Symptoms, Anger, Hostility, and Risk of Stroke and Transient Ischemic Attack in the Multi-Ethnic Study of Atherosclerosis, <i>Stroke</i> . 2014;45:2318-2323		H, R, F
4155		Farias, Javier M., et al. "Low testosterone concentration and atherosclerotic disease markers in male patients with type 2 diabetes." <i>The Journal of Clinical Endocrinology & Metabolism</i> 99.12 (2014): 4698-4703.		H, R, F
4156		Fatemi et al., Impact of Intensive Glycemic Control on the Incidence of Atrial Fibrillation and Associated Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study), <i>Am J Cardiol</i> 2014;114:1217e1222		H, R, F
4157		Faxon, et al., Atherosclerotic Vascular Disease Conference, Writing Group III: Pathophysiology		H, R, F
4158		Fenwick PB, Mercer S, Grant R, et al. Nocturnal penile tumescence and serum testosterone levels. <i>Arch Sex Behav</i> . Feb 1986;15(1):13-21.		H, R, F
4159		Filippi S, Vignozzi L, Morelli A, Chavalmane AK, Sarchielli E, Fibbi B. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. <i>J Sex Med</i> . 2009; 6:3274–3288.		H, R, F
4160		Finegold JA, Asaria P, Francis DP (4 December 2012). "Mortality from ischemic heart disease by country, region, and age: Statistics from World Health Organization and United Nations". <i>International Journal of Cardiology</i> . 168 (2): 934–45.		H, R, F
4161		Finkelstein JS, Lee H, Burnett-Bowie S, et al. Gonadal steroids and body composition, strength, and sexual function. <i>N Engl J Med</i> . 2013;369(11):1011-1022		H, R, F
4162		Finkelstein JS, Yu EW, Burnett-Bowie SA. Gonadal steroids and body composition, strength, and sexual function in men. <i>N Engl J Med</i> . Dec 19 2013;369(25):2457.		H, R, F
4163		Fisch, The Pendulum Swings: Prescribing Hormone Replacement Therapy 13 Years After the Women s Health Initiative Study		H, R, P, F
4164		Francomano D, Bruzziches R, Barbaro G, Lenzi A, Aversa A. Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study. <i>J Endocrinol Invest</i> . Mar 18 2014;37:401-411.		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4165		Freedman DS. Relation of serum testosterone levels to high density lipoprotein cholesterol and other characteristics in men. Arterioscler Thromb. 1991 Mar-Apr; 11(2): 307-15.		H, R, F
4166		Fuster V et al. Pathogenesis of CAD and ACS. NEJM 1992; 326: 310-318.		H, R, F
4167		Gandaglia G, Sun M, Popa I, et al. The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study. BJU Int. 2014;114(6b):E82-89.		H, R, F
4168		Gianatti EJ, Dupuis P, Hoermann R, et al. Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial. Diabetes Care. Aug 2014;37(8):2098-2107.		H, R, F
4169		Gianatti EJ, Dupuis P, Hoermann R, Zajac JD, Grossmann M. Effect of testosterone treatment on constitutional and sexual symptoms in men with type 2 diabetes in a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. Oct 2014;99(10):3821-3828.		H, R, F
4170		Giltay EJ, Tishova YA, Mskhalaya GJ, Gooren LJ, Saad F, Kalinchenko SY. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med. Jul 2010;7(7):2572-2582.		H, R, F
4171		Glueck CJ, Friedman J, Hafeez A, Hassan A, Wang P. Testosterone, thrombophilia, thrombosis. Blood Coagul Fibrinolysis. Oct 2014;25(7):683-687.		H, R, F
4172		Glueck CJ, Richardson-Royer C, Schultz R, Burger T, Bowe D, Padda J, Wang P. Testosterone therapy, thrombophilia-hypofibrinolysis, and hospitalization for deep venous thrombosis-pulmonary embolus: an exploratory, hypothesis-generating study. Clin Appl Thromb Hemost. Aug 7. Epub ahead of print. 2013. doi:10.1177/1076029613499819.		H, R, F
4173		Glueck et al. Thrombophilia in 67 Patients With Thrombotic Events After Starting Testosterone Therapy. Clin Appl Thromb Hemost. 2016 Sep;22(6):548-53 [2015 Nov 30 Epub ahead of print]		H, R, F
4174		Goff, David C., et al. "2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines." Journal of the American College of Cardiology 63.25_PA (2014).		H, R, F
4175		Golan R, Scovell JM, Ramasamy R. Age-related testosterone decline is due to waning of both testicular and hypothalamic-pituitary function. Aging Male. 2015;18(3):201-204.		H, R, F
4176		Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl. May-Jun 1994;15(3):212-215.		H, R, F
4177		Grober ED, Khera M, Soni SD, Espinoza MG, Lipshultz LI. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men. Int J Impot Res. Mar-Apr 2008;20(2):213-217.		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4178		Grossmann M, Hoermann R, Wittert G, Yeap BB. Effects of testosterone treatment on glucose metabolism and symptoms in men with type 2 diabetes and the metabolic syndrome: a systematic review and meta-analysis of randomized controlled clinical trials. Clinical endocrinology. Sep 2015;83(3):344-351.		H, R, F
4179		Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC, Sowers JR. Diabetes and cardiovascular disease: a statement for health professionals from the American Heart Association. Circulation. 1999; 100:1134-1146.		H, R, F
4180		Guay AT, Traish A. Testosterone deficiency and risk factors in the metabolic syndrome: implications for erectile dysfunction. Urol Clin North Am. May 2011;38(2):175-183.		H, R, F
4181		Guo C, Gu W, Min L, et al. Efficacy and safety of testosterone replacement therapy in men with hypogonadism: A meta-analysis study of placebo-controlled trials. Exp Ther Med. Mar 2016; 11(3): 853-863.		H, R, F
4182		Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med. Mar 2014;11(3):840-856.		H, R, F
4183		Hak AE, Witteman JC, De Jong FH, Geerlings MI, Hofman A, Pols HA. Low Levels Of Endogenous Androgens Increase The Risk Of Atherosclerosis In Elderly Men: The Rotterdam Study. J Clin Endocrinol Metab. 2002;87(8):3632-3639		H, R, F
4184		Halushka P, Thromboxane A2 and TP receptors: A trail of research, well traveled, Journal of the South Carolina Academo of Science 14(1) (Mar. 2016)		H, R, F
4185		Hanafy HM. Testosterone therapy and obstructive sleep apnea: is there a real connection? J Sex Med. Sep 2007;4(5):1241-1246.		H, R, F
4186		Haring R, Nauck M, Volzke H, et al. Low serum testosterone is associated with increased mortality in men with stage 3 or greater nephropathy. American journal of nephrology. 2011;33(3):209-217.		H, R, F
4187		Haring R, Teng Z, Xanthakis V, et al. Association of sex steroids, gonadotrophins, and their trajectories with clinical cardiovascular disease and all-cause mortality in elderly men from the Framingham Heart Study. Clinical endocrinology. Apr 2013;78(4):629-634.		H, R, F
4188		Haring R, Volzke H, Felix SB, et al. Prediction of metabolic syndrome by low serum testosterone levels in men: results from the study of health in Pomerania. Diabetes. Sep 2009;58(9):2027-2031.		H, R, F
4189		Haring R, Volzke H, Steveling A, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. European heart journal. Jun 2010;31(12):1494-1501.		H, R, F
4190		Hartung T. What Clinical Studies Tell Us About Preclinical Work? Johns Hopkins University, Bloomberg School of Public Health, CAAT, Baltimore, USA and University of Konstanz, CAAT-Europe, Germany		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4191		Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. <i>Circulation</i> . 115 (5): e69-171. doi:10.1161/CIRCULATION.AHA.106.179918. PMID 17194875. Retrieved 26 October 2015.		H, R, F
4192		Heinl RE, Dhindsa DS, Mahlof EN, et al. Comprehensive Cardiovascular Risk Reduction and Cardiac Rehabilitation in Diabetes and the Metabolic Syndrome. <i>Can J Cardiol</i> . Oct 2016;32(10S2):S349-S357.		H, R, F
4193		Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. <i>J Androl</i> . Nov-Dec 2009;30(6):726-733.		H, R, F
4194		Hildreth KL, Barry DW, Moreau KL, et al. Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels. <i>J Clin Endocrinol Metab</i> . 2013;98(5):1891-1900.		H, R, F
4195		Ho, Christopher C. K., Seng Fah Tong, Wah Yun Low, Chirk Jenn Ng, Ee Ming Khoo, Verna K. M. Lee, Zulkifli Md Zainuddin, and Hui Meng Tan. 2011. "A Randomized, Double-Blind, Placebo-Controlled Trial on the Effect of Long-Acting Testosterone Treatment as Assessed by the Aging Male Symptoms Scale." <i>BJU International</i> 110 (2): 260-65		H, R, F
4196		Hormone Replacement Therapy 13 Years after the Women's Health Initiative Study. American Council of Science and Health... August 3rd 2015		H, R, A, F
4197		Hsueh WA, Hsu TH, Federman DD. Endocrine features of Klinefelter's syndrome. <i>Medicine</i> . 1978; 57:447-461.		H, R, F
4198		Hu X, Rui L, Zhu T, et al. Low testosterone level in middle-aged male patients with coronary artery disease. <i>European journal of internal medicine</i> . Dec 2011;22(6):e133-136.		H, R, F
4199		Hyde Z, Norman PE, Flicker L, et al. Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study. <i>The Journal of clinical endocrinology and metabolism</i> . Jan 2012;97(1):179-189.		H, R, F
4200		Idan A, Griffiths KA, Harwood DT, et al. Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial. <i>Annals of internal medicine</i> . Nov 16 2010;153(10):621-632.		H, R, F
4201		Ioannidis, John P A. 2005. "Why Most Published Research Findings Are False." <i>PLoS Medicine</i> 2 (8): 0696-0701. doi:10.1371/journal.pmed.0020124.		H, R, F
4202		Jankowska EA, Filippatos G, Ponikowska B, Borodulin-Nadzieja L, Anker SD, Banasiak W, Poole-Wilson PA, Ponikowski P. Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. <i>J Card Fail</i> . 2009 Jun; 15(5):442-50.		H, R, F, B

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4203		Jernberg et al., Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective, <i>European Heart Journal</i> (2015) 36, 1163–1170		H, R, F
4204		Johannsson G, Gibney J, Wolthers T, Leung KC, Ho KK. Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men. <i>The Journal of clinical endocrinology and metabolism</i> . Jul 2005;90(7):3989-3994.		H, R, F
4205		Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). <i>Diabetes Care</i> . Apr 2011;34(4):828-837.		H, R, F
4206		Jones TH, Channer KS. Deaths and cardiovascular events in men receiving testosterone. <i>JAMA</i> . 2014;311(9):962-3.		H, R, F
4207		Kabakci G, Yildirim A, Can I, Unsal I, Erbas B. Relationship between endogenous sex hormone levels, lipoproteins and coronary atherosclerosis in men undergoing coronary angiography. <i>Cardiology</i> . 1999;92(4):221-225.		H, R, F
4208		Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. <i>Clin Endocrinol (Oxf)</i> . Nov 2010;73(5):602-612.		H, R, F
4209		Kang SM, Jang Y, Kim J, et al. Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. <i>The American journal of cardiology</i> . Apr 1 2002;89(7):862-864.		H, R, F
4210		Kaplan AL, Hu JC. Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes. <i>Urology</i> . 2013;82(2):321-326.		H, R, F
4211		Kapoor D, Clarke S, Stanworth R, Channer KS, Jones TH. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. <i>Eur J Endocrinol</i> . 2007; 156:595–602.		H, R, F
4212		Karmali et al., Identifying Individuals at Risk for Cardiovascular Events Across the Spectrum of Blood Pressure Levels, <i>J Am Heart Assoc</i> . 2015		H, R, F
4213		Keating NL, O'Malley AJ, Freeland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. <i>J Natl Cancer Inst</i> . 2010; 102:39–46.		H, R, F
4214		Keating NL, O'Mally JA, Smith MR, Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer, <i>J Clinical Oncology</i> 24, no.27 (September 2006) 4448-4456		H, R, F
4215		Kenny AM, Bellantonio S, Gruman CA, Acosta RD, Prestwood KM. Effects Of Transdermal Testosterone On Cognitive Function And Health Perception In Older Men With Low Bioavailable Testosterone Levels. <i>J Gerontol A Biol Sci Med Sci</i> . 2002;57(5):M321-M325.		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4216		Kenny AM, Kleppinger A, Annis K, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc. 2010;58(6):1134-1143.		H, R, F
4217		Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2001;56(5):M266-M272.		H, R, F
4218		Khaw et al. Endogenous Testosterone and Mortality Due to All Causes, Cardiovascular Disease, and Cancer in Men. Circulation December 4, 2007, Volume 116, Issue 23		H, R, F
4219		Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS). J Sex Med. Nov 2011;8(11):3204-3213.		H, R, F
4220		Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS). Aging Male. Mar 2012;15(1):14-21.		H, R, F
4221		Khera M. Testosterone Therapies. Urol Clin North Am. May 2016;43(2):185-193.		H, R, F, B
4222		Kietsiriroje N. Human Immunodeficiency Virus Infection and Male Hypogonadism: A Review. J Med Assoc Thai. Oct 2015;98(10):1045-1055.		H, R, F
4223		Kim S, Snipes W, Hodgen GD, Anderson F. Pharmacokinetics of a single dose of buccal testosterone. Contraception. Nov 1995;52(5):313-316.		H, R, F
4224		Kim, Catherine, Mary Cushman, Dawn Kleindorfer, Lynda Lisabeth, Rita F Redberg, and Monika M Safford. 2015. "A Review of the Relationships between Endogenous Sex Steroids and Incident Ischemic Stroke and Coronary Heart Disease Events." Current Cardiology Reviews 11 (3): 252-60. http://www.ncbi.nlm.nih.gov/pubmed/25563292		H, R, F
4225		Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology. Jan 2001;57(1):127-132.		H, R, F
4226		Klapcinska, B., Jagsz, S., Sadowska-Krepa, E., Gorski, J., Kempa, K., and Langfort, J. (2008) Effects of castration and testosterone replacement on the antioxidant defense system in rat left ventricle. TheJournal of Physiological Sciences: JPS 58, 173-177		H, R, F
4227		Kloner et al. Testosterone and Cardiovascular Disease JAm Coll Cardiol. 2016;67(5):545-57.		H, R, F
4228		Kloner, Robert A. "Testosterone and cardiovascular health: safety of treatment of hypogonadism." Sexual Medicine Reviews 3.1 (2015): 56-62.		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4229		Kochanek KD, Xu JQ, Murphy SL, Miniño AM, Kung HC. (PDF). Retrieved 25 March 2013. National Vital Statistics Reports. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. Centers for Disease Control and Prevention, National Center for Health Statistics. National Vital Statistics System. Volume 60, Number 3. December 29, 2011.		H, R, F
4230		Kohli et al., NSAID Use and Association with Cardiovascular Outcomes in Outpatients with Stable Atherothrombotic Disease, The American Journal of Medicine (2014) 127, 53-60		H, R, F
4231		Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA. Jul 20 1994;272(3):205-211.		H, R, F
4232		Kuhn CM. Anabolic steroids. Recent Prog Horm Res. 2002;57:411-434.		H, R, F
4233		Kuhnert B, Byrne M, Simoni M, et al. Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial. Eur J Endocrinol. Aug 2005;153(2):317-326.		H, R, F
4234		Kumbhani et al., Adherence to Secondary Prevention Medications and Four-year Outcomes in Outpatients with Atherosclerosis, The American Journal of Medicine (2013) 126, 693-700		H, R, F
4235		Kyriazis J, Tzanakis I, Stylianou K, et al. Low serum testosterone, arterial stiffness and mortality in male haemodialysis patients. Nephrol Dial Transplant. Sep 2011;26(9):2971-2977.		H, R, F
4236		Lai et al. Reduced T levels in males with lone AF. Clin Cardiol. 2009; 32: 43-46.		H, R, P, F
4237		Lazarou S, Reyes-Vallejo L, Morgentaler A. Wide variability in laboratory reference values for serum testosterone. J Sex Med. Nov 2006;3(6):1085-1089.		H, R, F
4238		Leander et al., Family History of Coronary Heart Disease, a Strong Risk Factor for Myocardial Infarction Interacting with Other Cardiovascular Risk Factors: Results from the Stockholm Heart Epidemiology Program (SHEEP), Epidemiology 2001;12:215-221		H, R, F
4239		Lehtonen A, Huupponen R, Tuomilehto J, et al. Serum testosterone but not leptin predicts mortality in elderly men. Age and ageing. Jul 2008;37(4):461-464.		H, R, F
4240		Leibowitz et al., Association Between Achieved Low-Density Lipoprotein Levels and Major Adverse Cardiac Events in Patients With Stable Ischemic Heart Disease Taking Statin Treatment, JAMA Intern Med. 2016;176(8):1105-1113		H, R, F
4241		Lerchbaum E, Pilz S, Boehm BO, Grammer TB, Obermayer-Pietsch B, Marz W. Combination of low free testosterone and low vitamin D predicts mortality in older men referred for coronary angiography. Clinical endocrinology. Sep 2012;77(3):475-483.		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4242		Li H, Benoit K, Wang W, Motsko S. Association between Use of Exogenous Testosterone Therapy and Risk of Venous Thrombotic Events among Exogenous Testosterone Treated and Untreated Men with Hypogonadism. J Urol. Apr 2016;195(4P1):1065-1072.		H, R, P, A, F, B
4243		Li L, Guo CY, Jia EZ, et al. Testosterone is negatively associated with the severity of coronary atherosclerosis in men. Asian J Androl. Nov 2012;14(6):875-878.		H, R, P, F
4244		Lloyd et al. Pronounced increase in risk of acute ST-segment elevation myocardial infarction in younger smokers Heart 2016		H, R, F
4245		Lloyd-Jones et al, Parental Cardiovascular Disease as a Risk Factor for Cardiovascular Disease in Middle-aged Adults, JAMA. 2004;291:2204-2211		H, R, F
4246		Loke et al., Association of Obstructive Sleep Apnea With Risk of Serious Cardiovascular Events A Systematic Review and Meta-Analysis, Circ Cardiovasc Qual Outcomes. 2012;5:720-728		H, R, P, F
4247		Lokshyn, Sergiy, Christian Mewis, and Volker Kuhlkamp. "Atrial fibrillation in coronary artery disease." International journal of cardiology 72.2 (2000): 133-136.		H, R, P, F
4248		MacDonald AA, Herbison GP, Showell M, Farquhar CM. The impact of body mass index on semen parameters and reproductive hormones in human males: a systematic review with meta-analysis. Hum Reprod Update. May-Jun 2010;16(3):293-311.		H, R, F
4249		Maganty A, Kovac JR, Ramasamy R. The putative mechanisms underlying testosterone and cardiovascular risk. F1000Res. 2014;3:87.		H, R, F
4250		Malkin CJ, Jones TH, Channer KS. The Effect Of Testosterone On Insulin Sensitivity In Men With Heart Failure. Eur J Heart Fail. 2007;9(1):44-50.		H, R, F
4251		Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS. Low serum testosterone and increased mortality in men with coronary heart disease. Heart. Nov 2010;96(22):1821-1825.		H, R, F
4252		Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J. Jan 2006;27(1):57-64.		H, R, F
4253		Marin et al., Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study, Lancet 2005; 365: 1046–53		H, R, F
4254		Maseroli E, Corona G, Rastrelli G, et al. Prevalence of endocrine and metabolic disorders in subjects with erectile dysfunction: a comparative study. J Sex Med. Apr 2015;12(4):956-965.		H, R, F
4255		McCullough A. Alternatives to testosterone replacement: testosterone restoration. Asian J Androl. Mar-Apr 2015;17(2):201-205.		H, R, F
4256		McCullough AR, Khera M, Goldstein I, Hellstrom WJ, Morgentaler A, Levine LA. A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel((R))) insertion. J Sex Med. Feb 2012;9(2):594-601.		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4257		McNicholas TA, Dean JD, Mulder H, Carnegie C, Jones NA. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int. Jan 2003;91(1):69-74.		H, R, F
4258		Menke A, Guallar E, Rohrmann S, et al. Sex steroid hormone concentrations and risk of death in US men. American journal of epidemiology. Mar 1 2010;171(5):583-592.		H, R, F
4259		Militaru C, Donoiu I, Dracea O, Ionescu DD. Serum testosterone and short-term mortality in men with acute myocardial infarction. Cardiology journal. 2010;17(3):249-253.		H, R, P, F
4260		Millar AC, Lau AN, Tomlinson G, et al. Predicting low testosterone in aging men: a systematic review. CMAJ. Sep 20 2016;188(13):E321-330.		H, R, F
4261		Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab. Nov 2002;87(11):5001-5007.		H, R, F
4262		Morgentaler A, Miner MM, Caliber M, Guay AT, Khara M, Traish AM. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc. Feb 2015;90(2):224-251.		H, R, F
4263		Morgentaler, Abraham, and Ravi Kacker. "Andrology: Testosterone and cardiovascular risk [mdash] deciphering the statistics." Nature Reviews Urology 11.3 (2014): 131-132.		H, R, F
4264		Morris PD, Channer KS. Testosterone and cardiovascular disease in men. Asian J Androl. 2012 May; 14(3): 428-435.		H, R, F
4265		Mozzafarian D, Benjamin EJ, Go AS, et al. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016;133:e38-e360		H, R, F
4266		Muller, Majon, Yvonne T van der Schouw, Jos H H Thijssen, and Diederick E Grobbee. 2003. "Endogenous Sex Hormones and Cardiovascular Disease in Men." The Journal of Clinical Endocrinology and Metabolism 88 (11): 5076-86.		H, R, F
4267		Muraleedharan V, Jones TH. Clin Endocrinology. 2014; 81 (4), 477-487.		H, R, F
4268		Murray MP, Gardner GM, Mollinger LA, Sepic SB. Strength of isometric and isokinetic contractions: knee muscles of men aged 20 to 86. Physical therapy. Apr 1980;60(4):412-419.		H, R, F
4269		Nguyen PL, Alibhai SM, Basaria S, et al. Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them. European urology. Aug 2 2014.		H, R, F
4270		Nieschlag E, Behre HM, Bouchard P, et al., Testosterone Replacement Therapy: Current Trends And Future Directions. Hum Reprod Update. 2004;10(5):409-419.		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4271		Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes care. Jan 2002;25(1):55-60.		H, R, F
4272		Ohlsson C, Barrett-Connor E, Bhasin S, Orwoll E, Labrie F, Karlsson M, Ljunggren O, Vandenput L, Mellstrom D, Tivesten A. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic fractures in men) study in Sweden. J Am Coll Cardiology. 2011;58:1674-1682.		H, R, F
4273		Ong PJ, Patrizi G, Chong WC, Webb CM, Hayward CS, Collins P. Testosterone enhances flow-mediated brachial artery reactivity in men with coronary artery disease. Am J Cardiol. Jan 15 2000;85(2):269-272.		H, R, F
4274		Orengo CA, Fullerton L, Kunik ME. Safety And Efficacy Of Testosterone Gel 1% Augmentation In Depressed Men With Partial Response To Antidepressant Therapy. J Geriatr Psychiatry Neurol. 2005;18(1):20-24.		H, R, F
4275		Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. Dec 16 1998;280(23):2001-2007.		H, R, F
4276		Orwoll E, Lambert LC, Marshall LM, et al. Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med. 2006;166(19):2124-2131.		H, R, F
4277		Pastuszak AW. Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer. J of Urology. 2015 Volume 194, Issue 5, Pages 1271-1276.		H, R, F
4278		Pastuszak et al. Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen, Sex Med 2015;3:165-173		H, R, F
4279		Personal communication with John E. Hall, Ph. D.; Arthur C. Guyton Professor and Chair; Department of Physiology and Biophysics; Director, Mississippi Center for Obesity Research; University of Mississippi Medical Center		H, F, P, R
4280		Petak SM, Nankin HR, Spark RF, Swerdloff RS, Rodriguez-Rigau LJ. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients--2002 update. Endocr Pract. Nov-Dec 2002;8(6):440-456.		H, R, F
4281		Pexman-Fieth C, Behre HM, Morales A, Kan-Dobrosky N, Miller MG. A 6-Month Observational Study Of Energy, Sexual Desire, And Body Proportions In Hypogonadal Men Treated With A Testosterone 1% Gel. Aging Male. 2014;17(1):1-11.		H, R, F
4282		Phillips et al. The association of hyperestrogenemia with coronary thrombosis in men. J Clin Epidemiol 1988; 41: 1151-1156.		H, R, F
4283		Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 1994;14:701-706.		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4284		Ponikowska B, Jankowska EA, Maj J, et al. Gonadal and adrenal androgen deficiencies as independent predictors of increased cardiovascular mortality in men with type II diabetes mellitus and stable coronary artery disease. International journal of cardiology. Sep 3 2010;143(3):343-348.		H, R, F
4285		Pope HG, Jr., Cohane GH, Kanayama G, Siegel AJ, Hudson JI. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry. Jan 2003;160(1):105-111.		H, R, F
4286		Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA. Aug 28 2002;288(8):980-987.		H, R, F
4287		Previtali et al. Risk factors for venous and arterial thrombosis Blood Transfus 2011;9:120-38		H, R, F
4288		Pugh PJ, Jones RD, West JN, Jones TH, Channer KS. Testosterone treatment for men with chronic heart failure. Heart. Apr 2004;90(4):446-447.		H, R, F
4289		Pye SR, Huhtaniemi IT, Finn JD, et al. Late-onset hypogonadism and mortality in aging men. J Clin Endocrinol Metab. Apr 2014;99(4):1357-1366.		H, R, F
4290		Ray et al., Prescription of Long-Acting Opioids and Mortality in Patients With Chronic Noncancer Pain, JAMA. 2016;315(22):2415-2423		H, R, F
4291		Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med. 10 1996;156(11):1173-1177.		H, R, F
4292		Rich M, "Cardiovascular Disease in Older Patients," in Cuculich & Kates, Cardiology Subspecialty Consult, 3d ed. (2014)		H, R, F
4293		Riche DM, Baker WL, Koch CA. Deaths and cardiovascular events in men receiving testosterone. JAMA. 2014;311(9):963-4.		H, R, F
4294		Rimm EB, Stampfer MJ, Giovannucci E, et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol. Jun 15 1995;141(12):1117-1127.		H, R, F
4295		Rosano G, Sheiban I, Massaro R, Pgnotta P, Marazzi G, Vitale C, Mercurio G, Volterrani M, Aversa A, Fini M. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res. 2007; 19:176-182.		H, R, F
4296		Rosano GM, Leonardo F, Pagnotta P, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation. Apr 6 1999;99(13):1666-1670.		H, R, F
4297		Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. Feb 2007;92(2):405-413.		H, R, F
4298		Roy TA, Blackman MR, Harman SM, et al. Interrelationships of serum testosterone and free testosterone index with FFM and strength in aging men. Am. J. Physiol Endocrinol Metab. Aug. 2002; 283(2): E284-E294.		H, R, F
4299		Ruff et al., Long-Term Cardiovascular Outcomes in Patients with Atrial Fibrillation and Atherothrombosis in the REACH Registry, International Journal of Cardiology 170 (2014) 413-418		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4300		Saad et al. Type 2 diabetes and mortality in hypogonadal men improve upon long-term treatment with injectable Testosterone Undecanoate (TU): a controlled registry study. EASD Abstract #374, September 2016		H, R, F
4301		Saad F, Haider A, Doros G, Traish A. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring). Oct 2013;21(10):1975-1981.		H, R, F
4302		Saad F, Haider A, Giltay EJ, Gooren LJ. Age, Obesity And Inflammation At Baseline Predict The Effects Of Testosterone Administration On The Metabolic Syndrome. Hormone Molecular Biology And Clinical Investigation. Horm Mol Biol Clin Investig. 2011;6(1):193-199.		H, R, F
4303		Saad F. Androgen Therapy In Men With Testosterone Deficiency: Can Testosterone Reduce The Risk Of Cardiovascular Disease. Diabetes Metab Res Rev. 2012;28(Suppl 2):52-59.		H, R, F
4304		Schneider G, Nienhaus K, Gromoll J, Heuft G, Nieschlag E, Zitzmann M. Aging males' symptoms in relation to the genetically determined androgen receptor CAG polymorphism, sex hormone levels and sample membership. Psychoneuroendocrinology. May 2010;35(4):578-587.		H, R, F
4305		Schneider G, Nienhaus K, Gromoll J, Heuft G, Nieschlag E, Zitzmann M. Depressive symptoms in men aged 50 years and older and their relationship to genetic androgen receptor polymorphism and sex hormone levels in three different samples. Am J Geriatr Psychiatry. Mar 2011;19(3):274-283.		H, R, F
4306		Schneider G, Nienhaus K, Gromoll J, Heuft G, Nieschlag E, Zitzmann M. Sex hormone levels, genetic androgen receptor polymorphism, and anxiety in >=50-year-old males. J Sex Med. Dec 2011;8(12):3452-3464.		H, R, F
4307		Schneider G, Zitzmann M, Gromoll J, Ladwig KH, Berger K. The relation between sex hormone levels, the androgen receptor CAGn-polymorphism and depression and mortality in older men in a community study. Psychoneuroendocrinology. Oct 2013;38(10):2083-2090.		H, R, F
4308		Schreijer AJ, Reitsma PH, Cannegieter SC. High hematocrit as a risk factor for venous thrombosis. Cause or innocent bystander? Haematologica. Feb 2010;95(2):182-184.		H, R, F
4309		Shea et al., Family History as an Independent Risk Factor for Coronary Artery Disease, JACC Vol 4. No 4 October 1984 793-801		H, R, F
4310		Shores MM, Biggs ML, Arnold AM, et al. Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study. The Journal of clinical endocrinology and metabolism. Jun 2014;99(6):2061-2068.		H, R, F
4311		Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Archives of internal medicine. Aug 14-28 2006;166(15):1660-1665.		H, R, F
4312		Shores, Molly M., and Alvin M. Matsumoto. "Testosterone, aging and survival: biomarker or deficiency." Current opinion in endocrinology, diabetes, and obesity 21.3 (2014): 209.		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4313		Shores, Molly M., et al. "Increased Incidence of Diagnosed Depressive Illness in Hypogonadal Older Men." Archives of General Psychiatry 61.2 (2004): 162-167.		H, R, F
4314		Silberberg et al., Risk Associated with Various Definitions of Family History of Coronary Heart Disease, Am J Epidemiol 1998;147:1133-9.		H, R, F
4315		Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. The Journal of clinical endocrinology and metabolism. Feb 2002;87(2):599-603.		H, R, F
4316		Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. Apr 2004;63(4):742-745.		H, R, F
4317		Smyth M. Thromboxane and the thromboxane receptor in cardiovascular disease. Clin Lipidol. Emer. 2010. Apr 1; 5(2): 209–219.		H, R, F
4318		Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999;84(8):2647-2653.		H, R, F
4319		Soisson V, Brailly-Tabard S, Helmer C, et al. A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: the French 3C cohort study. Maturitas. Jul 2013;75(3):282-288.		H, R, F
4320		Solomon et al., Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention, N Engl J Med 2005;352:1071-80		H, R, F
4321		Solomon et al., Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials The Cross Trial Safety Analysis, Circulation. 2008;117:2104-2113		H, R, F
4322		Solomon et al., The Comparative Safety of Analgesics in Older Adults With Arthritis, Arch Intern Med. 2010;170(22):1968-1978		H, R, F
4323		Somers et al. Sleep Apnea and Cardiovascular Disease. Circulation. 2008; 118:1080-1111.		H, R, F
4324		Stoch SA, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. Jun 2001;86(6):2787-2791.		H, R, F
4325		Sullivan ML, Martinez CM, Gennis P, Gallagher EJ. Progress in Cardiovascular Diseases Vol. 41, No. 1. July/August 1998.		H, R, F
4326		Sumii, K., et al. "Prospective assessment of health-related quality of life in men with late-onset hypogonadism who received testosterone replacement therapy." Andrologia 48.2 (2016): 198-202.		H, R, F
4327		Swerdlow AJ, Schoemaker MJ, Higgins CD, Wright AF, Jacobs PA, UK Clinical Cytogenetics Group Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. J Natl Cancer Inst. 2005; 97:1204–1210.		H, R, F
4328		Szulc, Pawel, Bruno Claustrat, and Pierre D. Delmas. 2009. "Serum Concentrations of 17β-E2 and 25-Hydroxycholecalciferol (25OHD) in Relation to All-Cause Mortality in Older Men - The MINOS Study." Clinical Endocrinology 71 (4): 594–602. doi:10.1111/j.1365-265.2009.03530.x.		H, R, F
4329		Tan et al. Myocardial Infarction and Stroke Risk in Young Healthy Men Treated with Injectable Testosterone, Int J Endocrinol 2015 (6/1/2015)		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4330		Tan WS, Low WY, Ng CJ, et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. <i>BJU international</i> . Jun 2013;111(7):1130-1140.		H, R, F
4331		Teo, Koon K., et al. "Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study." <i>The lancet</i> 368.9536 (2006): 647-658.		H, R, F
4332		Testosterone treatment of men with alcoholic cirrhosis: a double-blind study. The Copenhagen Study Group for Liver Diseases. <i>Hepatology</i> . Sep-Oct 1986;6(5):807-813.		H, R, F
4333		The Endocrine Society. Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline. 2010		H, R, F
4334		Tivesten A, Vandenput L, Labrie F, et al. Low serum testosterone and estradiol predict mortality in elderly men. <i>The Journal of clinical endocrinology and metabolism</i> . Jul 2009;94(7):2482-2488.		H, R, F
4335		Toma M, McAlister FA, Coglianese EE, et al. Testosterone supplementation in heart failure: a meta-analysis. <i>Circulation. Heart failure</i> . May 1 2012;5(3):315-321.		H, R, F
4336		Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. <i>J Androl</i> . Jan-Feb 2009;30(1):10-22.		H, R, F
4337		Traish AM, Guay AT, Morgentaler A. Death by testosterone? We think not! <i>J Sex Med</i> . 2014;11(3):624-9.		H, R, F
4338		Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. <i>Endocrinology</i> . Apr 1999;140(4):1861-1868.		H, R, F
4339		Traish AM, Saad F, Feeley RJ, Guay A. The dark side of testosterone deficiency: III. Cardiovascular disease. <i>J Androl</i> . Sep-Oct 2009;30(5):477-494.		H, R, F
4340		Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. <i>J Androl</i> . Jan-Feb 2009;30(1):23-32.		H, R, F
4341		Traish AM. Testosterone therapy in men with testosterone deficiency: are the benefits and cardiovascular risks real or imagined? <i>Am J Physiol Regul Integr Comp Physiol</i> . Sep 1 2016;311(3):R566-573.		H, R, F
4342		Travison, Thomas G., et al. "Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation." <i>The Journals of Gerontology Series A: Biological Sciences and Medical Sciences</i> (2011): glr100.		H, R, F
4343		Tsilidis KK, Rohrmann S, McGlynn KA, et al. Association between endogenous sex steroid hormones and inflammatory biomarkers in US men. <i>Andrology</i> . 2013;1(6):919-928.		H, R, F
4344		Van Hemelrijck M, Adolfsson J, Garmo H, et al. Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. <i>Lancet Oncol</i> . May 2010;11(5):450-458.		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4345		Van Rooijen JH, Ooms MP, Weber RF, Brinkmann AO, Grootegoed JA, Vreeburg JT. Comparison of the response of rat testis and accessory sex organs to treatment with testosterone and the synthetic androgen methyltrienolone (R1881). Journal of andrology. Jan-Feb 1997;18(1):51-61.		H, R, F
4346		Vandenplas et al. Estradiol and CV disease in healthy men: review and meta-analysis of prospective studies. Heart. 2012; 98: 1478-1482.		H, R, F
4347		Vaya A, Suescun M. Hemorheological parameters as independent predictors of venous thromboembolism. Clin Hemorheol Microcirc. 2013;53(1-2):131-141.		H, R, F
4348		Vergel, Nelson. "ExcelMale. com> Testosterone Replacement, Low T, HCG, & Beyond> Testosterone-Miscellaneous Studies> FDA Panel Backs Limits on Testosterone Drugs but Rejects Petition for More Regulations."		H, R, F
4349		Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. Oct 1999;84(10):3666-3672.		H, R, F
4350		Vianello F, Cella G, Osto E, et al. Coronary microvascular dysfunction due to essential thrombocythemia and polycythemia vera: the missing piece in the puzzle of their increased cardiovascular risk? Am J Hematol. Feb 2015;90(2):109-113.		H, R, F
4351		Vigen C, Hodis HN, Chandler WL, Lobo RA, Mack WJ. Postmenopausal oral estrogen therapy affects hemostatic factors, but does not account for reduction in the progression of subclinical atherosclerosis. J Thromb Haemost. Jun 2007;5(6):1201-1208.		H, R, F
4352		Vikan T, Schirmer H, Njolstad I, Svartberg J. Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromso Study. European journal of endocrinology / European Federation of Endocrine Societies. Sep 2009;161(3):435-442.		H, R, F
4353		Vikan T, Schirmer H, Njolstad I, Svartberg J. Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men. Eur J Endocrinol. 2010; 162:747-754.		H, R, F
4354		Waaseth M, Bakken K, Dumeaux V, et al. Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer postgenome cohort - a cross-sectional analysis. BMC Womens Health. Jan 14 2008;8:1.		H, R, F
4355		Wang C, Jackson G, Jones TH, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. Jul 2011;34(7):1669-1675.		H, R, F
4356		Wang C, Swerdloff RS, Iranmanesh A, et al; Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2839-53.		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4357		Webb CM, Adamson DL, de Zeigler D, Collins P. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. The American journal of cardiology. Feb 1 1999;83(3):437-439, A439.		H, R, F
4358		Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation. Oct 19 1999;100(16):1690-1696.		H, R, F
4359		Wehr E, Pilz S, Boehm BO, Marz W, Grammer T, Obermayer-Pietsch B. Low. Free testosterone is associated with heart failure mortality in older men Referred for coronary angiography. Eur J Heart Fail. 2011; 13:482-488.		H, R, F
4360		Wei et al., Low Cardiorespiratory Fitness and Physical Inactivity as Predictors of Mortality in Men with Type 2 Diabetes, Ann Intern Med. 2000;132:605-611		H, R, F
4361		Wei et al., Relationship Between Low Cardiopiratory Fitness and Mortaility in Normal Weight, Overweight and Obese Men, JAMA 1999;282:1547-1553		H, R, F
4362		Wells M & Eisenberg T, Letter by Wells and Eisenberg Regarding Article "Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia: Results From the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and Meta-Analysis of Women from Primary Prevention Trials," Circulation, 2010;122:e575		H, R, F
4363		White WB, Grady D, Guidice L, et al. A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder. Am Heart J 2012; 163: 27-32		H, R, F
4364		White, William B., et al. "Alogliptin after acute coronary syndrome in patients with type 2 diabetes." New England Journal of Medicine 369.14 (2013): 1327-1335.		H, R, F
4365		White, William B., et al. "Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE trial." Diabetes Care (2016): dc160303.		H, R, F
4366		Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular Testosterone Esters And Plasma Lipids In Hypogonadal Men: A Meta-Analysis. Am J Med. 2001;111(4):261-269.		H, R, F
4367		Wilmot et al., Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis, Diabetologia (2012) 55:2895-2905		H, R, F
4368		Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of Coronary Heart Disease Using Risk Factor Categories. Circulation 1998; 97:1837-1847		H, R, F
4369		Xu J, Xia LL, Song N, Chen SD, Wang G. Testosterone, Estradiol, and Sex Hormone-Binding Globulin in Alzheimer's Disease: A Meta-Analysis. Curr Alzheimer Res. 2016; 13(3):215-22.		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4370		Yassin AA, Nettleship J, Almeahmadi Y, Salman M, Saad F. Effects Of Continuous Long-Term Testosterone Therapy (TTh) On Anthropometric, Endocrine And Metabolic Parameters For Up To 10 Years In 115 Hypogonadal Elderly Men: Real-Life Experience From An Observational Registry Study. <i>Andrologia</i> . 2016;48(7):793-799.		H, R, F
4371		Yeap BB, Hyde Z, Almeida OP, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. <i>The Journal of clinical endocrinology and metabolism</i> . Jul 2009;94(7):2353-2359.		H, R, F
4372		Yeap, Bu Beng. 2014. "Sex Steroids and Cardiovascular Disease." <i>Asian Journal of Andrology</i> 16 (2): 239–47 ("Yeap (2014)").		H, R, F
4373		Zannad, Faiez, et al. "Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial." <i>The Lancet</i> 385.9982 (2015): 2067-2076.		H, R, F
4374		Zhang Y, Gao Y, Tan A, et al. Endogenous sex hormones and C-reactive protein in healthy Chinese men. <i>Clin Endocrinol</i> . 2013;78(1):1365-2265.		H, R, F
4375		Zhao SP, Li XP. The association of low plasma testosterone level with coronary artery disease in Chinese men. <i>International journal of cardiology</i> . Jan 31 1998;63(2):161-164.		H, R, F
4376		Zitzmann, Michael, et al. "IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men." <i>The journal of sexual medicine</i> 10.2 (2013): 579-588.		H, R, F
4377		Zoungas et al., Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes, <i>N Engl J Med</i> 371;15		H, R, F
4378		George et al. Testosterone Replacement Therapy for Secondary Hypogonadism and Risk of Myocardial Infarction, Stroke or All-Cause-Mortality. AACE abstract 906. May 4, 2017		H, R, F
4379		Glueck, et al., Thrombotic event after starting exogenous testosterone in men with previously undiagnosed familial thrombophilia, <i>Transitional Research</i> , October 2011		H, R, F
4380		Grabner, Khera et al. Topical Testosterone Therapy Adherence Among Males with Primary or Secondary Hypogonadism. AACE abstract 925. May 5, 2017		H, R, F
4381		Haider et al. Erectile Function in 656 Hypogonadal Men Improves Over 8 Years with Testosterone Undecanoate Injections (TU) in Comparison to an Untreated Control Group. AUA abstract MP91-12. May 16, 2017		H, R, F
4382		Lipshultz et al. Clinical improvements in erectile function and mood in hypogonadal men treated with 4.5% nasal testosterone gel. AUA abstract PD69-06. May 16, 2017		H, R, F
4383		Tan et al. Age Distribution of Myocardial Infarction Patients on Testosterone: The Low T Experience. AACE abstract 922. May 5, 2017		H, R, F
4384		Yassin et al. Cardiovascular Disease (CVD), Hypogonadism & ED: Positive Effects under Long-Term Treatment with testosterone Undecanoate Injections (TU). AUA abstracts MP91-14. May 16, 2017		H, R, F

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

4385		Yassin et al. Positive Effects of Long-Term Treatment with Testosterone Undecanoate Injections (TU) on Renal Function in Hypogonadal Men: Real-Life Data from a Prospective Controlled Registry Study. AUA abstract MP91-11. May 16, 2017		H, R, F
4386		Sharma, et al. Normalization of testosterone levels after TRT associated with decrease in incidence of atrial fibrillation, J Am Heart Assoc. 2017;6:e004880. DOI: 10.1161/JAHA.116.004880		H, F, R

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

AbbVie's Trial Exhibits - Jeffrey Konrad

Exhibit Number	Date	Description	Bates	Plaintiffs' Objections
5000		Traffic Consultants, Inc. Webpage		R, P
5001		AndroGel Brochure - PPR	KONRADJ-38PPR-01035	B
5002	2010.07.09	Images/films of cardiac catheterization, Baptist Memorial Hospital-Memphis		NPO
5003		Konrad: Selected Medical Records	KONRADJ-23MGR-00353 KONRADJ-23MGR-00350-352 KONRADJ-23MGR-00349 KONRADJ-23MGR-00337 KONRADJ-15GON-00102-104 KONRADJ-15GON-00013 KONRADJ-23MGR-00325 KONRADJ-23MGR-00347 KONRADJ-23MGR-00345 KONRADJ-23MGR-00357 KONRADJ-23MGR-00341-343 KONRADJ-23MGR-00175 KONRADJ-23MGR-00054 KONRADJ-23MGR-00055-56 KONRADJ-23MGR-00148-150 KONRADJ-23MGR-00092 KONRADJ-23MGR-00172 KONRADJ-23MGR-00063 KONRADJ-23MGR-00171 KONRADJ-23MGR-00088 KONRADJ-23MGR-00084-85 KONRADJ-23MGR-00086-87 KONRADJ-23MGR-00062 KONRADJ-23MGR-00169 KONRADJ-17SCF-00184-186 KONRADJ-17SCF-00269-271 KONRADJ-17SCF-00182-183 KONRADJ-23MGR-00320-321 KONRADJ-17SCF-00180-181 KONRADJ-23MGR-00061 KONRADJ-17SCF-00178-179 KONRADJ-17SCF-00175-176 KONRADJ-23MGR-00165 KONRADJ-17SCF-00173-174 KONRADJ-17SCF-00266-268	H, P, I, C, B

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

KONRADJ-17SCF-00171-172
KONRADJ-17SCF-00169-170
KONRADJ-17SCF-00166-167
KONRADJ-23MGR-00164
KONRADJ-23MGR-00060
KONRADJ-23MGR-00120, 122
KONRADJ-23MGR-00163
KONRADJ-10PPR-00208
KONRADJ-23MGR-00071
KONRADJ-23MGR-00162
KONRADJ-17SCF-00282-304
KONRADJ-14BMHM-00302-303
KONRADJ-14BMHM-00304-309
KONRADJ-14BMHM-00337-340
KONRADJ-14BMHM-00354-355
KONRADJ-14BMHM-00356
KONRADJ-14BMHM-00363-366
KONRADJ-14BMHM-00300-301
KONRADJ-14BMHM-00315-316
KONRADJ-14BMHM-00341-348
KONRADJ-14BMHM-00367-368
KONRADJ-14BMHM-00290-291
KONRADJ-14BMHM-00292-293
KONRADJ-17SCF-00164-165
KONRADJ-17SCF-00160-161
KONRADJ-17SCF-00263-265
KONRADJ-17SCF-00157-158
KONRADJ-15GON-00093-101
KONRADJ-15GON-00086-90
KONRADJ-23MGR-00294-295
KONRADJ-17SCF-00155-156
KONRADJ-17SCF-00394-396
KONRADJ-15GON-00080-85
KONRADJ-17SCF-00153-154
KONRADJ-23MGR-00161
KONRADJ-17SCF-00151-152
KONRADJ-15GON-00073-79
KONRADJ-17SCF-00149-150
KONRADJ-17SCF-00327-373
KONRADJ-17SCF-00147-148
KONRADJ-15GON-00064-72
KONRADJ-17SCF-00140-141
KONRADJ-17SCF-00138-139
KONRADJ-17SCF-00135-136

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

			KONRADJ-14BMHM-00088 KONRADJ-17SCF-00132-133 KONRADJ-23MGR-00159 KONRADJ-17SCF-00129-130 KONRADJ-23MGR-00158 KONRADJ-17SCF-00127-128 KONRADJ-15GON-00042-48 KONRADJ-17SCF-00124-125 KONRADJ-17SCF-00121-122 KONRADJ-23MGR-00157 KONRADJ-15GON-00031-38 KONRADJ-17SCF-00117-118 KONRADJ-23MGR-00104 KONRADJ-23MGR-00155-156 KONRADJ-17SCF-00115-116 KONRADJ-23MGR-00098 KONRADJ-23MGR-00154 KONRADJ-17SCF-00109-110 KONRADJ-21BMH-00051-56 KONRADJ-15GON-00025-27 KONRADJ-15GON-00022-24 KONRADJ-17SCF-00106-107 KONRADJ-15GON-00005-6 KONRADJ-15GON-00020-21 KONRADJ-23MGR-00190-199 KONRADJ-15GON-00017-19 KONRADJ-23MGR-00216-222 KONRADJ-17SCF-00103-104 KONRADJ-17SCF-00257-259 KONRADJ-17SCF-00224; 305 KONRADJ-15GON-00014-16 KONRADJ-41GON-00139-141 KONRADJ-71GHA-00012-00015 KONRADJ-71GHA-00018-00022 KONRADJ-54PPR-01127 - 01131 KONRADJ-41GON-00136-138 KONRADJ-41GON-00144-145 KONRADJ-47SCF-00462-465 KONRADJ-58GON-00156-158	
--	--	--	---	--

TRT MDL 2545 (Konrad/Mitchell)

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

5004		Konrad - Group Exhibit to Support Summary re Medical Data	KONRADJ-23MGR-00354 KONRADJ-23MGR-00366-367 KONRADJ-23MGR-00350-352 KONRADJ-23MGR-00364-365 KONRADJ-23MGR-00349 KONRADJ-23MGR-00362 KONRADJ-15GON-00102-104 KONRADJ-15GON-00126 KONRADJ-15GON-00123 KONRADJ-23MGR-00347 KONRADJ-23MGR-00359 KONRADJ-23MGR-00345 KONRADJ-23MGR-00357 KONRADJ-23MGR-00341-343 KONRADJ-23MGR-00355-356	H, R, P, I, C, B
------	--	---	---	------------------

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

KONRADJ-23MGR-00148-150
KONRADJ-23MGR-00141-144
KONRADJ-23MGR-00172
KONRADJ-21BMH-00083-84
KONRADJ-23MGR-00138-140
KONRADJ-23MGR-00171
KONRADJ-23MGR-00134-137
KONRADJ-23MGR-00169
KONRADJ-23MGR-00133
KONRADJ-17SCF-00184-186
KONRADJ-17SCF-00269-271
KONRADJ-17SCF-00182-183
KONRADJ-17SCF-00180-181
KONRADJ-23MGR-00129-131
KONRADJ-23MGR-00168
KONRADJ-23MGR-00167
KONRADJ-23MGR-00166

KONRADJ-17SCF-00178-179
KONRADJ-17SCF-00428-432
KONRADJ-17SCF-00175-176
KONRADJ-17SCF-00422-425
KONRADJ-23MGR-00126-128
KONRADJ-17SCF-00171-172
KONRADJ-17SCF-00169-170
KONRADJ-17SCF-00166-167
KONRADJ-23MGR-00124-125
KONRADJ-23MGR-00164
KONRADJ-23MGR-00120-123
KONRADJ-23MGR-00163
KONRADJ-14BMHM-00302-303
KONRADJ-14BMHM-00337-340
KONRADJ-14BMHM-00341-348
KONRADJ-14BMHM-00372

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

KONRADJ-28PPR-00509
KONRADJ-17SCF-00160-161
KONRADJ-17SCF-00409-410
KONRADJ-17SCF-00157-158
KONRADJ-15GON-00114
KONRADJ-15GON-00086-90
KONRADJ-17SCF-00400-405
KONRADJ-23MGR-00294-295
KONRADJ-17SCF-00155-156
KONRADJ-17SCF-00394-396
KONRADJ-15GON-00080-85
KONRADJ-17SCF-00153-154
KONRADJ-23MGR-00115-116
KONRADJ-17SCF-00151-152
KONRADJ-15GON-00073-79
KONRADJ-17SCF-00149-150
KONRADJ-17SCF-00147-148
KONRADJ-15GON-00064-72
KONRADJ-17SCF-00140-141

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

KONRADJ-17SCF-00138-139
KONRADJ-17SCF-00135-136
KONRADJ-17SCF-00132-133
KONRADJ-23MGR-00112; 160
KONRADJ-23MGR-00159
KONRADJ-17SCF-00129-130
KONRADJ-23MGR-00108-109; 158
KONRADJ-17SCF-00121-122
KONRADJ-23MGR-00105; 157
KONRADJ-15GON-00031-38
KONRADJ-17SCF-00117-118
KONRADJ-23MGR-00104
KONRADJ-23MGR-00155-156
KONRADJ-23MGR-00100
KONRADJ-23MGR-00097-99

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

KONRADJ-23MGR-00096; 152 KONRADJ-21BMH-00051-56 KONRADJ-15GON-00025-27 KONRADJ-14BMHM-00063 KONRADJ-15GON-00022-24 KONRADJ-14BMHM-00018; 26; 29-30 KONRADJ-15GON-00020-21 KONRADJ-23MGR-00182-199 KONRADJ-23MGR-00190-199 KONRADJ-23MGR-00205-215 KONRADJ-17SCF-00103-104 KONRADJ-15GON-00105 KONRADJ-01132-1133 KONRADJ-47SCF-00462-465

AbbVie reserves the right to supplement its exhibit list with any newly obtained or received medical records.

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

AbbVie's Trial Exhibits - Jesse Mitchell

Exhibit Number	Date	Description	Bates	Plaintiffs' Objections
5500	11/8/2012	Photo of AndroGel box	Mitchell Dep. Ex. 3	NPO
5501	9/1/2009	AndroGel MedGuide	Mitchell Dep. Ex. 3A	I, B
5502	2006	INTERHEART Study Lancet. 2006;368 (9536):647-58		H, P, F
5503	2016	Lloyd A et al. Heart 2016; 0: 1-6. doi: 10.1136/heartjnl-2016-309595		H, P, F
5504	11/18/2012	Images/films of cardiac catheterization, Portland Adventist Medical Center		NPO
5505	1/29/2003 - 10/31/2016	Selected Medical Records	MITCHELLJ-16RSC-00026 MITCHELLJ-16RSC-00054 MITCHELLJ-16RSC-00025 MITCHELLJ-16RSC-00023 MITCHELLJ-16RSC-00053 MITCHELLJ-16RSC-00022 MITCHELLJ-9PPR-00630 - 00631 MITCHELLJ-16RSC-00020 MITCHELLJ-16RSC-00051 - 00052 MITCHELLJ-16RSC-00050 MITCHELLJ-16RSC-00019 MITCHELLJ-10PPR-00664 - 00666 MITCHELLJ-16RSC-00048 MITCHELLJ-16RSC-00018 MITCHELLJ-16RSC-00017 MITCHELLJ-16RSC-00047 MITCHELLJ-16RSC-00046 MITCHELLJ-16RSC-00016 MITCHELLJ-16RSC-00043 - 00045 MITCHELLJ-16RSC-00015 MITCHELLJ-16RSC-00014 MITCHELLJ-16RSC-00041 - 00042 MITCHELLJ-16RSC-00038 - 00040 MITCHELLJ-16RSC-00013 MITCHELLJ-16RSC-00012 MITCHELLJ-16RSC-00035 - 00037 MITCHELLJ-16RSC-00011	P, I, C

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

MITCHELLJ-16RSC-00011
MITCHELLJ-16RSC-00028 - 00029
MITCHELLJ-18NWC-00076 - 00078
MITCHELLJ-1PPR-00324 - 00327
MITCHELLJ-21PAMC-00426 - 00429
MITCHELLJ-21PAMC-00430 - 00432
MITCHELLJ-21PAMC-00464 - 00466
MITCHELLJ-23PAMC-01061 - 01063
MITCHELLJ-32PAMC-01857-1858
MITCHELLJ-23PAMC-01532 - 01533
MITCHELLJ-23PAMC-01542
MITCHELLJ-32PAMC-01788-1793
MITCHELLJ-1PPR-000368 - 000369
MITCHELLJ-18NWC-00073-75
MITCHELLJ-23PAMC-1526;1540
MITCHELLJ-18NWC-00059-00061
MITCHELLJ-23PAMC-1524
MITCHELLJ-18NWC-00056 - 00058
MITCHELLJ-18NWC-00054-55
MITCHELLJ-18NWC-00052-53
MITCHELLJ-18NWC-00047 - 00050
MITCHELLJ-21PAMC-00218 - 00219
MITCHELLJ-18NWC-00039 - 00040
MITCHELLJ-18NWC-00043 - 00045
MITCHELLJ-21PAMC-00414 - 00418
MITCHELLJ-16RSC-00010
MITCHELLJ-18NWC-00037-38

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

			MITCHELLJ-16RSC-00027	
			MITCHELLJ-21PAMC-00216 - 00217	
			MITCHELLJ-19NWCI-00127-28	
			MITCHELLJ-21PAMC-00207 - 00209	
			MITCHELLJ-21PAMC-0139 - 0140	
			MITCHELLJ-21PAMC-0188 - 0191	
			MITCHELLJ-19NWCI-00112-13	
			MITCHELLJ-31NWCI-00255 - 00260	
			MITCHELLJ-19NWCI-00106-07	
			MITCHELLJ-19NWCI-00093 - 00101	
			MITCHELLJ-21PAMC-00074 - 00076	
			MITCHELLJ-16RSC-00002 - 00003	
			MITCHELLJ-19NWCI-00086-87	
			MITCHELLJ-19NWCI-00088-93	
			MITCHELLJ-19NWCI-00084-85	
			MITCHELLJ-21PAMC-00008 - 00010	
			MITCHELLJ-19NWCI-00079-81	
			MITCHELLJ-25RSC-00064 - 00066	
			MITCHELLJ-25RSC-00070	

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

5506	1/29/2003 - 10/31/2016	Group Exhibit to Support Summary re Medical Data	MITCHELLJ-16RSC-00026 MITCHELLJ-16RSC-00054 MITCHELLJ-16RSC-00025 MITCHELLJ-16RSC-00024 MITCHELLJ-16RSC-00023 MITCHELLJ-16RSC-00053 MITCHELLJ-16RSC-00022 MITCHELLJ-16RSC-00021 MITCHELLJ-9PPR-00630 - 00631 MITCHELLJ-9PPR-00660 MITCHELLJ-16RSC-00020 MITCHELLJ-16RSC-00051 - 00052 MITCHELLJ-16RSC-00019 MITCHELLJ-16RSC-00048 MITCHELLJ-16RSC-00017 - 00018 MITCHELLJ-16RSC-00047 MITCHELLJ-16RSC-00046 MITCHELLJ-16RSC-00016 MITCHELLJ-16RSC-00043 - 00045 MITCHELLJ-16RSC-00015 MITCHELLJ-16RSC-00014 MITCHELLJ-16RSC-00041 - 00042 MITCHELLJ-16RSC-00013 MITCHELLJ-16RSC-00038 - 00040 MITCHELLJ-16RSC-00012 MITCHELLJ-16RSC-00035 - 00037 MITCHELLJ-16RSC-00011	P, I, C
------	------------------------	--	---	---------

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

MITCHELLJ-16RSC-00011
MITCHELLJ-16RSC-00028 - 00029
MITCHELLJ-1PPR-00324 - 00327
MITCHELLJ-21PAMC-00430 - 00432
MITCHELLJ-21PAMC-00476 - 00477
MITCHELLJ-23PAMC-01061 - 01063
MITCHELLJ-23PAMC-01532 - 01533
MITCHELLJ-23PAMC-01542
MITCHELLJ-23PAMC-01526, 1540
MITCHELLJ-21PAMC-00488 - 00489
MITCHELLJ-18NWCI-00059 - 00060
MITCHELLJ-23PAMC-01524, 01540
MITCHELLJ-18NWCI-00056 - 00058
MITCHELLJ-31NWCI-00278
MITCHELLJ-18NWCI-00054 - 00055
MITCHELLJ-18NWCI-00052 - 00053
MITCHELLJ-18NWCI-00047 - 00050
MITCHELLJ-21PAMC-00218 - 00219
MITCHELLJ-18NWCI-00039 - 00040
MITCHELLJ-21PAMC-00414 - 00418
MITCHELLJ-18NWCI-00037 - 00038
MITCHELLJ-16RSC-00010
MITCHELLJ-16RSC-00027
MITCHELLJ-18NWCI-00035 - 00036
MITCHELLJ-16RSC-00008 - 00009
MITCHELLJ-21PAMC-00216 - 00217
MITCHELLJ-18NWCI-00033 - 00034

Schedule D to Final Pretrial Order -- AbbVie's Trial Exhibit List with Plaintiffs' Objections

			<p>MITCHELLJ-21PAMC-00207 - 00209 MITCHELLJ-21PAMC-00139 - 00140 MITCHELLJ-21PAMC-00188 - 00191 MITCHELLJ-16RSC-00006 - 00007 MITCHELLJ-16RSC-00004 - 00005 MITCHELLJ-21PAMC-00087 MITCHELLJ-NWCI-00029 - 00030 MITCHELLJ-31NWCI-00255 - 00256 MITCHELLJ-21PAMC-00083 - 00085 MITCHELLJ-18NWCI-00021 - 00022 MITCHELLJ-19NWCI-00094 - 00101 MITCHELLJ-21PAMC-00074 - 00076 MITCHELLJ-16RSC-00002 - 00003 MITCHELLJ-31NWCI-00249 - 00251 MITCHELLJ-18NWCI-00008 - 00009 MITCHELLJ-25RSC-00067 - 00069 MITCHELLJ-18NWCI-00005 - 00007 MITCHELLJ-21PAMC-00008 - 00010 MITCHELLJ-25RSC-00064 - 00066 MITCHELLJ-34RSC-00074 - 00076 MITCHELL-35NWCI-00294-00296 Select Medical Records from Columbia River Surgery Center</p>	
--	--	--	--	--

AbbVie reserves the right to supplement its exhibit list with any newly obtained or received medical records.

Schedule E

QUESTIONNAIRE FOR PROSPECTIVE JURORS-- KONRAD

Question	Comments ¹
1. Your full name	
2. Your age	
3. What city do you live in? (If Chicago, please identify what part of the city you live in.)	
4. What is your place of birth?	
5. Do you own your home? _____ Rent? _____ Live with a relative or friend? _____	
6. Please list other cities where you have lived in the past 10 years:	
7. Highest level of education completed?	
8. Please list your occupation, including job title and main job duties, your current employer, and how long you have worked for that employer (if you are retired or unemployed, please list your last employer)	Modified to combine CQ # 8 & 9 ²
9. What other jobs have you held in the past ten years?	
10. Have you ever supervised anyone at any job you have held? <input type="checkbox"/> Yes <input type="checkbox"/> No	Joint proposed question.
11. List the age, occupation and employer of your spouse and any other adult living in your home. (If the person is retired, list their last occupation and employer.)	Joint proposed question
12. If you have children, please list their ages, and occupations, if any.	
13. Have you, or a family member or a close friend ever worked for, or owned stock in, or done business in any way with: (Check all that apply.) <input type="checkbox"/> AbbVie <input type="checkbox"/> Abbott <input type="checkbox"/> Solvay <input type="checkbox"/> Unimed <input type="checkbox"/> Any pharmaceutical company	Joint proposed question, except Defendants object to “any pharmaceutical company.”
14. Have you ever worked in, or received any training or education, in any of the following areas: (Check all that apply.) <input type="checkbox"/> Law/Legal Field/Law Enforcement <input type="checkbox"/> Mental Health/ Counseling/Psychology <input type="checkbox"/> Medicine or Health <input type="checkbox"/> Pharmaceuticals <input type="checkbox"/> Property Management/Construction/ Engineering	Joint proposed question, except with respect to “Property Management/Construction/Engineering” Defendants object to “Property

¹ If no comment is provided, the posed question is from the Court’s jury questionnaire for civil personal injury cases.

² “CQ# ___” shall refer to a question in the Court’s jury questionnaire for civil personal injury cases.

<input type="checkbox"/> Insurance Claims Adjusting <input type="checkbox"/> Banking/Finance/Accounting <input type="checkbox"/> Marketing/Public Relations, advertising, sales <input type="checkbox"/> Education or Teaching <input type="checkbox"/> Government, regulatory agency, FDA	Management/Construction/Engineering.”
15. List your hobbies and other things you like to do in your spare time:	
16. List any television or radio shows that you watch or listen to regularly:	
17. List any organization that you belong to, or support, or donate to (civic, church, job-related, etc.):	Modified from CQ# 15 to add “donate to.”
18. If you have any bumper stickers on your vehicle, what do they say?	Joint proposed question.
19. Have you ever served on a jury? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, were you the foreperson? <input type="checkbox"/> Yes <input type="checkbox"/> No	Modified from CQ # 27 to ask whether prospective juror served as foreperson.
20. Have you, or a family member or a close friend, ever made a claim or filed a lawsuit based on injuries suffered in any sort of accident or personal injury? <input type="checkbox"/> Yes <input type="checkbox"/> No	Modified from CQ # 20 to delete “disaster” and add “personal injury.”
21. Have you, or a family member or a close friend ever been sued, or filed a lawsuit of any type? (Include cases you may have been involved in through your employment. <input type="checkbox"/> Yes <input type="checkbox"/> No	Joint proposed question.
22. Have you ever thought you had a legal claim but chose not to file a lawsuit? <input type="checkbox"/> Yes <input type="checkbox"/> No	Joint proposed question.
23. Do you believe in limiting the amount of jury awards in personal injury lawsuits? <input type="checkbox"/> Yes <input type="checkbox"/> No	Joint proposed question.
24. Have you or anyone close to you ever suffered from any of the following: (a) a heart attack or heart problems; (b) low testosterone; (c) hormone imbalance or deficiency? (circle all that apply)	Joint proposed question.
25. Have you or anyone you know ever taken AndroGel or any other form of Testosterone product? <input type="checkbox"/> Yes <input type="checkbox"/> No	Joint proposed question.
26. Do you agree or disagree that most people fail to take personal responsibility for their actions? <input type="checkbox"/> Agree <input type="checkbox"/> Disagree	Plaintiff proposed. Defendants object.
27. Do you feel that if someone takes a drug to treat the symptoms of getting older and suffers an injury as a result, that he or she should not be able to bring a lawsuit? <input type="checkbox"/> Yes <input type="checkbox"/> No	Plaintiff proposed. Defendants object.
28. How much independent research do you usually do when a doctor prescribes a medication for you to take?	Plaintiff proposed. Defendants object.

(Check only one.) <input type="checkbox"/> A lot <input type="checkbox"/> Some <input type="checkbox"/> Little <input type="checkbox"/> None	
29. With regard to Government agencies, do you feel their regulations are: (Check only one.) <input type="checkbox"/> Not tough enough <input type="checkbox"/> About right <input type="checkbox"/> Too tough <input type="checkbox"/> No opinion	Plaintiff proposed. Defendants object.
30. With regard to FDA regulations over drugs, do you feel its regulations are: (Check only one) <input type="checkbox"/> Not tough enough <input type="checkbox"/> About right <input type="checkbox"/> Too tough <input type="checkbox"/> No opinion	Plaintiff proposed. Defendants object.
31. Do you feel that if the FDA approves a drug, and someone suffers an injury that is caused by the drug, that the injured person should not be allowed to sue the drug manufacturer? <input type="checkbox"/> Yes <input type="checkbox"/> No	Plaintiff proposed. Defendants object.
32. To your knowledge, has your employer ever been sued? <input type="checkbox"/> Yes <input type="checkbox"/> No	Plaintiff proposed. Defendants object.
33. Do you agree that people who cause their own problems often try to blame others? <input type="checkbox"/> Agree <input type="checkbox"/> Disagree?	Plaintiff proposed. Defendants object.
34. Do you have any beliefs or concerns that Low-T (low testosterone levels) in men is a serious problem or condition? <input type="checkbox"/> Yes <input type="checkbox"/> No	Defendants proposed. Plaintiff objects.
35. Have you or anyone close to you ever experienced a serious adverse reaction or serious side effect to a medication? <input type="checkbox"/> Yes <input type="checkbox"/> No	Defendants proposed. Plaintiff objects.
36. Do you have any feelings, beliefs, or experiences regarding pharmaceutical companies that would make it difficult for you to be a fair and impartial juror in this case? <input type="checkbox"/> Yes <input type="checkbox"/> No	Defendants proposed. Plaintiff objects.
37. Do you have any negative opinions about, or had a negative experience with, the pharmaceutical companies Unimed, Solvay, Abbott Laboratories, or AbbVie (or any drug manufactured or sold by any of these companies)? <input type="checkbox"/> Yes <input type="checkbox"/> No	Defendants proposed. Plaintiff objects.
38. Do you think you might have a bias for or against either side, even a slight one, if you were a juror in a case involving a man who claims he was severely injured by a prescription medication? <input type="checkbox"/> Yes <input type="checkbox"/> No	Defendants proposed. Plaintiff object.
39. Are there any facts or circumstances you believe that the court or the parties to the case should know that might affect your ability to serve as a fair and impartial juror in this case? <input type="checkbox"/> Yes <input type="checkbox"/> No	
If yes, please explain:	

PROPOSED SUPPLEMENTAL COURT VOIR DIRE

In the event any of the questions proposed above are not included in the Juror Questionnaire, the parties request that they be asked by the Court during voir dire. Further the parties propose the following additional questions for voir dire:

Defendants' Proposed Supplemental Court Voir Dire

Question	Comments
1. Do you have any familiarity with, or knowledge of, AbbVie or Abbott Laboratories outside of a general awareness of the company? If yes, what have you heard or read, and where did you hear or read it?	
2. Based on the short statement of the case that I read to you earlier, do you have any experiences that sound similar to what this case is about? If yes, please explain.	
3. Have you or someone close to you ever taken a medical or exercise "stress test" ordered by a doctor or healthcare professional? If yes, please explain the circumstances.	
4. Do you have any strong feelings, beliefs, or concerns about the safety of prescription medications? If yes, please explain. a. Do you have beliefs against, or are you opposed to, taking any prescription medications?	
5. Do you have any beliefs or concerns about the adequacy of warnings on prescription medications that are provided by the pharmaceutical company?	Plaintiff objects.
6. Do you have opinions, beliefs, or concerns about the FDA and its standards for approving prescription medications? If yes, please explain.	Plaintiff objects.
7. Have you or a family member served in the military? If yes, please explain.	
8. Have you ever had a serious, negative experience with, or held a strong negative opinion about, a large corporation? If yes, please explain.	
9. In a lawsuit between an individual and a corporation, would you favor one side over the other, regardless of the evidence?	

<p>10. Does anyone feel like they might not be able to set aside feelings of sympathy and base a decision in this case only on the evidence presented at trial and the law that I give to you? If yes, please explain.</p>	
<p>11. Does anyone disagree with our justice system placing the burden of proof on the person who brings a lawsuit? If yes, please explain.</p>	<p>Plaintiff objects.</p>
<p>12. The Plaintiff will be given the first opportunity to present his case and then AbbVie is given an opportunity to present its case. Can everyone wait until all the evidence has been presented, before making a decision for or against either party?</p>	
<p>13. Are you acquainted with any of the members of this panel or any of the other prospective jurors before coming to court today? If yes, please explain.</p>	
<p>14. Is there anything else that you wish to tell the Court or the parties that might affect your ability to serve as a juror in this case? If yes, please explain.</p>	
<p>15. You are prohibited from doing any independent investigation whatsoever regarding this case, the parties, the subject matter, or the attorneys involved in the case. You may not do any Internet searches (Google, etc.) regarding any person, company, or topic in any way involved in this trial until after the trial is concluded. You may not post any information on any social media websites (Facebook, Twitter, etc.). To do so compromises the fairness of the trial and violates your oath as a juror. This prohibition will extend through the end of your jury service in this case. Is there anyone who will not faithfully follow this order as a juror?</p>	

Plaintiff Konrad’s Proposed Supplemental Court Voir Dire

Question	Comments
1. After hearing the statement of the case, how many of you feel that this case lacks merit or that the plaintiff is taking advantage of the system?	Defendants object.
2. How many of you feel the civil justice system is broke, people are abusing the system to make money?	Defendants object
3. How many of you feel that personal injury lawsuits have a direct and significant impact on the economy making consumer goods more expensive?	Defendants object
4. How many of you feel that most personal injury cases are frivolous?	Defendants object
5. How many of you feel that most people who file personal injury lawsuits were lying and waiting for something bad to happen to them so they could file a lawsuits?	Defendants object
6. How many of you feel that lawyers are the main cause of frivolous lawsuits?	Defendants object